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Supplement introduction
Welcome to the ifth Supplement to the Health Technology Assessment journal series. The series 
is now over 10 years old and has published more 
than 500 titles, covering a wide range of health 
technologies in a diverse set of applications. In 
general, the series publishes each technology 
assessment as a separate issue within each annual 
volume.
The Supplements depart from that format by 
containing a series of shorter articles. These are all 
products from a ‘call-off contract’, which the HTA 
programme holds with a range of academic centres 
around the UK, at the universities of Aberdeen, 
Birmingham, Exeter, Liverpool, Shefield, 
Southampton and York. These centres are retained 
to provide a highly responsive resource, which 
meets the needs of national policy makers, notably 
the National Institute for Health and Clinical 
Excellence (NICE).
Until recently, these HTA Technology Assessment 
Review (TAR) centres provided academic input to 
policy making through independent analyses of 
the impact and value of health technologies. As 
many readers will be aware, the perception that 
the advice NICE provides to the NHS could be 
made more timely has led to the development of 
the ‘Single Technology Appraisal’ process. In this 
approach, manufacturers of technologies, which 
are, in general, pharmaceuticals close to the time 
of launch, submit a dossier of evidence aiming to 
demonstrate effectiveness and cost-effectiveness. 
The independent academic input to NICE’s 
process, which continues to be supported by the 
TAR centres around the UK under contract to the 
HTA programme, is to scrutinise, critique and 
explore this dossier of evidence.
The papers included in this Supplement report 
on this HTA programme funded work, and we 
hope that the summaries of the work carried out 
to inform the development of NICE guidance for 
these technologies will be of interest and value to 
readers.
The papers included here contain reports of the 
position that the NICE guidance had reached 
at the time of submission to Health Technology 
Assessment for inclusion in this supplement.  As we 
collect a series of papers together for an issue, the 
process of developing NICE guidance may have 
moved on further for some topics than others.  
Further details on the current position regarding 
each of the NICE Appraisals are available on the 
NICE website (www. nice.org.uk) and we welcome 
comments on the summaries via the HTA website 
(www.hta.ac.uk/correspond/).
Professor Tom Walley 
Director, NIHR HTA programme 
Editor-In-Chief, Health Technology Assessment
Professor Ken Stein 
Chair, Editorial Board, Health Technology Assessment
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of certolizumab 
pegol (CZP) for adults with active rheumatoid 
arthritis (RA) that have not responded adequately 
to treatment with conventional disease modifying 
anti-rheumatic drugs (DMARDs) including 
methotrexate (MTX), in accordance with the 
licensed indication, based upon the evidence 
submission from the manufacturer to the National 
Institute for Health and Clinical Excellence (NICE) 
as part of the single technology appraisal (STA) 
process. The outcome measures included American 
College of Rheumatology (ACR) 20, 50 and 70 
response rates and quality of life measures after 
3 months and 6 months of treatment. The ERG 
examined the submission’s search strategies and 
considered they appeared comprehensive and that 
it was unlikely that relevant studies would have 
been missed. Only English language studies were 
considered in the submission and non-English 
language studies relevant to the decision problem 
may possibly have been ignored. The ERG 
analysed the irst submitted economic model so as 
to itemise in detail clariication points that were 
brought to the attention of the manufacturer. In 
response the manufacturer submitted a modiied 
cost-effectiveness analysis. The ERG undertook 
further analysis of this second model and other 
additional submitted evidence. The clinical 
evidence was derived from two multicentre blinded 
randomised controlled trials (RCTs) comparing 
CZP + MTX to placebo + MTX (the RAPID 1 and 
RAPID 2 trials). RAPID 1 lasted 52 weeks with 982 
&HUWROL]XPDESHJROIRUWKHWUHDWPHQWRIUKHXPDWRLGDUWKULWLV
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patients and RAPID 2 24 weeks with 619 patients. 
Evidence for clinical effectiveness of CZP in mono-
therapy came from the 24-week FAST4WARD trial 
with 220 patients that compared CZP (400 mg 
every 4 weeks) versus placebo. The three key RCTs 
demonstrated statistically signiicant superiority 
of CZP + MTX versus placebo + MTX and of 
CZP versus placebo with respect to a variety of 
outcomes including ACR 20, ACR 50 and ACR 
70 measures and quality of life measures at 3 and 
6 months. On the basis of results from the indirect 
comparison meta-analyses, the manufacturer 
suggested that CZP may be at least as effective as 
other ‘biological’ DMARD (bDMARD) comparators 
and, in a few ACR measures at 3 and 6 months, 
more effective. CZP is an effective therapy for adult 
RA patients whose disease has failed to respond 
adequately to cDMARDs including MTX or who 
are intolerant of MTX. The cost-effectiveness of 
CZP relative to other bDMARDs is unclear because 
the economic modelling undertaken may have 
ignored relevant effectiveness data and potential 
differences between trial populations, and so may 
have included effectiveness results that were biased 
in favour of CZP; underestimated uncertainty in 
the relative effectiveness of compared DMARDs; 
and ignored the potential inluence of differences 
between bDMARDs with regard to adverse events 
and their related costs and health impacts. The 
NICE guidance issued in October 2009 states 
that: the Committee is minded not to recommend 
certolizumab pegol as a treatment option for 
people with RA; and the Committee recommends 
that NICE asks the manufacturer of CZP for more 
information on the clinical effectiveness and cost-
effectiveness of CZP for the treatment of people 
with RA. On receipt of this information and 
details of a patient access scheme NICE issued 
inal guidance recommending CZP, under certain 
criteria, as a treatment option for people with RA.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is speciically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of the Institute.
This paper presents a summary of the ERG report 
for the STA submission that considered the clinical 
effectiveness and cost-effectiveness of certolizumab 
pegol (CZP) for adults with active rheumatoid 
arthritis (RA) that has not responded adequately 
to treatment with conventional disease modifying 
anti-rheumatic drugs (cDMARDs) including 
methotrexate (MTX).2 CZP is a ‘biological’ DMARD 
(bDMARD) whose effectiveness could be compared 
to cDMARDs or to other bDMARDs administered 
within their licensed indications.
Description of the underlying 
health problem
This section is taken from the NICE scope for this 
STA.
Rheumatoid arthritis is a chronic, disabling 
autoimmune disease characterised by inlammation 
of the synovial tissue of the peripheral joints, which 
causes swelling, stiffness, pain and progressive 
joint destruction. For a small proportion of people, 
inlammatory disease outside the joints (e.g. 
eye and lung disease, vasculitis) can also pose a 
signiicant problem. RA is heterogeneous, it is 
usually a chronic relapsing condition which has a 
pattern of lare-ups followed by periods of lower 
disease activity, but in a minority of cases the 
disease is constantly progressive. Most patients with 
RA develop damage to affected joints, with the 
amount of damage ranging from mild to severe. 
RA has a severe impact on quality of life and it is 
estimated that 40% of people with RA will stop 
working within 5 years of diagnosis.
Rheumatoid arthritis is three times more prevalent 
in women than in men. It can develop at any age, 
but usually starts between 40 and 60 years of age. 
RA affects 1% of the population, or approximately 
400,000 people in England and Wales. Of these, 
approximately 15% have severe disease.
People with RA are usually treated in an outpatient 
setting rather than in primary care. There is 
no cure, and treatment aims to improve quality 
of life and to prevent or reduce joint damage. 
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Treatment for RA usually includes: non-steroidal 
anti-inlammatory agents (NSAIDs) which reduce 
pain, fever and joint swelling/inlammation; and 
DMARDS which slow the disease process and 
reduce joint damage. Corticosteroids may also be 
used to control inlammation. DMARDs are usually 
started soon after diagnosis. MTX and sulfasalazine 
are two commonly used DMARDs. NICE guidance 
recommends the use of a TNF (tumour necrosis 
factor)-F inhibitor (adalimumab, etanercept and 
inliximab; types of bDMARD) after the failure 
of two cDMARDs such as MTX and sulfasalazine. 
NICE guidance recommends the use of rituximab 
(a bDMARD that depletes B cells) after the failure 
of a TNF inhibitor, but does not recommend the 
use of abatacept after the failure of a TNF inhibitor.
Scope of the evidence 
review group report
The scope for this STA was to address the clinical 
effectiveness and cost-effectiveness of CZP relative 
to cDMARDs and to bDMARDs for the treatment 
of adults with active RA whose disease had not 
responded adequately to cDMARDs including 
MTX. The STA was initiated prior to the granting 
of formal marketing authorisation. The anticipated 
marketing authorisation for CZP speciied a dose 
regimen of 400 mg administered subcutaneously on 
weeks 0, 2 and 4, followed by 200 mg every other 
week. CZP is indicated for use in ‘combination’ 
therapy with MTX or as ‘monotherapy’ (without 
MTX) for patients intolerant of MTX. The 
acquisition cost of CZP is £357.50 per 200-mg 
syringe, excluding VAT (value added tax).
The key sources of evidence on clinical 
effectiveness of CZP in combination therapy 
came from two multicentre blinded randomised 
controlled trials (RCTs) comparing CZP + MTX to 
placebo + MTX [the RA Prevention of Structural 
Damage (RAPID) 13 and RAPID 24 trials]. RAPID 
1 lasted 52 weeks with 982 patients and RAPID 2 
24 weeks with 619 patients. Evidence for clinical 
effectiveness of CZP in mono-therapy came from 
the 24-week FAST4WARD trial5 with 220 patients 
that compared CZP (400 mg every 4 weeks) versus 
placebo. There were no head-to-head trials that 
compared the effectiveness of CZP to the other 
bDMARDs. To estimate the relative clinical 
effectiveness between bDMARDs the manufacturer 
undertook indirect comparison meta-analyses 
(ICMs)6 using the results from various placebo-
controlled trials of bDMARDs.
The manufacturer submitted a de novo economic 
model that was used to estimate the cost per 
quality-adjusted life-year (QALY) gained from CZP 
in comparison with anti-TNF agents (adalimumab, 
etanercept and inliximab) or with rituximab. 
Model inputs for clinical effectiveness of the 
different bDMARDs were derived from results 
from ICMs and based on the American College 
of Rheumatology (ACR) 20, 50 and 70 response 
rates7 after 3 months and 6 months of treatment. 
The estimated ACR response rates in the absence 
of bDMARD treatment were single point values 
(no associated uncertainty) and were obtained by 
simple aggregation of the rates reported across the 
control arms of the included trials.
Health-related quality of life (HRQoL) utilities 
for the irst 6 months of treatment were obtained 
by regression analysis of the relationship between 
ACR response and European Quality of Life-5 
Dimensions (EQ-5D) scores observed for European 
patients participating in CZP trials. Utilities while 
continuing on treatment and utility after cessation 
of treatment were obtained by converting Health 
Assessment Questionnaire measures using a 
published algorithm proposed by Brennan et al.8 
Costs were mainly obtained from standard sources.
Methods
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process.
Owing to the central importance of the RAPID 
1, RAPID 2 and FAST4WARD studies, these 
were formally fully appraised by the ERG, taking 
advantage of responses to requests for clariication 
from the manufacturer.
The ERG examined the submission’s search 
strategies and considered they appeared 
comprehensive and that it was unlikely that 
relevant studies would have been missed. Only 
English language studies were considered in the 
submission and non-English language studies 
relevant to the decision problem may possibly have 
been ignored.
The ERG critically appraised the submitted ICM 
with focus on the validity of selection of studies 
for inclusion, the reproducibility of results and the 
exploration of heterogeneity. The ERG considered 
the relative merits of alternative approaches to the 
ICM submitted.
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The ERG analysed the irst submitted economic 
model so as to itemise in detail clariication 
points that were brought to the attention of the 
manufacturer. In response the manufacturer 
submitted a modiied cost-effectiveness analysis. 
The ERG undertook further analysis of this second 
model and other additional submitted evidence.
Results
Summary of submitted 
clinical evidence
The three key RCTs demonstrated statistically 
signiicant superiority of CZP + MTX versus 
placebo + MTX and of CZP versus placebo with 
respect to a variety of outcomes including ACR 20, 
ACR 50 and ACR 70 measures and quality of life 
measures at 3 and 6 months.
On the basis of results from the ICMs, the 
manufacturer suggested that CZP may be at least 
as effective as other bDMARD comparators and, 
in a few ACR measures at 3 and 6 months, more 
effective. These ICM estimates were associated 
with considerable uncertainty. Some evidence 
was presented that CZP inhibits progression of 
structural damage to joints.
Summary of submitted cost-
effectiveness evidence
The inputs for the irst model were modiied in 
the second model submitted. Some modiications 
were introduced in response to NICE’s requests 
for clariication, others depended on new results 
obtained from unprompted reanalyses of trial 
data undertaken by the manufacturer. The main 
changes made were exclusion of adverse events, 
exact calculation of discontinuation rates and 
modiied annual utility decrement upon cessation 
of bDMARD treatment. The main results from the 
second model are shown in Table 1. The submission 
also included an economic analysis encompassing 
a proposed patient access scheme. At the time, this 
scheme was not approved by the Department of 
Health (DoH) and as such it was not considered in 
the irst appraisal meeting.
Commentary on the robustness 
of submitted evidence
In the three CZP trials there were large numbers 
of early patient withdrawals from the control arms 
that were imposed for lack of a rapidly established 
clinical effectiveness response.
In the RAPID 1 trial, of 199 patients receiving 
placebo + MTX, 63% had withdrawn by week 16 
and 78% by the end of the trial; this compared 
to 21% and 35%, respectively, of patients 
receiving CZP. In RAPID 2, 87% of patients in the 
placebo + MTX arm had withdrawn by the end 
of the trial (week 24). In the FAST4WARD mono-
therapy trial, 54% of control arm patients had 
withdrawn by week 12 and 74% by the end of the 
trial at 24 weeks.
The high withdrawal rates at early phases of the 
CZP trials, especially seen in the control arms, 
TABLE 1 %DVHFDVHUHVXOWVIURPWKHPDQXIDFWXUHU·VVHFRQGHFRQRPLFPRGHOXVLQJLQGLUHFWFRPSDULVRQHIIHFWLYHQHVVDQDO\VLV
Mean cost (£) Mean QALYs ICER
Combination therapy
CZP + MTX 89,158 6.654 
Etanercept + MTX 86,165 6.589 46,192
Adalimumab + MTX 86,034 6.412 12,937
Rituximab + MTX 82,940 6.362 21,345
,QÁL[LPDE07; 95,599 6.196 CZP dominates
Monotherapy
CZP 85,424 6.305 
Etanercept 85,941 6.435 (3991)a
Adalimumab 84,201 6.09 5687
CZP, certolizumab pegol; ICER, incremental cost-effectiveness ratio; MTX, methotrexate; QALYs, quality-adjusted life-years.
a ICER for etanercept compared with CZP.
Health Technology Assessment 2010; Vol. 14: Suppl. 2
© 2010 Queens Printer and Controller of HMSO. All rights reserved.
5
necessitated that estimates of effectiveness at later 
time points required many ‘last observations’ to be 
carried forward, and somewhat compromised the 
robustness of these estimates.
Owing to a lack of head-to-head trials of different 
bDMARDs, the manufacturer undertook random 
effects ICMs to gain an estimate of their relative 
clinical effectiveness.
The effectiveness of CZP relative to other 
bDMARDs was based on ACR 20, ACR 50 and 
ACR 70 outcomes measured at 12 and 24 weeks in 
various trials analysed by ICM. The robustness of 
these comparisons was potentially compromised by 
the high withdrawal rates in the CZP trials relative 
to those observed in the other included trials.
For combination therapy ACR responses at 24 
weeks, the ICM included 10 trials [two with CZP 
(RAPID 1 and 2), three with adalimumab, two 
with inliximab and one each with etanercept, 
rituximab and tocilizumab]. Seven trials were used 
for responses at 12 weeks [two with CZP (RAPID 
trials), two with etanercept and one each with 
adalimumab, inliximab and tocilizumab]. For 
monotherapy ACR responses at 12 and 24 weeks, 
the ICM included four trials (two with adalimumab 
and one each with CZP and etanercept).
The reported results from the ICMs (odds ratios) 
were associated with considerable uncertainty and 
there were some errors in the reported values for 
ACR 70. Of the 85 indirect comparisons made 
between pairs of bDMARDs, only four reached 
statistical signiicance. Two of these were for 
superiority of CZP at 24 weeks in the ACR 20 
outcome.
Several aspects of the ICMs reported by the 
manufacturer were a cause of concern:
(a) The inclusion and exclusion of studies for the 
ICM did not appear to be systematic.
(b) The inclusion of data from the included 
studies lacked some consistency.
(c) There was a possibility that relevant 
information from several excluded studies, 
including an unpublished industry sponsored 
randomised trial of CZP + MTX versus 
MTX + placebo (study C87014), could have 
been used in the ICM.
(d) There was insuficient consideration and 
exploration of underlying heterogeneity 
amongst the studies included for ICM.
(e) The development of effectiveness input for 
the economic analysis included data for a 
bDMARD comparator omitted from the 
subsequent economic analysis, raising the issue 
of whether data for other omitted bDMARDs 
should also have been included.
(f) The development of clinical effectiveness 
input for the economic analysis used a 
point estimate derived by aggregation 
across trial control arms and sacriiced 
some of the strengths of randomisation and 
underestimated associated uncertainty.
The validity of ICM rests on an assumption of 
exchangeability between trials such that the 
placebo arms of the trials are interchangeable. 
The submission lacked an assessment or discussion 
of clinical or statistical heterogeneity amongst 
the trials used for ICM and did not comment on 
whether baseline characteristics of participants 
were similar across these RCTs. As such there 
was no consideration of potential sources of non-
comparability of the placebo-controlled arms of the 
trials.
The ERG undertook an analysis of the 
heterogeneity amongst the control arms of the 
studies used in the estimation of effectiveness for 
the 24-week ACR 20 outcome for combination 
therapy. This choice was made because it involved 
the largest number of studies and the largest 
number of events. The results are shown in 
Figure 1. Data for four study level variables (chosen 
by the ERG) are also included in the igure.
The control rate in the two CZP RCTs was the 
lowest amongst the 10 trials, and the I2 statistic 
indicated considerable heterogeneity. When the 
two CZP studies were omitted from the analysis, 
the I2 statistic was reduced to 70% and the pooled 
estimate increased to 28%.
The four study level variables that were looked 
at as potential contributors to the observed 
heterogeneity were: entry level MTX dose as a 
potential indicator of treatment intensity and 
population differences; percentage withdrawals 
for the ACR 20 outcome as indicator of 
completeness of data; duration of RA; and number 
of previous DMARDs trialed as indicators of 
possible population differences. For each of these 
variables the two CZP RCTs were at the extreme 
of the distributions. The brief examination of 
heterogeneity amongst the studies used for ICMs 
indicated that an indirect comparison or mixed-
&HUWROL]XPDESHJROIRUWKHWUHDWPHQWRIUKHXPDWRLGDUWKULWLV
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FIGURE 1 5LVNRI$&5LQSODFHERSOXV07;DUPVRIWULDOVXVHGIRU,&0DWPRQWKV $&5 $PHULFDQ&ROOHJHRI5KHXPDWRORJ\&,
FRQÀGHQFHLQWHUYDO'0$5'VGLVHDVHPRGLI\LQJDQWLUKHXPDWLFGUXJV07;PHWKRWUH[DWH
Study
MTX
mg/wk
%
Loss
Previous 
DMARDs
Disease
duration % Risk (95% Cl)
Certolizumab + MTX
RAPID 24 12.2 79 1.2 5.6 8.66 (4.40 to 14.97)
RAPID 13 13.4 62 1.4 6.2 13.57 (9.14 to 19.12)
Adalimumab + MTX
ARMADA9 16.5 unclear 2 11.1 14.52 (6.86 to 25.78)
Kim 200710 16.3 37.5 1 to 2 6.9 36.51 (24.73 to 49.60)
Keystone 200411 16.7 30 1.4 10.9 29.50 (23.28 to 36.34)
Etanercept + MTX
Weinblatt 199912 18 20 1.8 13 25.81 (12.28 to 45.89)
Infliximab + MTX
START13 15 17 1.3 8.4 23.97 (19.67 to 28.70)
ATTEST14 16.6 3 NR 8.4 41.82 (32.48 to 51.61)
Rituximab + MTX
Strand 200615 13.7 8 2.6 11 37.50 (22.73 to 54.20)
Tocilizumab + MTX
OPTION16 14.8 39 1.7 7.8 26.47 (20.55 to 33.08)
Overall Overall (I2 = 87.1%, p = 0.000) 23.78 (21.60 to 26.04)
0 20 40 55
% ACR 20
treatment analysis with methods that allow for 
differences in control rate or baseline risk (similar 
to the Bayesian analyses undertaken by Nixon et 
al.17) probably represents the preferred choice of 
methodology for the decision problem.
Regarding the economic model, the robustness of 
quality of life and health-utility inputs was dificult 
to determine through lack of detail of how many 
patients were given HRQoL questionnaires and 
what response rates were elicited. It was not clear 
how this uncertainty might affect the estimates of 
cost-effectiveness generated by the model.
Adverse event costs as well as their related health 
outcomes were not included in the revised model 
although they were included in the original 
submission. There was a lack of information 
to justify this revision, so it was unclear what 
sources of data were used in this exercise. An 
assumption of no difference in adverse effects 
between drugs (CZP, inliximab, adalimumab, 
etanercept, rituximab) may on average be shown 
to be reasonable, but on the basis of the submitted 
information the assumption cannot be considered 
to be evidence based.
Conclusions
Certolizumab pegol is an effective therapy for adult 
RA patients whose disease has failed to respond 
adequately to cDMARDs including MTX or who 
are intolerant of MTX.
A reasonable interpretation of the results is that 
there is little convincing evidence that CZP is more 
or less effective than the comparators examined.
Patients with RA may respond differently to 
different bDMARDs and effectiveness of a 
bDMARD for a speciic patient is currently 
unpredictable; an increase in the variety of 
available bDMARDs might potentially increase the 
overall proportion of patients responsive to these 
drugs.
The cost-effectiveness of CZP relative to other 
bDMARD is unclear because the economic 
modelling undertaken may have ignored relevant 
effectiveness data and potential differences 
between trial populations, and so may have 
included effectiveness results that were biased 
in favour of CZP; underestimated uncertainty in 
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the relative effectiveness of compared DMARDs; 
and ignored the potential inluence of differences 
between bDMARDs with regard to adverse events 
and their related costs and health impacts.
Summary of NICE guidance 
issued as a result of the STA
At the time of drafting this report, the guidance 
appraisal consultation document issued by NICE in 
October 2009 states that:
1.1 The Committee is minded not to recommend 
certolizumab pegol as a treatment option for 
people with rheumatoid arthritis (RA).
1.2 The Committee recommends that NICE 
asks the manufacturer of certolizumab pegol for 
more information on the clinical effectiveness and 
cost-effectiveness of certolizumab pegol for the 
treatment of people with RA. This information 
should be made available for the second Appraisal 
Committee meeting, and should cover the 
following issues:
Estimation of the clinical effectiveness of 
certolizumab pegol relative to other TNF-F 
inhibitors for the treatment of RA, including 
consideration of uncertainty around the estimate. 
In order to clarify this issue the Committee 
requests:
t provision of a mixed-treatment comparison 
(MTC) analysis, rather than an indirect 
comparison meta-analysis
t details of potentially relevant studies, including 
study C87014, that were excluded from the 
analysis
t provision of data from the C87014 trial 
and an assessment of the impact on the 
incremental cost-effectiveness ratios (ICERs) 
when the American College of Rheumatology 
(ACR) response for certolizumab pegol in 
combination with methotrexate is calculated 
using data from the C87014 plus the RAPID 1 
and 2 trials.
Clariication of how the original economic model 
was revised:
t further justiication of why a utility decrease 
of 0.037 per year after assessment of clinical 
response at 6 months was assumed in the 
original model, but a utility increase of 0.0402 
per year was assumed in the revised model
t further details of how the assumed utility 
decrease of 0.0025 per year when treatment is 
discontinued was derived
t clariication and a full breakdown of the direct 
and indirect costs included in the model, 
including an explanation of why the mean cost 
for the intervention and comparators differed 
between the original and revised models, and 
an explanation of how these changes relate to 
costs associated with adverse events
t clariication of how incorporating an estimated 
relationship between ACR 20, 50 and 70 would 
affect cost effectiveness in the revised model.
Provision of an incremental cost-effectiveness 
analysis:
t comparing certolizumab pegol with other 
TNF-F inhibitors (that is, not including 
rituximab)
t including univariate sensitivity analysis 
exploring the effect of lowering the estimate 
for the cost of administering inliximab in 
line with the range of costs used in previous 
appraisals
t including a comparison of all treatments 
with full reporting of results of probabilistic 
sensitivity analysis, including but not limited to 
presentation of cost-effectiveness acceptability 
curves, with all treatments plotted and a 
scatter plot of all treatments on the same cost-
effectiveness plane.
The manufacturer responded to the ACD with 
a new submission that incorporated a MTC that 
included the industry sponsored CZP study C87014 
and two additional studies previously excluded 
from the ICMs. The major change to the economic 
analysis was the introduction of a DOH-approved 
patient access scheme (PAS) that considerably 
reduced the initial cost of CZP treatment by 
making early treatment syringes free of charge.
The MTC more faithfully relected the inherent 
uncertainty in the estimates of relative effectiveness 
of the compared DMARDs (Figure 2) and the PAS 
improved the cost-effectiveness of CZP treatment. 
The main new cost-effectiveness results submitted 
are summarised in Table 2.
The inal appraisal document for this technology 
was issued by NICE shortly before this article was 
sent to press. The appraisal document states:
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TABLE 2 0DQXIDFWXUHU·VUHYLVHGFRVWHIIHFWLYHQHVVUHVXOWVLQFRUSRUDWLQJPL[HGWUHDWPHQWFRPSDULVRQRIHIIHFWLYHQHVVDQG'2+DSSURYHG
SDWLHQWDFFHVVVFKHPH
Mean cost (£) Mean QALYs ICER
Combination therapy
CZP + MTX 85,583 6.654 
Etanercept + MTX 86,165 6.589 CZP dominates
Adalimumab + MTX 86,034 6.412 CZP dominates
Rituximab + MTX 82,940 6.362 9072
,QÁL[LPDE07; 95,599 6.196 CZP dominates
Monotherapy
CZP 81,849 6.305 
Etanercept 85,941 6.435 (31,582)a
Adalimumab 84,201 6.09 CZP dominates
CZP, certolizumab pegol; ICER, incremental cost-effectiveness ratio; MTX, methotrexate; QALYs, quality-adjusted life-years.
a ICER for etanercept compared with CZP.
INDIRECT MTC
ACR 20 odds ratio
CZP + MTX vs Placebo + MTX 10.57 11.12
CZP + MTX vs Adalimumab + MTX 2.17 2.18
CZP + MTX vs Etanercept + MTX 1.56 1.54
CZP + MTX vs Infiximab + MTX 3.64 3.82
CZP + MTX vs Rituximab + MTX 2.41 2.46
CZP + MTX vs Toclizumab + MTX 2.70 2.85
ACR 50 odds ratio
CZP + MTX vs Placebo + MTX 9.08 10.01
CZP + MTX vs Adalimumab + MTX 1.35 1.35
CZP + MTX vs Etanercept + MTX 0.49 0.32
CZP + MTX vs Infiximab + MTX 2.74 2.98
CZP + MTX vs Rituximab + MTX 1.75 1.84
CZP + MTX Toclizumab + MTX 1.40 1.51
ACR 70 odds ratio
CZP + MTX vs Placebo + MTX 10.18 12.76
CZP + MTX vs Adalimumab + MTX 1.61 1.85
CZP + MTX vs Etanercept + MTX 0.89 0.43
CZP + MTX Infiximab + MTX 3.10 3.78
CZP + MTX vs Rituximab + MTX 1.85 1.89
CZP + MTX vs Toclizumab + MTX 0.72 0.83
Odds ratio (log scale)
0.01 0.1 1 10 100
FIGURE 2 0DQXIDFWXUHU·VUHVXOWVIRU,&0KROORZV\PERODQG07&VROLGV\PEROZLWKDVVRFLDWHGXQFHUWDLQW\$&5RXWFRPHV
$&5 $PHULFDQ&ROOHJHRI5KHXPDWRORJ\&=3FHUWROL]XPDESHJRO07&PL[HGWUHDWPHQWFRPSDULVRQ07;PHWKRWUH[DWH
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Cetolizumab pegol is recommended as an option 
for the treatment of people with rheumatoid 
arthritis only if:
t certolizumab pegol is used as described for 
other tumour necrosis factor (TNF) inhibitor 
treatments in ‘Adalimumab, etanercept and 
inliximab for the treatment of rheumatoid 
arthritis (NICE technology appraisal guidance 
130) and
t the manufacturer provides the irst 12 weeks 
of certolizumab pegol (10 pre-loaded 200-mg 
syringes) free of charge to all patients starting 
treatment.
Key references
1. NICE. Guide to single technology (STA) 
process. 2006. URL: www.nice.org.uk/page.
aspx?o=STAprocessguide.
2. Connock MJ, Tubeuf S, Malottki K, Uthman 
A, Round J, Bayliss S, et al. Certolizumab pegol 
(CIMZIA®) for the treatment of Rheumatoid 
Arthritis. URL: www.nice.org.uk/guidance/index.
jsp?action=download&o=45795.
3. Keystone E, Heijde DV, Mason D, Jr., Landewe 
R, Vollenhoven RV, Combe B, et al. Certolizumab 
pegol plus methotrexate is signiicantly more 
effective than placebo plus methotrexate in active 
rheumatoid arthritis: Findings of a ifty-two-week, 
phase III, multicenter, randomized, double-blind, 
placebo-controlled, parallel-group study. Arthritis 
Rheum 2008;58:3319–29.
4. Smolen J, Landewe RB, Mease P, Brzezicki J, 
Mason D, Luijtens K, et al. Eficacy and safety 
of certolizumab pegol plus methotrexate in 
active rheumatoid arthritis: the RAPID 2 study. 
A randomised controlled trial. Ann Rheum Dis 
2009;68:797–804.
5. Fleischmann R, Vencovsky J, van Vollenhoven 
RF, Borenstein D, Box J, Coteur G, et al. Eficacy 
and safety of certolizumab pegol monotherapy 
every 4 weeks in patients with rheumatoid arthritis 
failing previous disease-modifying antirheumatic 
therapy: the FAST4WARD study. Ann Rheum Dis 
2009;68:805–11.
6. Bucher HC, Guyatt GH, Grifith LE, Walter SD. The 
results of direct and indirect treatment comparisons 
in meta-analysis of randomized controlled trials. 
J Clin Epidemiol 1997;50:683–91.
7. Felson DT, Anderson JJ, Boers M, Bombardier 
C, Furst D, Goldsmith C, et al. American College 
of Rheumatology. Preliminary deinition of 
improvement in rheumatoid arthritis. Arthritis 
Rheum 1995;38:727–35.
8. Brennan A, Bansback N, Nixon R. Modelling the 
cost effectiveness of TNF-a inhibitors in the management 
of rheumatoid arthritis: results from the British Society 
for Rheumatology Biologics Registry. University of 
Shefield ScHARR; 2006. Report No.: 06/12.
9. Weinblatt M, Keystone E, Furst D, Moreland L, 
Weisman M, Birbara C, et al. Adalimumab, a fully 
human anti-tumor necrosis factor alpha monoclonal 
antibody, for the treatment of rheumatoid arthritis 
in patients taking concomitant methotrexate: The 
ARMADA Trial. Arthritis Rheum 2003;48:35–45.
10. Kim H-Y. A randomized, double-blind, placebo-
controlled, phase III study of the human anti-tumor 
necrosis factor antibody adalimumab administered 
as subcutaneous injections in Korean rheumatoid 
arthritis patients treated with methotrexate. APLAR 
Journal of Rheumatology 2007;10:9–16.
11. Keystone E, Kavanaugh A, Sharp J, Tannenbaum 
H, Hua Y, Teoh L, et al. Radiographic, Clinical, 
and Functional Outcomes of Treatment with 
Adalimumab (a human anti-tumour necrosis 
factor monoclonal antibody) in patients with 
active rheumatoid arthritis receiving concomitant 
methotrexate therapy: a randomized, placebo-
controlled 52-week trial. Arthritis Rheum 
2004;50:1400–11.
12. Weinblatt M, Kremer J, Bankhurst A, Bulpitt K, 
Fleischmann R, Fox R, et al. A Trial of Etanercept, 
a Recombinant Tumor Necrosis Factor Receptor: 
Fc fusion protein, in patients with Rheumatoid 
Arthritis receiving Methotrexate. N Engl J Med 
1999;340:253–9.
13. Westhovens R, Yocum D, Han J. The safety of 
inliximab, combined with background treatments, 
among patients with rheumatoid arthritis and 
various comorbidities: a large, randomized, 
placebo-controlled trial. Arthritis Rheum 
2006;54:1075–86.
14. Schiff M, Keiserman M. Eficacy and safety of 
abatacept or inliximab vs placebo in ATTEST: 
a phase III, multi-centre, randomised, double-
blind, placebo-controlled study in patients with 
rheumatoid arthritis and an inadequate response to 
methotrexate. Ann Rheum Dis 2008;67:1096–103.
15. Strand V, Balbir-Gurman A, Pavelka K. Sustained 
beneit in rheumatoid arthritis following one 
&HUWROL]XPDESHJROIRUWKHWUHDWPHQWRIUKHXPDWRLGDUWKULWLV
10
course of rituximab: improvements in physical 
function over 2 years. Rheumatology (Oxford) 
2006;45:1505–13.
16. Smolen JSB. Effect of interleukin-6 receptor 
inhibition with tocilizumab in patients with 
rheumatoid arthritis (OPTION study): a double-
blind, placebo-controlled, randomised trial. Lancet 
2008;371:987–97.
17. Nixon RM, Bansback N, Brennan A. Using mixed 
treatment comparisons and meta-regression to 
perform indirect comparisons to estimate the 
eficacy of biologic treatments in rheumatoid 
arthritis. Stat Med 2007;26:1237–54.
Health Technology Assessment 2010; Vol. 14: Suppl. 2
© 2010 Queens Printer and Controller of HMSO. All rights reserved.
11
Capecitabine for the treatment of advanced 
gastric cancer
G Norman,* M Soares, P Peura, S Rice, D Suh, K Wright,  
M Sculpher and A Eastwood
Centre for Reviews and Dissemination, University of York, York, UK
*Corresponding author
'HFODUHGFRPSHWLQJLQWHUHVWVRIDXWKRUVM Sculpher has a minority shareholding in a consulting company 
that has undertaken work for Roche during the last 3 years, but not in the clinical area of gastric cancer. He did 
not participate personally in this consultancy. M Seymour is a co-investigator in a trial (321GO), which includes 
capecitabine as treatment for patients with advanced gastroesophageal cancer. The trial is peer reviewed and 
IXQGHGE\&DQFHU5HVHDUFK8.EXWDOVRUHFHLYHVVRPHVXSSOHPHQWDU\ÀQDQFLDOVXSSRUWIURP5RFKHNRYHU
2 years). M Seymour also attended the ASCO Oncology Conference last year as a guest of Roche. D Suh is also a 
co-investigator on the 321GO study. Roche have also offered to sponsor his trip to ASCO this year. Stephen Kelly 
DFFHSWHGÀQDQFLDOVXSSRUWIURP5RFKHLQDQGWRDWWHQGWKH%ULWLVK2QFRORJ\3KDUPDFLVWV$VVRFLDWLRQ
Annual Symposium on behalf of the Leeds Teaching Hospitals NHS Trust Pharmacy Department.
HTA 08/85/01
'DWHRI(5*VXEPLVVLRQ  
16 February 2010
7$5&HQWUHV 
CRD and CHE Technology Assessment Group
/LVWRIDXWKRUV  
G Norman, M Soares, P Peura, S Rice, D Suh, 
K Wright, M Sculpher and A Eastwood
&RQWDFWGHWDLOV 
Gill Norman, Centre for Reviews and Dissemination, 
University of York, York YO10 5DD, UK
E-mail: gn5@york.ac.uk
The research reported in this article of the journal 
supplement was commissioned and funded by the HTA 
programme on behalf of NICE as project number 08/95/01. 
The assessment report began editorial review in June 2010 
and was accepted for publication in July 2010. See the 
HTA programme website for further project information 
(www.hta.ac.uk). This summary of the ERG report was 
compiled after the Appraisal Committees review.
The views and opinions expressed therein are those of 
WKHDXWKRUVDQGGRQRWQHFHVVDULO\UHÁHFWWKRVHRIWKH
Department of Health.
Discussion of ERG reports is invited. Visit the HTA website 
correspondence forum (www.hta.ac.uk/correspond).
Abstract
This paper presents a summary of the evidence 
review group (ERG) report into capecitabine for 
advanced gastric cancer (aGC). Capecitabine is an 
oral prodrug of 5-luorouracil (5-FU). The decision 
problem addressed was the use of capecitabine (X) 
compared to 5-FU (F), in combination regimens 
with platinum agents [cisplatin (C) or oxaliplatin 
(O)] with or without epirubicin (E), in patients with 
inoperable aGC. Approximately 7000 new cases 
of gastric cancer are diagnosed in England and 
Wales every year. Of these, 80% are candidates for 
palliative chemotherapy and around 2900 receive 
such treatment. The standard UK practice for 
patients with aGC who are considered it enough 
has consisted of a triplet regimen comprising 
intravenous 5-FU in combination with a platinum 
agent (capecitabine or oxaliplatin) and epirubicin.
The manufacturer’s submission (MS) focused on 
direct evidence from two phase III non-inferiority 
randomised controlled trials (RCTs), REAL-2 
(Randomized ECF for Advanced and Locally 
advanced oesophagogastric cancer-2; n = 1002) and 
ML17032 (n = 316). REAL-2 randomised patients 
to four regimens (ECF, ECX, EOF and EOX) to 
compare 5-FU with capecitabine and cisplatin 
with oxaliplatin, whereas ML17032 compared CX 
with CF. Eficacy outcomes from these trials were 
DOI: 10.3310/hta14suppl2/02
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pooled in an individual patient data (IPD) meta-
analysis. Both RCTs demonstrated statistically 
signiicant non-inferiority of capecitabine on the 
outcome of overall survival (OS) assessed in the 
per-protocol population; equivalent results were 
also demonstrated for progression-free survival 
(PFS). The IPD meta-analysis found a statistically 
signiicant beneit in OS for capecitabine 
compared with 5-FU [unadjusted hazard ratio 
(HR): 0.87; 95% conidence interval (CI) 0.77 
to 0.98, p = 0.027]. There was no evidence of a 
poorer safety proile for capecitabine overall, nor 
of any difference in quality of life (QoL) between 
the two luoropyrimidines. The MS included a 
de novo economic evaluation based on a cost-
minimisation analysis (CMA), where the costs 
of capecitabine-based regimens were compared 
with their equivalent 5-FU-based regimens in 
aGC. A time horizon of 5.5 cycles (each lasting 
for 21 days) was used in the base-case analysis, 
representing the duration of treatment. The results 
of the manufacturer’s base-case analysis showed 
that capecitabine regimens are associated with 
mean net cost savings of £1620 (ECX vs ECF), 
£1572 (EOX vs EOF) and £4210 (CX vs CF). The 
manufacturer failed to comment explicitly on the 
uncertainty around the estimates of eficacy and 
on the fact that the IPD meta-analysis suggests 
that capecitabine may actually be more effective 
on average. Further analyses exploring additional 
costs incurred by the UK NHS from extending 
survival duration showed that these are unlikely 
to have a material effect on conclusions. A full 
probabilistic analysis was not performed; however, 
the evidence explored by the MS and ERG is 
consistent in suggesting that capecitabine has a 
lower mean cost than 5-FU-based regimens. The 
submission was considered to contain convincing 
evidence of the non-inferiority of capecitabine to 
5-FU on survival; this evidence was considered 
to be applicable to UK practice. Although some 
uncertainty remains, the ERG deemed CMA to be 
an appropriate framework with which to analyse 
this decision problem. Overall cost estimates for 
the CMA were generated appropriately and were 
robust to uncertainties regarding assumptions 
and sources. At the time of writing, the guidance 
document issued by NICE on 28 July 2010 states 
that capecitabine in combination with a platinum-
based regimen is recommended for the irst-line 
treatment of inoperable advanced gastric cancer.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) 
process1 is speciically designed for the appraisal 
of a single product, device or other technology, 
with a single indication, where most of the 
relevant evidence lies with one manufacturer 
or sponsor (Roche). Typically, it is used for new 
pharmaceutical products close to launch. The 
principal evidence for an STA is derived from a 
submission by the manufacturer/sponsor of the 
technology. In addition, a report reviewing the 
evidence submission is prepared by the evidence 
review group (ERG), an external organisation 
independent of the Institute. This paper presents 
a summary of the ERG report for the STA entitled 
‘Capecitabine for the treatment of advanced gastric 
cancer’.2
Description of the underlying 
health problem
Gastric cancer is the 10th most commonly 
diagnosed cancer in the UK, with approximately 
7000 new cases diagnosed in England and 
Wales every year. Of these, some 80% of patients 
are unsuitable for curative treatment and are 
candidates for palliative chemotherapy. It is 
estimated that just over one-half (around 2900) of 
these patients with advanced gastric cancer (aGC) 
receive such treatment.
The standard UK practice for patients with aGC, 
who are considered it enough, has consisted of 
a triplet regimen comprising a luoropyrimidine, 
intravenous 5-luorouracil (5-FU) in combination 
with a platinum agent (cisplatin or oxaliplatin) and 
an anthracycline (epirubicin).
Scope of the ERG report
The decision problem addressed was the use 
of capecitabine (Xeloda) in combination with 
platinum-based chemotherapy regimens (cisplatin 
or oxaliplatin) with or without epirubicin, 
compared with 5-FU in combination with such 
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regimens, in patients with inoperable aGC. 
Capecitabine is an oral prodrug of 5-FU, and is 
licensed for the irst-line treatment of aGC in 
combination with a platinum-based regimen. 
Oral chemotherapies are usually considered to 
be preferred by patients and may have fewer 
associated costs and/or adverse events.
The outcome measures considered were overall 
survival (OS), progression-free survival (PFS), 
response rates, adverse effects of treatment and 
health-related quality of life (QoL). These were 
assessed in direct comparisons by two open-label 
non-inferiority randomised controlled trials 
(RCTs), assessing doublet or triplet regimens.3,4
Economic outcomes included cost per life-year 
gained (LYG) and cost per quality-adjusted life-
year (QALY) gained. The manufacturer proposed 
evaluating the cost-effectiveness of capecitabine-
based regimens compared with 5-FU-based 
regimens by using cost-minimisation analyses 
(CMAs).
Methods
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology, based upon the 
manufacturer’s/sponsor’s submission (MS) to NICE 
as part of the STA process. The ERG checked the 
literature searches and carried out a search for 
ongoing trials. The review methodology including 
inclusion criteria was appraised. The validity 
assessments of the included RCTs were critiqued 
and the ERG carried out its own assessment using 
the CRD guidelines for the critical appraisal of 
RCTs.
In evaluating the cost effectiveness of capecitabine, 
the manufacturer used a cost-minimisation 
approach. The ERG has thus irst commented on 
the appropriateness of using such methodology, 
within this speciic decision problem, taking into 
consideration NICE’s reference case methods.5 
Next, the ERG assessed the manufacturer’s de 
novo economic evaluation using Drummond et 
al.’s checklist.6 In response to the ERG’s points of 
clariication regarding the initial submission, the 
manufacturer provided additional evidence on the 
costs of adverse events, drug acquisition inputs and 
costs of additional survival. The ERG considered 
this evidence throughout. Based on the identiied 
limitations in the MS, the ERG revisited the base 
case according to drug use, unit costs of treatments 
and pharmacy drug preparation costs. The ERG 
also undertook additional sensitivity analyses 
based on the revised base case, and conducted 
a threshold analysis, evaluating the maximum 
costs that the NHS would be willing to pay for the 
extension of survival time implied by prespeciied 
cost-effectiveness thresholds.
Results
Summary of submitted 
clinical evidence
The MS focused on direct evidence from two phase 
III non-inferiority RCTs.3,4
Eficacy outcomes from these trials were 
pooled in an individual patient data (IPD) 
meta-analysis.7 REAL-2 (Randomized 
ECF for Advanced and Locally advanced 
oesophagogastric cancer-2) was a 2 w 2 factorial 
trial that compared 5-FU with capecitabine 
and cisplatin with oxaliplatin.3 The following 
regimens were used: epirubicin + cisplatin + 5-FU 
(ECF); epirubicin + cisplatin + capecitabine 
(ECX); epirubicin + oxaliplatin + 5-FU (EOF); 
and epirubicin + oxaliplatin + capecitabine 
(EOX). A second trial, ML17032, compared 
cisplatin + capecitabine (CX) with cisplatin + 5-FU 
(CF).4
REAL-2 found statistically signiicant non-
inferiority of capecitabine on the primary 
outcome of OS assessed in the per-protocol 
population adjusted [hazard ratio (HR) 0.89, 95% 
conidence interval (CI) 0.77 to 1.02]. ML17032 
found statistically signiicant non-inferiority of 
capecitabine on the primary outcome of PFS in 
the per-protocol population (adjusted HR 0.85, 
95% CI 0.65 to 1.11). Statistically signiicant non-
inferiority on OS (unadjusted HR 0.85, 95% CI 
0.64 to 1.13) was also demonstrated.
The IPD meta-analysis of the intention-to-treat 
(ITT) populations of the REAL-2 and ML17032 
trials found a statistically signiicant beneit in OS 
for capecitabine compared with 5-FU (unadjusted 
HR 0.87, 95% CI 0.77 to 0.98, p = 0.027).7
There was minimal QoL data reported in the MS. 
The REAL-2 trial was reported as assessing QoL 
using the European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire 
C30 (EORTC-30), version 3,8 administered at 
baseline, and after 3, 6, 9 and 12 months. The 
manufacturer subsequently provided the levels 
of compliance, data on the baseline scores for all 
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subscales, and changes from baseline at 12 weeks 
and 24 weeks for the REAL-2 trial. These showed 
few statistically signiicant differences between the 
individual trial arms.
Safety analyses showed some signiicant differences 
in adverse events proiles between capecitabine 
and 5-FU regimens. However, in the REAL-2 trial, 
all statistical analyses were pairwise comparisons 
with the ECF arm, which the trial was not powered 
to assess. Of particular note was grade 3 or 4 
neutropenia, which occurred signiicantly more 
often in the ECX arm (p < 0.05) and signiicantly 
less often in the EOX and EOF arms (p < 0.01) 
compared with the ECF arm; grade 3 or 4 
diarrhoea, which occurred signiicantly more often 
in the EOX and EOF arms compared with the 
ECF arm (p < 0.05); and grade 3 or 4 hand–foot 
syndrome, which occurred signiicantly more 
often in the ECX arm compared with the ECF 
arm (p < 0.05). In the ML17032 trial, stomatitis 
occurred more often, and with greater severity, in 
the CF arm, while hand–foot syndrome was more 
common in the CX arm.
Summary of submitted cost-
effectiveness evidence
The manufacturer’s literature search identiied 
one economic evaluation relevant to this decision 
problem. This was Roche’s 2007 submission to the 
Scottish Medicines Consortium for capecitabine in 
this indication. The methods and results reported 
are consistent with the current submission.
The MS included a de novo economic evaluation 
based on a CMA, where the costs of capecitabine-
based regimens were compared with their 
equivalent 5-FU-based regimens (ECX vs ECF, 
EOX vs EOF, CX vs CF) in the treatment of 
advanced gastric cancer. A time horizon of 5.5 
cycles (each lasting for 21 days) was used in the 
base-case analysis, representing the duration of 
treatment of the alternative regimens.
The cost-minimisation approach was based on 
evidence from two clinical trials – REAL-2 and 
ML17032 – reporting that capecitabine is at least 
as effective as intravenous 5-FU (see above). The 
calculations considered costs relating to drug 
acquisition and to drug administration. The 
drug administration costs comprised the costs of 
TABLE 1 'UXJDGPLQLVWUDWLRQDFWLYLWLHVFRVWHGIRUHDFKF\FOHRIDWUHDWPHQWUHJLPHQDQGWKHGD\VLQHDFKF\FOHRIGD\VGXULQJZKLFK
WKHDFWLYLW\WDNHVSODFH
Activity/component Activity cost (£)
ECF and 
EOF
ECX and 
EOX CF CX
Line insertion 445.77 Day 1a Day 1a
Drug delivery, 1st attendance; 
outpatient/day case
281.45 Day 1 Day 1 Day 1b Day 1
Drug delivery, subsequent 
DWWHQGDQFHVQXUVHFRVWWRÁXVK
central line a change pump
36.83 Days 7, 14
Drug delivery, subsequent 
attendances; outpatient/day case
198.72 Days 24b
Drug delivery; inpatient stay 5 
days
1435.64 Days 15c
Pump cost 38.50 Days 1, 7, 14
Transport cost (20% of patients) 28.43 Days 1, 7, 14 Day 1 Days 15
Pharmacy preparation Complex 
(intravenous): 41.87
Days 7, 14 
Complex
Day 1 
Simple
Days 15 
Complex
Day 1 
Simple
Simple (oral): 25.34
CF, cisplatin + 5-FU; CX, cisplatin + capecitabine; ECF, epirubicin + cisplatin + 5-FU; ECX, epirubicin + cisplatin + 
FDSHFLWDELQH(2)HSLUXELFLQR[DOLSODWLQ)8(2;HSLUXELFLQR[DOLSODWLQFDSHFLWDELQH)8ÁXRURXUDFLO
D /LQHLQVHUWLRQZDVRQO\FRQVLGHUHGDWWKHVWDUWRIWKHÀUVWF\FOH
b Base-case activity.
c Activity in scenario analysis, which replaces the outpatient/day case drug-delivery activities.
Shaded cells indicate that the activity was not costed for the regimen.
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hospital visits (central line insertion, delivery of 
chemotherapy, and subsequent care by a nurse 
to lush central line and change the pump), 
pharmacy drug preparation costs, ambulatory 
pump costs and NHS transport costs (Table 1). 
The manufacturer assumed that there were no 
signiicant economically important differences 
in the incidence or severity of adverse events 
between capecitabine and 5-FU-based regimens, 
and therefore the costs of treatment-related 
adverse events were not included in the analysis. 
After a request for clariications, the manufacturer 
presented the expected costs associated with the 
relevant adverse events.
The results of the manufacturer’s base-case 
analysis showed that capecitabine regimens are 
cost saving compared with their equivalent 5-FU-
based regimens. The total net cost savings for 
capecitabine-based regimens were £1620 (ECX 
vs ECF), £1572 (EOX vs EOF), and £4210 (CX 
vs CF). Capecitabine remained cost saving in 
the manufacturer’s one-way sensitivity analysis, 
scenario analysis and worst-case analysis. The 
manufacturer did not conduct probabilistic 
sensitivity analysis or subgroup analysis. The 
submission also included a threshold analysis that 
explored the additional effectiveness (in terms of 
QALYs) needed for 5-FU to be considered cost-
effective.
Commentary on the robustness 
of submitted evidence
The MS appears to include all relevant evidence 
from completed RCTs with respect to the question 
of eficacy; the ERG’s search revealed no additional 
completed RCTs, although one additional ongoing 
trial was located.
The ERG identiied a number of issues and errors 
in the review process, which had the potential 
to exclude relevant studies. However, it did not 
appear that this had impacted on the results of the 
review.
Two RCTs that directly addressed the comparison 
between capecitabine and 5-FU in combination 
with platinum in the licensed population were 
included.
The REAL-2 trial was large (n = 1002), adequately 
powered, and closely relective of UK standard 
practice. The patient population was also 
representative of those UK patients who were 
considered it enough for standard chemotherapy, 
although these patients are signiicantly younger 
than the UK aGC patient population as a whole. 
The trial included a majority of patients who 
are outside the licensed indication, having 
advanced inoperable cancer of the oesophagus 
or gastroesophageal junction. The ERG’s clinical 
experts conirmed that treatment for each of these 
cancers would follow the same course as that for 
advanced inoperable gastric cancer. There was also 
no evidence of a statistically signiicant difference 
in prognosis based on primary tumour location.9
The ML17032 (n = 316) trial assessed doublet 
therapy, which the ERG’s clinical advisors indicated 
would be used in patients who were considered 
unable to tolerate triplet therapy. However, such 
doublets would be given at a lower dose than was 
used in the trial. The trial population was also 
unrepresentative of UK patients, being younger 
and having a different ethnic composition. When 
the non-inferiority analyses of eficacy outcomes 
were performed using a margin of 1.25 relative 
to the eficacy of 5-FU, rather than 1.40 as the 
protocol had speciied, the trial had only 50% 
power to detect statistically signiicant non-
inferiority.
Both trials were necessarily open-label, and 
REAL-2 was unblinded for all outcomes, whereas 
for ML1703 the MS reported blinded outcome 
assessment only for the primary outcome of PFS. 
The ERG requested these independently assessed 
data for the outcomes of tumour response and 
adverse events. The manufacturer subsequently 
supplied these data for response rates and, 
although differences in the data sets were present, 
there was no indication of systematic bias.
The primary weakness of the initial MS was the 
limited QoL data. This is of particular importance 
where the decision problem centres on an issue of 
clinical non-inferiority and patient preference.
With respect to economic evaluation, the ERG 
deems CMA to be an appropriate framework with 
which to analyse the decision problem. However, it 
should be noted that the appropriateness of using 
such an approach is dependent not only on clinical 
evidence from the REAL-2 and ML17032 trials, 
but also on evidence relating to QoL and adverse 
events. The weaknesses identiied above regarding 
the evidence presented by the manufacturer are 
therefore relevant. The manufacturer has also 
failed fully to consider uncertainty when justifying 
the use of CMA.
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Overall, cost estimates for the CMA were generated 
appropriately. The ERG identiied a number of 
shortcomings and potential uncertainties related 
to resource utilisation, unit costs, utilities and 
sensitivity analysis in the MS. However, these were 
considered minor, and additional analysis provided 
by the manufacturer, and further evaluations by the 
ERG, showed no impact on the overall conclusions. 
Results from the MS and ERG’s additional analysis 
are compared in Table 2.
A full probabilistic analysis was not performed, so 
the probabilities that capecitabine is less and more 
costly than its comparators have not been formally 
quantiied. However, the mean estimates, sensitivity 
analyses and worst-case scenario are consistent 
in suggesting that capecitabine has a lower mean 
cost than 5-FU-based regimens. Further analyses 
exploring the additional costs incurred by the NHS 
resulting from extending survival duration show 
that these are unlikely to have a material effect on 
decision-making regarding capecitabine.
Conclusions
The submission was considered to contain 
convincing evidence of the non-inferiority of 
capecitabine to 5-FU on the outcomes of OS 
and PFS; this evidence was considered to be 
applicable to UK practice. There was evidence 
of some differences in adverse event proiles, 
but there was no evidence of a poorer safety 
proile for capecitabine overall. There was also no 
evidence of any difference in QoL between the two 
luoropyrimidines.
Although some uncertainty remains over the issues 
identiied above, the ERG deems CMA to be an 
appropriate framework with which to analyse the 
current decision problem. Overall, cost estimates 
for the CMA were generated appropriately and 
were robust to uncertainties regarding assumptions 
and sources.
Summary of NICE guidance 
issued as a result of the STA
At the time of writing, the guidance document 
issued by NICE on 28 July 2010 states that: 
Capecitabine in combination with a platinum-
based regimen is recommended for the irst-line 
treatment of inoperable advanced gastric cancer.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report on the clinical 
effectiveness and cost-effectiveness of rituximab 
with chemotherapy compared to chemotherapy 
only for the treatment of relapsed/refractory 
chronic lymphocytic leukaemia (CLL) based on 
the manufacturer’s submission to the National 
Institute for Health and Clinical Excellence (NICE) 
as part of the single technology appraisal (STA) 
process. Evidence was available in the form of one 
open-label, ongoing, unpublished randomised 
controlled trial (RCT), REACH (Rituximab in 
the Study of Relapsed Chronic Lymphocytic 
Leukemia), conducted by the manufacturer, 
which compared rituximab with a ludarabine 
and cyclophosphamide combination (R-FC) to 
ludarabine and cyclophosphamide (FC) only. 
REACH was scheduled to run for 8 years; however, 
the data provided were immature, with a median 
observation time at the time of data analysis of 
2.1 years. REACH provided evidence of prolonged 
progression free survival with R-FC compared to FC 
(10 months, investigators’ data), but no evidence 
of an overall survival beneit with R-FC. Patients 
refractory to ludarabine and with prior rituximab 
exposure were excluded from REACH and no 
controlled studies were identiied by the ERG 
for these patient groups. The ERG had concerns 
about the structure of the economic model 
submitted by the manufacturer, which did not allow 
DOI: 10.3310/hta14suppl2/03
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improvement in quality of life from treatment while 
in a progressed state. The manufacturer’s model 
further assumed a divergence in cumulative deaths 
between the R-FC and FC treatment arms from the 
outset, which did not accord with observed data 
from REACH. When the survival advantage was 
removed, the manufacturer’s base-case incremental 
cost-effectiveness ratio (ICER) changed from 
£15,593 to between £40,000 and £42,000 per 
quality-adjusted life-year (QALY). With no survival 
advantage, the ICER became sensitive to changes 
in utility. There was no good empirical evidence 
on the utility of CLL patients in different states. 
Allowing for the possibility of a survival advantage 
with rituximab (although not supported by current 
evidence), the ERG performed further modelling, 
which found that rituximab would be cost-effective 
at £20,000/QALY (£30,000/QALY) if a reduction in 
survival advantage relative to the manufacturer’s 
base case of 40% (80%) was assumed. The guidance 
issued by NICE in July 2010 as a result of the 
STA recommends rituximab with FC for people 
with relapsed or refractory chronic lymphocytic 
leukaemia, except when the condition is refractory 
to ludarabine or where there has been previous 
treatment with rituximab.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process1 
is speciically designed for the appraisal of a 
single product, device or other technology, with 
a single indication, where most of the relevant 
evidence lies with one manufacturer or sponsor 
(here, Roche Products Ltd). Typically, it is used 
for new pharmaceutical products close to launch. 
The principal evidence for an STA is derived from 
a submission by the manufacturer/sponsor of the 
technology. In addition, a report reviewing the 
evidence submission is submitted by the evidence 
review group (ERG), an external organisation 
independent of NICE. This paper presents a 
summary of the ERG report for the STA entitled 
‘Rituximab for relapsed/refractory chronic lymphocytic 
leukaemia’.2
Description of the underlying 
health problem
The underlying health problem is relapsed/
progressed and refractory chronic lymphocytic 
leukaemia (CLL). CLL is deined as relapsed in a 
patient who has previously achieved the criteria 
for a complete or partial response, but after a 
period of 6 or more months demonstrates evidence 
of disease progression. Refractory disease is 
deined as treatment failure (stable disease or non-
response) or disease progression within 6 months 
of the last therapy.3 Median age at diagnosis 
lies between 65 and 70 years, so will be higher 
for relapse, and the incidence rate at diagnosis 
is 3/100,000. The proportion of patients that 
progress in a 1-year period is estimated at 30–40% 
(Dr Jim Murray, University Hospitals Birmingham, 
personal communication). Prognosis can vary 
depending on the presence or absence of various 
cytogenetic abnormalities. Loss or mutation in the 
p-arm of chromosome 17 (del 17) is associated with 
decreased survival.
Treatment of CLL is with cytotoxic drugs/drug 
combinations (chemotherapy) including alkylating 
agents (chlorambucil, cyclophosphamide, 
bendamustine) or antimetabolites/purine analogues 
(ludarabine, cladripine). Drug combinations 
are also used, such as FC (ludarabine and 
cyclophosphamide), CHOP [cyclophosphamide, 
doxorubicin hydrochloride, vincristine (also 
called oncovin), prednisolone] and CVP 
[cyclophosphamide, vincristine (also called 
oncovin), prednisolone]. Monoclonal antibodies 
(biological therapy, immunotherapy) such as 
rituximab or alemtuzumab are also used, with 
rituximab (+FC) recently approved for irst-line 
treatment by NICE [technology appraisal (TA) 
1744].
In UK practice, most patients receive ludarabine 
or FC as irst-line treatment then on progression 
may receive F(C) again, CVP, CHOP or CVP/
CHOP with (off-licence) rituximab. Chlorambucil 
is predominantly reserved for patients unable 
to tolerate ludarabine or FC. Testing for 
genetic markers for tailoring treatment is not 
routinely undertaken but is being investigated 
in clinical trials. The choice of irst and second-
line treatment, and the decision about the stage 
of disease at which to (re-)initiate treatment is 
made on a patient-by-patient basis and varies 
according to regional treatment policies, previous 
treatment(s) and itness of the patient. The British 
Committee for Standards in Haematology 2004 
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guidelines5 are in the process of being updated to 
relect indings of recent trials.
Scope of the evidence 
review group report
The key research question was the clinical 
effectiveness and cost-effectiveness of rituximab 
plus chemotherapy compared to chemotherapy 
only in the treatment of patients with relapsed/
refractory CLL, including patients with a del 
17p mutation. Rituximab (MabThera®; Roche 
Products Ltd, Welwyn Garden City, UK) in 
combination with chemotherapy has been licensed 
for use in relapsed/refractory chronic lymphocytic 
leukaemia.6
The bulk of the clinical effectiveness data 
submitted by the manufacturer was based on one 
ongoing, open-label, 8-year randomised controlled 
trial (RCT) [REACH (Rituximab in the Study 
of Relapsed Chronic Lymphocytic Leukemia), 
n = 552], which compared rituximab with a 
ludarabine and cyclophosphamide combination 
(R-FC) versus FC alone. At the time of data analysis 
(on which this report is based) median observation 
time was 2.1 years. Refractory patients included 
in the trial were those refractory to alkylators 
(CHOP, CVP, chlorambucil). The trial was not 
representative of all UK rituximab eligible patients 
as it excluded those refractory to ludarabine and 
those with prior rituximab exposure. Outcome 
measures in REACH were progression-free survival 
(PFS), overall survival (OS), event-free survival and 
response rates. Quality of life (QoL) measurements 
were based on the Functional Assessment of Cancer 
Therapy-General and measured for 1 year only and 
only up to the time of a patient experiencing an 
event.
Further (unpublished) evidence was submitted 
by the manufacturer in the form of uncontrolled 
studies to support evidence of effectiveness of 
rituximab in ludarabine refractory patients and for 
rituximab in combination with other chemotherapy 
regimens.
The manufacturer submitted an economic model to 
assess the cost per quality-adjusted life-year (QALY) 
of R-FC compared to FC. Clinical effectiveness 
parameters were based mainly on the REACH trial. 
QoL in REACH was not measured in a way that 
allowed conversion into utility values. Estimated 
(non-preference based) utility values were obtained 
from the literature.7
Methods
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process.
The ERG reran the searches for RCTs using slightly 
modiied versions of the search strategies employed 
by the manufacturer and independently assessed 
the validity of the REACH trial. The ERG also 
looked at commercial-in-conidence (CIC) results 
based on an independent (blinded) assessment 
of progression (as well as the investigators’ 
assessment); summary data (rather than individual 
patient data) on the independent analysis were 
supplied by the manufacturer in a separate 
document.
The main results on PFS and OS in the submission 
were presented in Kaplan–Meier plots. These 
plots were modelled using a variety of parametric 
distributions (exponential, lognormal, log logistic, 
Weibull, Gompertz and gamma) to identify the best 
itting function according to Akaike’s information 
criteria. For economic modelling, the its were 
extrapolated beyond observed data to a time 
horizon of 25 years. The ERG would have liked 
to independently obtain their own parametric its 
in order to (a) test the biological plausibility of all 
the PFS extrapolations used in the manufacturer’s 
economic modelling, (b) make a comparison of the 
relative advantage of R-FC versus FC delivered by 
the various parametric models and (c) effectively 
compare the investigator and independent 
assessments of PFS. This was not possible as 
individual patient data were not made available, 
and furthermore not all the requested parameters 
were supplied by the manufacturer.
The model structure and internal model validity 
were analysed by the ERG, and model parameters 
were assessed for their appropriateness. A number 
of additional sensitivity analyses were run based 
on varying assumptions set out in the submission, 
and the effect on the incremental cost-effectiveness 
ratio (ICER) was assessed.
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Results
Summary of submitted 
clinical evidence
Progression-free survival
Investigators’ assessment The curves for the 
FC and R-FC arm were similar in slope for 
most of the time represented but separated 
from each other especially during a 3-month 
period between 15 and 18 months. There was a 
statistically signiicant difference in median time to 
progression of 10.2 months in favour of R-FC. At 
the time of this analysis, an event had occurred in 
53% of patients, the remainder were censored.
Independent assessment An independent, blinded 
assessment of progression, which is less likely to 
be susceptible to bias, was performed as part of 
REACH. The results are CIC.
Overall survival
At the time of data analysis, 75% (FC arm) and 
78% (R-FC arm) of patients were still alive. Median 
survival could not be estimated for the R-FC arm. 
The curves were the same for both arms up to 
2.5 years, after which they separated (Figure 1). 
There was no statistically signiicant difference 
between the curves (hazard ratio 0.83; 95% 
conidence interval 0.59 to 1.17).
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Non-randomised studies
The manufacturer provided data from one 
uncontrolled study on salvage therapy with R-FC 
in sub-groups of patients with and without prior 
ludarabine exposure, and with and without prior 
rituximab exposure. These conidential results were 
provided ahead of publication, and the ERG were 
unable to identify data in the public domain.
Summary of submitted cost-
effectiveness evidence
The cost per QALY for the base case 
(manufacturer’s calculation) was £15,593. This was 
based on utility values of 0.8 for PFS and 0.6 for 
progression, and on a difference in mean life-years 
between the R-FC arm and FC arm of 0.671, and 
a difference in mean QALYs of 0.585. The results 
for a number of one-way sensitivity analyses varied 
between £13,017 and £23,790. Parameters that 
were varied in the submission include the utility 
values, type of curve it, rituximab costs, adverse 
event costs and supportive care costs.
A number of alternative analyses were carried out 
by the ERG in order to test the effect of changes 
to various assumptions within the manufacturer’s 
submission. The effects on the ICER can be found 
in Table 1.
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TABLE 1 6HQVLWLYLW\DQDO\VHVDURXQG,&(5SHUIRUPHGE\WKH(5*
General issue Details for this submission Effect on ICER (£)
5RFKHEDVHFDVHIROORZLQJFODULÀFDWLRQTXHVWLRQV 15,593
Model structure Alternative choice of curves for PFS 13,14017,317
Correction of minor errors of logic 15,584
Measurement of 
effectiveness
5HPRYDORIRYHUDOOVXUYLYDOEHQHÀWIURPULWX[LPDE 31,00947,963
Use of PFS curves based on independent assessment of progression 16,91117,467
Measurement of utility Halving and doubling difference between utilities for PFS and 
progressed states
13,01717,306
Adverse events Doubling costs for rituximab arm only 16,455
Rituximab costs One fewer or one more 100-mg vial per cycle 13,80317,383 
Retiming of rituximab costs 15,27720,110
Assessment of 
progression
Independent (blinded) assessment rather than investigators 
assessment (Weibull)
17,507
Survival 1R26EHQHÀW 40,56842,444
Combination ,QGHSHQGHQWDVVHVVPHQWRISURJUHVVLRQFRPELQHGZLWKQR26EHQHÀW 44,66948,385
Combination 1R26EHQHÀWDQGXWLOLWLHV3)6 SURJUHVVHG  20,28421,222
Combination 1R26EHQHÀWDQGXWLOLWLHV3)6 SURJUHVVHG  81,13584,889
ICER, incremental cost-effectiveness ratio; OS, overall survival; PFS, progression-free survival.
TABLE 2 (IIHFWRIUHGXFLQJRYHUDOOVXUYLYDODGYDQWDJHPRGHOOHGE\(5*
Case considered ICER (£)
Percentage reduction in OS advantage for rituximab Amended 1a Amended 2b
0 (as base case) 15,593 15,593
10 16,457 16,478
20 17,453 17,508
30 18,615 18,721
40 19,991 20,169
50 21,647 21,925
60 23,681 24,098
70 26,242 26,852
80 29,573 30,455
90 34,088 35,365
100 (no OS advantage) 40,568 42,444
ICER, incremental cost-effectiveness ratio; OS, overall survival.
a The cumulative probability of death calculated in the comparator arm of the model was applied also to the rituximab 
arm.
b The cumulative probability of death calculated for the rituximab arm was applied also to the comparator arm.
Removing the survival effect had the most 
substantial impact on the ICER and results were 
subsequently more sensitive to changes in utilities.
Intermediate results can be obtained by taking a 
weighted average of the two survival curves. This 
makes it possible to consider any desired fraction 
of the modelled advantage in overall survival from 
rituximab. Table 2 shows the effect of such changes, 
using a Weibull curve for PFS. Similar patterns 
could be expected for other curve options.
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Commentary on the robustness 
of submitted evidence
The analysis relies on the results of a single open-
label, unpublished, ongoing RCT with immature 
data (median observation time of only 2.1 years at 
the time of analysis).
There was evidence that treatment with R-FC 
compared to FC alone results in a statistically 
signiicantly longer period of progression-free 
survival (10 months investigators’ assessment; 
independent assessment results CIC) in both 
patients with and without the del 17 mutation. It is 
likely that this delay was associated with QoL gains, 
although there was a lack of suitable empirical 
evidence.
For OS, the median had not yet been reached in 
the R-FC arm and 75% and 78% of patients were 
still alive in the FC and R-FC arms respectively. 
There was no convincing evidence that there was 
a survival beneit in the R-FC arm. The Kaplan–
Meier curves separate out after 2.5 years (see 
Figure 1), and the ERG was unsure whether there 
was a biologically plausible reason for why this 
might happen. Because of crossover from the FC 
to the R-FC arm over time, the curves are likely to 
become increasingly susceptible to bias.
The patients in REACH do not appear 
representative of a general relapsed CLL 
population, but may be representative of those 
eligible for treatment with FC. The median age 
in REACH was 63 years at relapse compared to 
a median age of 65–70 years at diagnosis in the 
general population. Ten per cent of included 
relapsed patients were at Binet stage A, which 
appears high. Younger and/or healthier patients 
are less likely to drop out due to side effects.
In REACH, ludarabine and cyclophosphamide 
were given as an infusion. These drugs are usually 
given orally in the UK. It is unclear whether this 
would have an impact on the effectiveness of the 
drugs.
There was no evidence on the effectiveness of R-FC 
compared to another treatment in ludarabine 
refractory patients or patients with prior rituximab 
exposure.
The model submitted by Roche follows the 
same structure as that used in the assessment of 
rituximab for irst line treatment of CLL. There 
are three states in the model: PFS, progressed and 
death. No transition from progressed to PFS is 
possible. We share the concerns of the Peninsula 
Technology Assessment Group (PenTAG) about 
this structure. In summary, this has the effect of 
combining all patients post-progression into a 
single state. It is therefore not possible to improve 
QoL from treatment while in the progressed state.
There was considerable uncertainty associated with 
estimates of OS in the economic model. OS has 
been modelled by applying death rates to the PFS 
and progressed states in each arm of the model 
separately. The cumulative deaths modelled show 
a divergence between the two arms of the model 
from the start (Figure 2): this is not in accord with 
the observed pattern of deaths in the trial (see 
Figure 1). When the survival advantage is removed, 
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the base-case ICER changes from £15,593 to 
between £40,000 and £42,000/QALY.
With no OS advantage for the rituximab arm, the 
economic model output becomes sensitive to the 
differential in utility between the non-progressed 
and the progressed state. There is a lack of 
empirical evidence about the utility of patients in 
these states.
While a range of different parametric curves have 
been applied to the data for PFS, none of them is 
a particularly good it to the data, and there are 
doubts about the long term extrapolation of these 
curves.
The model assumes that the costs of rituximab 
are incurred throughout a cycle, so a patient 
progressing after half a cycle incurs only half of 
that cycle’s cost. As rituximab is given as a one-off 
infusion at the start of each cycle, this assumption 
does not seem appropriate.
The model uses the investigators’ assessment of 
progression rather than the independent (blinded) 
assessments, which are likely to give less biased 
results. However, when parametric its were made 
to the independent analysis results, only small 
differences in the resulting ICERs were observed 
and the direction of change was not consistent.
An area of uncertainty is the difference in the 
cost of relapse therapy with rituximab (£9128) 
compared to the cost of irst line therapy (£11,617) 
as given in the recent submission on rituximab in 
CLL.8
Conclusions
The ERG found evidence that R-FC delays 
progression by 10 months (investigators’ 
assessment) compared to treatment with FC alone 
in patients who have previously received alkylator-
containing chemotherapy or ludarabine alone, are 
ludarabine sensitive and are considered suitable 
for treatment with FC. There was no evidence from 
current data to show that R-FC prolongs survival 
compared to FC. With no survival beneit assumed 
in the economic model, the base-case ICER 
changes from £15,593 to between £40,000 and 
£42,000/QALY and becomes sensitive to changes 
in utility. Further modelling around a hypothetical 
survival beneit found that rituximab would be cost-
effective at a threshold of around £20,000/QALY 
(£30,000/QALY) when a 40% (80%) reduction in 
survival beneit relative to the manufacturer’s base 
case was assumed. Further evidence is needed on 
whether there is a survival beneit, the extent of 
this beneit and the associated utilities. Robust 
evidence is lacking on (a) the effectiveness of R-FC 
in patients who have previously received FC, R-FC 
or R-chemotherapy (other) as irst-line therapy and 
(b) the effectiveness of R-chemotherapy (other) as 
treatment for relapsed CLL.
Summary of NICE guidance 
issued as a result of the STA
NICE guidance from July 2010 recommends 
rituximab in combination with ludarabine and 
cyclophosphamide for people with relapsed or 
refractory chronic lymphocytic leukaemia, but 
not when there has been previous treatment with 
rituximab. Exceptions to the previous treatment 
with rituximab rule apply where this was in the 
context of a clinical trial (with any chemotherapy), 
or at a dose lower than the dose currently licensed 
for chronic lymphocytic leukaemia.
People who are currently receiving rituximab 
in combination with ludarabine and 
cyclophosphamide should have the option to 
continue treatment until they and their clinicians 
consider it appropriate to stop. The guidance is 
due to be reviewed in December 2010.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of rituximab 
for the irst-line treatment of chronic lymphocytic 
leukaemia (CLL) based upon a review of the 
manufacturer’s submission to the National 
Institute for Health and Clinical Excellence 
(NICE) as part of the single technology appraisal 
(STA) process. The manufacturer’s searches 
for clinical effectiveness and cost-effectiveness 
data were appropriate and included all relevant 
studies. The submission’s evidence came 
from a single, unpublished, well-conducted 
randomised controlled trial (RCT) comparing 
rituximab in combination with ludarabine and 
cyclophosphamide (R-FC) with ludarabine 
and cyclophosphamide (FC) alone for the irst-
line treatment of CLL. There was a statistically 
signiicant increase in progression-free survival 
(PFS) with R-FC compared with FC alone {median 
39.8 months vs 32.2 months; hazard ratio [HR] 
0.56 [95% conidence interval (CI) 0.43 to 0.72]}. 
However, the initial signiicant treatment beneit 
for R-FC compared with FC for overall survival was 
not maintained at a slightly longer follow-up time 
[median 25.4 months; adjusted HR 0.72 (95% CI 
0.48 to 1.09)]. Response rates, numbers of patients 
with event-free survival and duration of response 
all favoured treatment with R-FC. Additional 
evidence from a mixed-treatment comparison 
model indicated R-FC to be signiicantly superior 
to chlorambucil alone for both PFS and overall 
DOI: 10.3310/hta14suppl2/04
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and complete response rates. The incidence of 
grade 3 or 4 adverse events was higher in the 
R-FC arm (77%) than in the FC arm (62%). Dose 
modiications were also more frequent in this arm, 
but this did not lead to differences in treatment 
discontinuation. Roche used a three-state Markov 
model (PFS, progressed and death) to model 
the cost-effectiveness of R-FC compared with FC 
and chlorambucil alone. The model used a cycle 
length of 1 month and a lifetime time horizon. 
The approach taken to modelling was reasonable 
and the sources and justiication of estimates 
were generally sound. The base-case analysis 
produced an incremental cost-effectiveness ratio 
(ICER) of £13,189 per quality-adjusted life-year 
(QALY) for R-FC versus FC, and £6422 per QALY 
for the comparison of R-FC versus chlorambucil, 
suggesting that R-FC is cost-effective at normal 
willingness-to-pay thresholds. One-way sensitivity 
analyses produced a range of ICERs from £10,249 
to £22,661 per QALY for R-FC versus FC, and 
£5612 and £6921 per QALY for R-FC versus 
chlorambucil. Probabilistic sensitivity analysis 
results matched the deterministic results very 
closely. However, the sensitivity analysis did not 
fully investigate the uncertainty associated with 
differential values across arms or with the structural 
assumptions of the model, and utility values were 
not drawn from an empirical study. The NICE 
guidance issued as a result of the STA states that: 
Rituximab in combination with ludarabine and 
cyclophosphamide (R-FC) is recommended as 
an option for the irst-line treatment of chronic 
lymphocytic leukaemia in people for whom 
ludarabine in combination with cyclophosphamide 
(FC) is considered appropriate.  Rituximab in 
combination with chemotherapy agents other 
than ludarabine and cyclophosphamide is not 
recommended for the irst-line treatment of 
chronic lymphocytic leukaemia.
Introduction 
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is speciically designed for the appraisal of a single 
product, device or other technology, for a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of the clinical effectiveness and cost-effectiveness 
of rituximab for the irst-line treatment of chronic 
lymphocytic leukaemia.2 
Description of the 
underlying health problem
Chronic lymphocytic leukaemia (CLL) is the 
most common type of leukaemia, comprising 
approximately 30% of all adult leukaemias. The 
incidence is about 3 per 100,000, but this varies 
with age and sex. The median age of diagnosis 
is between 65 and 70 years, and men are twice as 
likely to be affected as women. Incidence increases 
signiicantly with age, with a rate of almost 50 per 
100,000 in patients over 70 years. 
The exact causes of CLL remain unknown; 
however, a combination of genetic and 
environmental factors is thought to be involved. 
The presentation of patients with CLL to health-
care providers is typically heterogeneous, with 
about 70–80% of patients diagnosed as an 
incidental inding following a full blood count test 
for some other reason. A deinitive diagnosis of 
CLL has a characteristic lymphocyte morphology 
on blood ilm, with a speciic immunophenotype 
(as shown by low cytometry), and requires an 
absolute B-cell lymphocytosis of at least 5 w 109/l.
Two methods have been devised to stage CLL: the 
Binet and Rai systems. The Binet system is more 
commonly used in Europe and comprises three 
stages: stage A, less than three lymphoid areas 
involved; stage B, more than three lymphoid areas 
involved; and stage C, haemoglobin < 10 g/dl 
or platelets 100 w 109/l. The course of CLL is 
heterogeneous and it is generally anticipated 
that approximately one-third of patients (usually 
with Binet stage A disease) will never need any 
form of treatment and will die with, rather than 
of, their disease.3 For the remaining majority of 
patients (usually with Binet stage B or C disease) 
CLL is incurable and has a median life expectancy 
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of between 5 and 10 years. Standard criteria 
from the International Workshop on Chronic 
Lymphocytic Leukaemia are used to guide whether 
patients should start treatment with a irst-line 
chemotherapeutic regimen.4 
As CLL is characterised by periods of active 
disease, during which patients are symptomatic, 
separated by chemotherapy-induced remissions, 
once patients have started treatment the main aim 
of therapy is to induce durable remissions during 
which patients are free of disease symptoms, the 
psychological burden of active life-threatening 
illness and the toxicity of chemotherapy.
Scope of the ERG report
Research question
What is the clinical effectiveness and cost-
effectiveness of rituximab in combination with 
ludarabine therapies versus ludarabine therapies 
alone or chlorambucil for the irst-line treatment of 
CLL?
Intervention
t Brand name: MabThera®.
t Approved name: rituximab.
t Therapeutic class: antineoplastic agents.
t Product licence holder: Roche Products.
Outcomes
Clinical effectiveness outcomes were progression-
free survival (PFS), overall survival (OS), event-
free survival, disease-free survival, response rates, 
duration of response, time to new CLL treatment, 
health-related quality of life and adverse effects 
of treatment. Cost-effectiveness outcomes were 
incremental cost per quality-adjusted life-year 
(QALY), resource utilisation and the cost of treating 
adverse events (blood transfusions and bone 
marrow transplants).
Type of clinical effectiveness/
cost-effectiveness data used
For clinical effectiveness, ‘time to event’ data were 
used, reported as median time in either days or 
months with the point estimates expressed as 
hazard ratios (HRs) and 95% conidence intervals 
(CIs). For cost-effectiveness, Roche built a three-
state Markov model. For the comparison of 
rituximab (R) in combination with ludarabine 
and cyclophosphamide (R-FC) versus ludarabine 
and cyclophosphamide (FC) alone the model 
was parameterised by effectiveness data from the 
German Chronic Lymphocytic Leukaemia trial 
(CLL-8).5 For the comparison of R-FC versus 
chlorambucil monotherapy, HRs for PFS were 
derived using a mixed-treatment comparison 
(MTC) model. Health-state utility values were taken 
from a report by Hancock and colleagues6 on the 
use of ludarabine as irst-line treatment for CLL; 
these values were estimated by the report authors. 
Costs were based on an NHS and Personal Social 
Services perspective.
Stated potential health effects 
Rituximab is a chimeric murine/human monoclonal 
antibody that binds selectively to the CD20 cell 
antigen expressed on the surface of mature B 
lymphocytes and any tumour cell that expresses 
CD20, including B-cell CLL. It causes depletion 
of normal and malignant B cells. Although its 
mechanism of action is not precisely deined, 
antibody-directed cytotoxicity, complement-
dependent cytotoxicity, induction of apoptosis and 
sensitisation of cells to conventional cytotoxic drugs 
are all likely to be important.7–9
Stated costs
Rituximab is available in two vials sizes: 10-ml 
vial (minus VAT) = £174.63; 50-ml vial (minus 
VAT) = £873.15.
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process.
The manufacturer’s search strategy was reviewed 
by an information scientist and the searches were 
rerun with text words and a full clinical trials ilter 
to see if any relevant trials had been omitted. 
The methods used by the manufacturer to report 
clinical effectiveness were critiqued using the 
principles advocated in the Centre for Reviews and 
Dissemination’s (CRD) guidance for undertaking 
reviews in health care.10 Roche’s economic 
evaluation was assessed against the following 
study quality checklists: NICE reference case,11 
Drummond and colleagues12 and Philips and 
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colleagues13 for decision model-based economic 
evaluations. The model was extensively checked 
and rerun to check for wiring and parameterisation 
errors.
Results 
Summary of submitted 
clinical evidence
The evidence for the submission was based 
on one phase III randomised controlled trial 
(RCT) comparing R-FC with FC for the irst-line 
treatment of people with CLL (the CLL-8 trial;5 
n = 810). Additional evidence was provided in the 
form of an MTC model based on PFS hazards 
from ive trials allowing for an indirect comparison 
of R-FC with chlorambucil monotherapy.5,14–17 
Chlorambucil had been included as a comparator 
in two of the ive trials.15,16
The CLL-8 trial was a randomised, parallel-group, 
multicentre trial; however, blinding of both patients 
and outcome assessors to treatment allocation was 
not attained, which may have introduced bias into 
the results. The trial was stopped early (median 
follow-up 20.7 months) at the time of the planned 
interim analysis because of signiicant differences 
in PFS between treatment arms. Data from four 
different sets of analyses of the trial are presented: 
(1) interim analysis (median follow-up 20.7 months; 
(2) snapshot analysis 1 (median follow-up 
25.4 months); (3) snapshot analysis 2 (median 
follow-up 25.5 months); and (4) economic analyses 
snapshot (median follow-up 26.4 months).
At 20.7 months follow-up there was a statistically 
signiicant increase in PFS with R-FC compared 
with FC alone [median 39.8 months vs 32.2 
months; HR 0.56 (95% CI 0.43 to 0.72)]. However, 
for OS, the initial treatment beneit for the R-FC 
regimen noted at the time of the interim analysis 
was no longer maintained at slightly longer follow-
up (snapshot analysis 1) [HR 0.72 (95% CI 0.48 to 
1.09)]. Patients in the R-FC arm remained event 
free (disease progression, relapse, death or start 
of new CLL treatment) signiicantly longer than 
those in the FC-arm [39.8 months vs 31.1 months; 
HR 0.55 (95% CI 0.43 to 0.70)]. Response rates 
also signiicantly favoured treatment with R-FC, 
with 36.0% of patients in this arm achieving 
complete response compared with 17.2% in the FC 
arm. Partial response rates were not signiicantly 
different between trial arms at 50.1% for R-FC and 
55.5% for FC respectively.
The incidence of grade 3 or 4 adverse events was 
higher in the R-FC arm (77%) than in the FC 
arm (62%), mostly because of a higher incidence 
of blood and lymphatic system disorders (57% 
versus 41%). Dose modiications were also more 
frequent in this arm. However, this did not lead 
to differences in treatment discontinuation. There 
were also no difference between arms in the rate of 
deaths considered related to therapy (2%).
Mixed-treatment comparison model
Based on results of the ive trials included in the 
MTC5,14–17 (with chlorambucil used as the reference 
treatment), R-FC signiicantly increased PFS 
compared with chlorambucil alone [mean HR 0.24 
(lower bound 0.17, upper bound 0.34)].
Summary of submitted cost-
effectiveness evidence
Roche used a Markov model with a three-state 
structure (PFS, progressed and death) to model the 
cost-effectiveness of R-FC compared with FC and 
chlorambucil alone. The model used a cycle length 
of 1 month and a lifetime time horizon (equating 
to 15 years). 
Roche’s base-case analysis produced an incremental 
cost-effectiveness ratio (ICER) of £13,189 per 
QALY for R-FC versus FC, and an ICER of 
£6422 per QALY for the comparison of R-FC 
versus chlorambucil. One-way sensitivity analyses 
produced a range of ICERs from £10,249 per 
QALY to £22,661 per QALY for the comparison of 
R-FC versus FC, and £5612 per QALY and £6921 
per QALY for R-FC versus chlorambucil. Results 
from further probabilistic sensitivity analysis 
matched the deterministic results very closely. 
Commentary on the robustness 
of submitted evidence
Strengths
The searches for clinical effectiveness and cost-
effectiveness data were appropriate and included 
all relevant studies. The identiied RCT was well 
conducted and the indings were likely to be 
reasonably robust. 
The approach taken to modelling was reasonable 
and the sources and justiication of estimates were 
generally sound.
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Weaknesses
The evidence was based on only one completed 
and unpublished RCT.
The sensitivity analysis was limited and did not 
fully investigate the uncertainty associated with 
differential values across arms or with the structural 
assumptions of the model. Utility values were not 
drawn from an empirical study.
Conclusions 
There was a statistically signiicant increase in PFS 
with R-FC compared with FC alone [median 39.8 
months vs 32.2 months; HR 0.56 (95% CI 0.43 to 
0.72)]. However, the initial signiicant treatment 
beneit for R-FC compared with FC for OS was 
not maintained at a slightly longer follow-up time 
[median 25.4 months; adjusted HR 0.72 (95% CI 
0.48 to 1.09)]. Response rates, numbers of patients 
with event-free survival and duration of response 
all favoured treatment with R-FC. 
The MTC model indicated R-FC to be signiicantly 
superior to chlorambucil alone for both PFS and 
overall and complete response rates.
With an ICER of £13,189 per QALY for R-FC 
versus FC, and £6422 for R-FC versus chlorambucil 
alone, there is a strong probability that R-FC 
is cost-effective at normal willingness-to-pay 
thresholds. 
Areas of uncertainty
It was unclear whether the observed treatment 
beneit for use of rituximab combination therapy 
for PFS was associated with longer-term gains in 
OS and how plausible it was to extrapolate any PFS 
beneits in the longer term. 
Key issues
Almost all data parameters for effectiveness were 
drawn from the CLL-8 trial. Although this trial was 
of reasonable quality, there are inherent limitations 
in an analysis that relies on data from a single 
clinical trial.
The issue of structural uncertainty in the model 
relating to the treatment of OS rates between the 
trial arms was not adequately explored in sensitivity 
analyses. This relates speciically to the assumption 
of aggregation in the post-relapse state. The ERG 
felt that this was likely to be clinically unrealistic 
as patients will receive further treatment at 
progression that may then result in further periods 
of PFS. The relapsing nature of CLL means that 
subsequent periods of progression are less likely to 
respond to further treatment, implying that later 
periods of progression in the course of disease are 
likely to be associated with higher disease-related 
mortality. This casts doubts over the simplifying 
assumption of a constant hazard of death after 
progression as modelled by Roche.
Additionally, it should be noted that once any 
assumed beneit for OS is removed, model outputs 
become highly sensitive to the utility parameters 
assumed for the PFS and progressed states, and 
these values are not currently available from an 
appropriate source.
Summary of NICE guidance 
issued as a result of the STA 
At the time of writing, the Appraisal Consultation 
Document issued by NICE on 26 March 2009 states 
that:
Rituximab in combination with ludarabine and 
cyclophosphamide (R-FC) is recommended as 
an option for the irst-line treatment of chronic 
lymphocytic leukaemia in people for whom 
ludarabine in combination with cyclophosphamide 
(FC) is considered appropriate.  Rituximab in 
combination with chemotherapy agents other 
than ludarabine and cyclophosphamide is not 
recommended for the irst-line treatment of 
chronic lymphocytic leukaemia.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of pemetrexed 
for the maintenance treatment of locally advanced 
or metastatic non-small cell lung cancer (NSCLC), 
in accordance with the licensed indication, 
based upon the evidence submission from the 
manufacturer (Eli Lilly) to the National Institute for 
Health and Clinical Excellence (NICE) as part of 
the single technology appraisal (STA) process. The 
primary clinical outcome measure was progression 
free survival (PFS). Secondary outcomes included 
overall survival (OS), time to worsening of 
symptoms, objective tumour response rate, adverse 
events and changes in lung cancer symptom 
scale. Data for two populations were presented: 
patients with non-squamous NSCLC histology 
and patients with adenocarcinoma histology. The 
clinical evidence was derived from a double-blind, 
placebo-controlled randomised controlled trial 
(RCT), the JMEN trial. The trial compared the 
use of pemetrexed + best supportive care (BSC ) 
as maintenance  therapy, with placebo + BSC in 
patients with NSCLC (n = 663) who had received 
four cycles  of platinum-based chemotherapy 
(CTX) and whose disease had  not progressed. 
In the licensed  population (patients  with non-
squamous histology), the trial  demonstrated 
greater median PFS for  patients treated with  
DOI: 10.3310/hta14suppl2/05
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pemetrexed than for patients in the placebo arm 
[4.5 vs 2.6 months; hazard  ratio (HR) 0.44; 95% 
conidence interval (CI) 0.36 to 0.55, p < 0.00001]. 
Median OS was also greater for  the pemetrexed- 
treated patients (15.5 vs 10.3 months; HR 0.70; 
95% CI 0.56 to 0.88, p = 0.002). In  addition, 
tumour  response and disease control rates were 
statistically signiicantly greater for patients  who 
received  pemetrexed. Patient survival rates at 1 
year and 2 years were higher in the pemetrexed  
arm. The  incremental cost-effectiveness ratios 
(ICERs) estimated by the manufacturer’s model 
were £33,732 per  quality adjusted life-year (QALY) 
for the licensed nonsquamous population, and 
£39,364 per QALY for  the  adenocarcinoma 
subgroup. Both of these ICERs were  above the 
standard NICE  willingness-to-pay range (£20,000–
£30,000 per QALY). The manufacturer also 
presented a case for pemetrexed to be considered 
as an end of life treatment. The  ERG identiied 
a number of problems in the economic model 
presented by the manufacturer; after correction, 
the base case  ICER was  re-estimated as £51,192 
per QALY gained and likely to exceed NICE’s 
willingness-to-pay thresholds. Following a  revised 
economic analysis submitted by the  manufacturer,  
the AC accepted that an ICER of £47,000 per 
QALY gained was most plausible. The AC also  
considered  that maintenance treatment with 
pemetrexed fulilled the end of life criteria.The 
guidance  issued by NICE, on 20 June 20 2010, 
in TA190 as a result of the STA states that: People 
who have received pemetrexed in combination 
with cisplatin as irst-line chemotherapy cannot 
receive pemetrexed maintenance treatment. 
1.1 Pemetrexed is recommended as an option for 
the maintenance treatment of people with locally 
advanced or metastatic non-small-cell lung cancer 
other than predominantly squamous cell histology 
if disease has not progressed immediately following 
platinum-based chemotherapy in combination with 
gemcitabine, paclitaxel or docetaxel. 
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is speciically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
entitled ‘Pemetrexed for the maintenance treatment of 
locally advanced or metastatic non-small cell lung cancer 
(NSCLC)’.
Description of the underlying 
health problem
Lung cancer is the second most common cancer 
diagnosed in the UK, with over 33,000 new cases 
diagnosed in England and Wales in 2006, and the 
leading cause of cancer death.2 Lung cancer is the 
second most common cancer in men after prostate 
cancer, and the third most common cancer in 
women after breast and bowel cancer.
Non-small cell lung cancer (NSCLC) accounts for 
approximately 80% of all lung cancers diagnosed. 
The main subtypes of NSCLC are squamous 
cell carcinoma (33%), adenocarcinoma (25%), 
large cell carcinoma (4%), and NSCLC ‘not-
otherwise speciied’ (NOS; 36%).3 A further 1% are 
‘carcinoma in situ’ and 1% are broncho-alveolar 
cell carcinoma. While cigarette smoking has been 
linked to all four types of lung cancer, the incidence 
of adenocarcinoma has been steadily increasing 
worldwide, and modiications to cigarette design 
are thought to be responsible for this shift in 
pathologic diagnosis pattern.4
Survival in patients with lung cancer is poor. It 
was responsible for approximately 29,600 deaths 
in England and Wales in 2007.2 For patients with 
stage IIIB, only 7–9% may live for 5 years and for 
patients with stage IV (metastatic) cancer, only 
about 2–13% survive for 5 years.2
One reason for this poor prognosis is the late 
identiication of the disease. Lung cancer is 
asymptomatic in the early stages and advanced 
disease is not amenable to curative treatment. 
Another reason, which explains the UK’s relatively 
poor performance in comparison with other 
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developed countries, is low active anti-cancer 
treatment rates. The National Lung Cancer 
Audit states that only 23.2% of NSCLC patients 
in England and Wales received irst-line CTX in 
2006.5
Maintenance treatment is a new treatment 
paradigm and is proposed as an alternative for the 
‘watch and wait’ phase of the current treatment 
pathway, for patients with complete or partial 
response/stable disease after four cycles of irst-line 
treatment.
The goal of maintenance treatment is to maintain 
the clinical beneit achieved with irst-line CTX. 
Maintenance treatment is continued until disease 
progression.
Scope of the evidence 
review group report
Pemetrexed is licensed in Europe as monotherapy 
for the maintenance treatment of patients with 
NSCLC, other than predominantly squamous cell 
histology. First-line treatment should be a platinum 
doublet with gemcitabine, paclitaxel or docetaxel.6
The ERG report presents the results of the 
evaluation of the manufacturer (Eli Lilly) evidence 
submission regarding the use of pemetrexed as a 
maintenance therapy in the patient group outlined 
above. The report includes an assessment of both 
the clinical effectiveness and cost-effectiveness 
evidence submitted by the manufacturer. The 
manufacturer submission (MS) described the use 
of pemetrexed + best supportive care (BSC) with 
BSC + placebo.
The primary clinical outcome measure was 
progression-free survival (PFS). Secondary 
outcomes included overall survival (OS), time to 
worsening of symptoms, objective tumour response 
rate, adverse events and changes in lung cancer 
symptom scale.
Cost-effectiveness was measured in terms of 
incremental cost-effectiveness ratio (ICER) per 
quality-adjusted life-year (QALY).
Data for two populations were presented: patients 
with non-squamous NSCLC histology and patients 
with adenocarcinoma histology.
Methods
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process.
The ERG evaluated the quality of the 
manufacturer’s clinical effectiveness review. 
Searches conducted by the manufacturer were 
assessed for completeness, and the single trial put 
forward as evidence of effectiveness was critically 
appraised using the manufacturer’s responses 
to speciic questions in the submission template. 
With regard to cost-effectiveness evidence, the 
ERG assessed the manufacturer’s searches for 
completeness, critically appraised the submitted 
economic model using a standard assessment 
tool,7 and conducted a detailed evaluation of 
the model. The ERG recalculated the base-case 
cost-effectiveness results, correcting a number 
of methodological errors and reanalysed the 
survival estimates. The ERG also undertook a basic 
probabilistic sensitivity analysis as this was not 
provided by the manufacturer.
Results
Summary of submitted 
clinical evidence
The evidence described in the MS is derived from 
a double-blind, placebo-controlled randomised 
controlled trial (RCT), the JMEN trial.8 The 
trial compared the use of pemetrexed + BSC 
as maintenance therapy, with placebo + BSC in 
patients with NSCLC (n = 663) who had received 
four cycles of platinum-based CTX and whose 
disease had not progressed. The MS focused on 
the clinical outcomes of the subgroup of patients 
with non-squamous histology (n = 481), which is 
the population for which pemetrexed is licensed 
in this indication; the MS also focused on a 
subgroup of the licensed population, patients with 
adenocarcinoma.
The results for the licensed non-squamous 
population are summarised in Table 1. In the 
licensed population the trial demonstrated greater 
median PFS for patients treated with pemetrexed 
than for patients in the placebo arm [4.5 vs 2.6 
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months; hazard ratio (HR) 0.44; 95% conidence 
interval (CI) 0.36 to 0.55, p < 0.00001]. Median 
OS was also greater for the pemetrexed-treated 
patients (15.5 versus 10.3 months; HR 0.70; 95% 
CI 0.56 to 0.88, p = 0.002). In addition, tumour 
response and disease control rates were statistically 
signiicantly greater for patients who received 
pemetrexed. Patient survival rates at 1 year and 
2 years were higher in the pemetrexed arm. 
The health-related quality of life (HRQoL) data 
presented were limited owing to high levels of 
censoring/missing data. Safety data demonstrated 
that patients treated with pemetrexed had 
statistically signiicantly higher rates of grade 3 
or 4 neutropenia, and experienced higher rates 
of transfusions and hospitalisation due to drug 
toxicity.
Summary of submitted cost-
effectiveness evidence
The manufacturer did not identify any published 
cost-effectiveness analyses of pemetrexed for 
the maintenance treatment of patients with 
NSCLC, and therefore developed a de novo 
economic model to support their economic 
case. The model compares pemetrexed + BSC 
with ‘watch and wait’ + BSC. The clinical data 
used in the economic model were primarily 
generated from the JMEN trial.8 Although the 
model was trial-based, there was also a modelling 
component to allow the extrapolation of health 
effects beyond the 29 month trial period up to 
6 years. The manufacturer’s economic evaluation 
adopts a lifetime horizon (taken as 6 years) for 
the consideration of costs and beneits, and the 
perspective is that of the UK NHS and Personal 
Social Services.
The ICERs estimated by the manufacturer’s model 
are £33,732 per QALY for the licensed non-
squamous population, and £39,364 per QALY 
for the adenocarcinoma subgroup. Both of these 
ICERs are above the standard NICE willingness-to-
pay range (£20,000–£30,000 per QALY).
The manufacturer also presented a case for 
pemetrexed to be considered as an end-of-life 
treatment.
Commentary on the robustness 
of submitted evidence
The manufacturer cited evidence from a well-
designed trial (JMEN)8 of the clinical beneit of 
pemetrexed + BSC as maintenance treatment 
compared with placebo + BSC. The trial recruited a 
substantial number of patients in a dificult disease 
area. It is noteworthy that patients and assessors 
in the JMEN8 trial were blinded to treatment 
group allocation and that investigators’ outcome 
assessments were independently veriied.
The ERG noted that there was only one relevant 
RCT (JMEN)8 that compared pemetrexed + BSC 
as maintenance treatment with placebo + BSC. 
Despite designing the trial to include a 
comprehensive analysis of HRQoL, very limited 
data was collected and reported in the MS. This 
means it was very dificult to determine how 
patients’ HRQoL would be affected by pemetrexed 
in a maintenance setting.
TABLE 1 .H\UHVXOWVRIWKH-0(1WULDOQRQVTXDPRXVSRSXODWLRQ
End point
Pemetrexed 
(n = 325)
Placebo 
(n = 156) HR (95% CI) p-value
Primary
PFS (months) median 4.5 2.6 0.44 (0.36 to 0.55) < 0.00001
Secondary
OS (months) median 15.5 10.3 0.70 (0.56 to 0.88) 0.002
Tumour response (%) (CR + PR) 7.4 1.9 0.018
Disease control rate (%) (CR+PR+SD) 57.7 32.7 < 0.001
Survival rate at 1 year (%) 60 42
Survival rate at 2 year (%) 28 22
&,FRQÀGHQFHLQWHUYDO&5FRPSOHWHUHVSRQVH+5KD]DUGUDWLR26RYHUDOOVXUYLYDO3)6SURJUHVVLRQIUHHVXUYLYDO35
partial response; SD, stable disease.
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TABLE 2 (IIHFWRIFRUUHFWLRQVDQGDPHQGPHQWVPDGHE\(5*WRWKHPDQXIDFWXUHU·VPRGHOIRUWKHQRQVTXDPRXVSRSXODWLRQ
Model amendment
Pemetrexed Placebo Incremental ICER Changes
Costs QALYs Costs QALYs Costs QALYs (£/QALY) Costs QALYs ICER
Submitted base case £17,455 0.9697 £8318 0.6988 £9137 0.2709 £33,732   
All cycles of pemetrexed and 
revised CTX costs
£20,638 0.9841 £8323 0.6989 £12,315 0.2852 £43,179 +£3178 +0.0143 +£9447
Revised utility values £17,455 0.9540 £8318 0.7057 £9137 0.2483 £36,798  0.0226 +£3066
Continuity correction £17,405 0.9467 £8288 0.6851 £9117 0.2615 £34,860 £20 0.0094 +£1128
Correct double discounting £17,522 1.0006 £8352 0.7149 £9169 0.2857 £32,091 +£32 +0.0148 £1641
Discounting assumptions £17,421 0.9617 £8312 0.6909 £9109 0.2708 £33,640 £60 0.0001 £88
Include monitoring costs £17,838 0.9697 £8452 0.6988 £9386 0.2709 £34,651 +£249  +£919
Correct arithmetic £17,398 0.9658 £8248 0.6953 £9149 0.2706 £33,817 +£12 0.0003 +£85
Combined effect of above 
changes
£20,925 0.9539 £8370 0.6881 £12,555 0.2658 £47,239 +£3418 0.0051 +£13,507
Combined effect of all 
changes including IPD survival 
DQDO\VLVH[FOXGLQJVLJQLÀFDQW
protocol violations)
£20,902 0.9851 £8382 0.7405 £12,520 0.2446 £51,192 +£3383 0.0263 +£17,460
CTX, chemotherapy; ICER, incremental cost-effectiveness ratio; IPD, individual patient data; QALYs, quality-adjusted life-years.
3HPHWUH[HGIRUORFDOO\DGYDQFHGRUPHWDVWDWLFQRQVPDOOFHOOOXQJFDQFHU
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The primary end point of the key trial was changed 
by the manufacturer from OS to PFS during the 
course of the trial. No information was provided 
that fully justiied the change of clinical end point.
The statistical analysis plan described by the 
manufacturer also included a test for treatment 
by histology interaction and corresponding 
subgroup analyses. The results for the subgroup 
of patients with non-squamous histology provided 
the clinical evidence in the MS. However, the trial 
randomisation process did not include stratiication 
by histology status. Moreover, the restriction of 
the licensed population to only the non-squamous 
subgroup effectively reduced the statistical power 
of the trial, with consequences of increased 
uncertainty in the cost-effectiveness analysis.
The projection of survival from the end of the 
trial period, the costing of CTX treatment and the 
utility values used in the manufacturer’s model 
were not ideal and underestimate the size of the 
ICER.
The manufacturer implemented a capping rule 
in its economic model to limit the maximum 
number of cycles of maintenance treatment that 
patients could receive. However, the cycle capping 
rule affected only costs; it did not take account 
of any reduction in outcomes caused by capping 
the maximum number of cycles at 17 rather than 
allowing the JMEN trial8 maximum of 55. Again, 
this capping rule underestimated the size of the 
ICER.
Making all of the necessary ERG corrections/
adjustments to the manufacturer’s model, the 
ERG’s base-case ICER for the non-squamous 
population was estimated at £51,192 per QALY 
(Table 2).
Conclusions
The generalisability of the JMEN trial8 to UK 
clinical practice is uncertain for a number of 
reasons:
t None of the patients in the trial were recruited 
from the UK. A sizeable proportion (35%) 
of patients were from Asian countries; these 
patients are documented in the literature as 
having a better prognosis for NSCLC than 
other ethnic groups, and the Asian patients 
in the trial appear to have improved survival 
times compared with patients of other 
ethnicities.9
t Patients in the trial were able to receive 
unlimited cycles of maintenance therapy. This 
is unlikely to be the case in clinical practice in 
England and Wales and it is unclear how this 
difference would impact on survival in a clinical 
setting.
t Paclitaxel was used in the JMEN trial as a 
irst-line treatment for a greater proportion 
of patients in the trial than might be the case 
in clinical practice in England and Wales. The 
impact of this when generalising the results is 
unknown.
t A number of patients in the trial received 
second-line therapies that are not available 
to patients in clinical practice in England 
and Wales, which may have affected the OS 
observed in the trial.
t Conirmed histological diagnosis of non-
squamous NSCLC is required before patients 
can be offered maintenance treatment with 
pemetrexed. While histological testing is 
routinely carried out in many centres in 
England and Wales, this will not be available 
to all patients. Therefore, it is unclear if 
pemetrexed for maintenance therapy will be 
available in all centres in the UK, which may 
give rise to equity concerns.
End-of-life criteria
Analysis of the JMEN trial8 individual patient data 
and revised projection modelling conirmed that 
the mean life extension from use of pemetrexed 
as maintenance therapy was likely to exceed 
3 months. However, the number of patients 
who would be eligible to receive pemetrexed is 
uncertain. The manufacturer’s estimates (used 
to present its end of life case) were based on 
amalgamation of information from different 
sources with differing deinitions. The methods of 
calculation are not well reported and a number of 
assumptions were made which may not be valid.
Several factors serve to limit the generalisability 
of the trial to UK clinical practice, and the ERG 
could not be conident that the clinical results 
presented in the MS give a true relection of the 
beneits that could be expected with pemetrexed 
for the maintenance treatment of patients with 
non-squamous NSCLC in UK clinical practice. 
Furthermore, in the economic analysis there were a 
number of problems identiied with the model (in 
addition to the JMEN trial8 data) which indicate 
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that the ICER (re-estimated as £51,192 per QALY 
gained) could well exceed NICE’s willingness-to-
pay thresholds.
Summary of NICE guidance 
issued as a result of the STA
Following a  revised economic analysis submitted by 
the  manufacturer,  the AC accepted that an ICER 
of £47,000 per QALY gained was most plausible. 
The  AC also  considered  that maintenance 
treatment with pemetrexed fulilled the end of life 
criteria. The guidance  issued by NICE, on 20 June 
2010, in TA190 as a result of the STA states that:
People who have received pemetrexed in 
combination with cisplatin as irst-line 
chemotherapy cannot receive pemetrexed 
maintenance treatment. 
1.1 Pemetrexed is recommended as an option for 
the maintenance treatment of people with locally 
advanced or metastatic non-small-cell lung cancer 
other than predominantly squamous cell histology 
if disease has not progressed immediately following 
platinum-based chemotherapy in combination with 
gemcitabine, paclitaxel or docetaxel.
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Abstract
This paper represents a summary of the evidence 
review group (ERG) report into the clinical eficacy, 
safety and cost-effectiveness of everolimus plus 
best supportive care (BSC) for the treatment of 
advanced renal cell carcinoma (RCC) which has 
progressed following or on vascular endothelial 
growth factor-targeted therapy (sunitinib, 
sorafenib, bevacizumab), compared to BSC alone. 
The submitting manufacturer’s case for clinical 
effectiveness and cost-effectiveness was mainly 
based on a well-conducted randomised controlled 
trial (RCT), Renal Cell Cancer Treatment with 
Oral RAD001 Given Daily-1 (RECORD-1), 
comparing BSC plus everolimus with BSC plus 
placebo and a de novo economic model. The 
RCT indicated a marked statistically signiicant 
effect on progression-free survival. The base-case 
incremental cost-effectiveness ratio (ICER) estimate 
was £52,000 per quality-adjusted life-year (this 
included a reduction in drug cost associated with 
an approved patient access scheme). The ERG 
undertook a critical appraisal of the submission. 
The ERG was generally in agreement with the 
submitting manufacturer concerning its estimates 
of effectiveness; however, there was greater concern 
surrounding the estimates of cost-effectiveness. 
The ERG judged that if potential errors in the 
model were corrected, the ICERs offered by the 
submitting manufacturer would overstate the cost-
effectiveness of everolimus for the second-line 
treatment of metastatic RCC (that this ICER would 
DOI: 10.3310/hta14suppl2/06
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be a higher value). Concerning the estimates of 
cost-effectiveness in RCC, the observations in the 
ERG report provide strong further support for 
research collecting rigorous estimates of utilities 
associated with the main health states likely to 
be experienced by patients with renal cell cancer. 
At the time of writing, NICE was yet to issue 
the Appraisal Consultation Document for this 
appraisal.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is speciically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of the Institute. This 
paper presents a summary of the ERG report 
for the STA entitled ‘Everolimus for the second-line 
treatment of advanced and/or metastatic renal cell 
cancer’.2
Description of the underlying 
health problem
Renal cell carcinoma (RCC), also called renal 
adenocarcinoma or hypernephroma, is a cancer 
usually originating in the lining of the tubules of 
the kidney. The stage of RCC is usually reported 
using the tumour, node and metastasis (TNM) 
classiication. This is based on the extent of the 
primary tumour (T), whether lymph nodes are 
affected (N) and whether metastases are present 
(M). Advanced and metastatic RCC falls within 
stages III and IV, stage III denotes disease that 
is locally advanced and/or has spread to regional 
lymph nodes and stage IV denotes that distant 
metastasis has occurred.
Early, small RCC tumours are usually 
asymptomatic; the diagnosis of early RCC is 
usually incidental after abdominal scans for 
other indications. The most common presenting 
symptoms of advanced RCC are blood in the urine 
(haematuria), a palpable mass in the lank or 
abdomen, and abdominal pain. Other non-speciic 
symptoms include fever, night sweats, malaise and 
weight loss.
Kidney cancer accounts for around 2% of all 
cancers in the UK. In 2004, 6180 new kidney 
cancers were diagnosed in England and Wales, of 
which an estimated 85–90% were RCC. RCC is 
nearly twice as common in men as in women, and 
most commonly affects adults aged 50–80 years 
old. In 2005, there were 3134 registered deaths 
from kidney cancer in England and Wales.
Approximately 25% of RCC patients present with 
advanced and/or metastatic disease (stage III 
or IV). An estimated 50% of patients who have 
curative resection for earlier stages will develop 
recurrent and/or metastatic disease. Without 
treatment, these patients have a median survival 
rate of only 6–12 months and a 2-year survival rate 
of 10–20%.
Surgical resection to remove the entire kidney 
(radical nephrectomy) or part of the kidney 
(partial nephrectomy) is the only accepted curative 
treatment for patients with non-metastatic RCC 
(TNM stage I–III), and the success of surgery 
depends on the stage of disease. Current 
standard treatment of metastatic RCC (stage IV) 
is immunotherapy with interleukin-2 (sometimes 
called aldesleukin) or interferon-alpha (IFN-F) 
which may lead to tumour shrinkage. Palliative 
surgery, arterial embolism or radiotherapy may 
also be considered in these patients. Bevacizumab 
plus IFN-F, sorafenib, sunitinib and temsirolimus 
all have UK marketing authorisations for use in the 
treatment of those with advanced and/or metastatic 
RCC who are suitable for immunotherapy and 
have an Eastern Cooperative Oncology Group 
performance status of 0 or 1.
Everolimus (Ainitor, Novartis Pharmaceuticals, 
Camberley, Surrey, UK) is an oral, once-daily 
selective inhibitor of the mammalian target of 
rapamycin protein, that controls tumour cell 
division, growth and angiogenesis. It does not 
have a UK marketing authorisation for use in 
advanced/metastatic RCC. However, in May 
2009, the European Medicines Agency adopted 
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a positive opinion, recommending everolimus 
for the treatment of patients with advanced RCC 
whose disease has progressed on, or after treatment 
with vascular endothelial growth factor targeted 
therapy.3 Everolimus has a marketing authorisation 
for other indications in the European Union.
Scope of the evidence 
review group report
The purpose of the ERG report was to comment 
on the validity of the manufacturer’s submission 
on the technology of interest. The scope for this 
submission and hence the scope for the ERG report 
is shown in Table 1.
Methods
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process.
Speciic steps undertaken by the ERG included:
t discussion of the nature of the problem with a 
clinical expert
t rerunning searches indicated to have been 
performed to inform the manufacturer’s 
submission
t extending searches
t formal critical appraisal of systematic review 
underpinning the manufacturer’s submission, 
using the principles found in the Centre for 
Reviews and Dissemination’s guidance for 
undertaking reviews in health care4
t checking and appraising the economic model 
submitted
t rerunning the model to correct for potential 
problems as best as possible within the limited 
time available
t commenting on further analyses provided 
by the company immediately prior to the 
appraisal committee
t the work was carried out between 30 
September 2009 and 30 November 2009.
Members of the ERG team attended and advised 
the meeting of the NICE appraisal committee 
where this guidance was discussed on 13 January 
2010.
TABLE 1 6XEPLVVLRQVFRSH
Appraisal objective 7RDSSUDLVHWKHFOLQLFDOHIÀFDF\VDIHW\DQGFRVWHIIHFWLYHQHVVRIHYHUROLPXVSOXV%6&IRUWKH
treatment of advanced RCC which has progressed after or during VEGF-targeted therapy 
(sunitinib, sorafenib, bevacizumab), compared to BSC alone
Intervention(s) Everolimus plus BSC
Population(s) Adults aged v 18 years with advanced RCC who had progressed on or within 6 months of 
stopping treatment with sunitinib, sorafenib or both drugs
Standard comparators The standard comparator to be considered was placebo plus BSC
Outcomes The outcome measures to be considered included:
overall survival
progression-free survival
objective tumour response rate
health-related quality of life
adverse effects of treatment
Economic analysis The reference case stipulates that the cost-effectiveness of treatments should be expressed in 
terms of incremental cost per quality-adjusted life-year
7KHWLPHKRUL]RQVKRXOGEHVXIÀFLHQWO\ORQJHQRXJKWRUHÁHFWDQ\GLIIHUHQFHVLQFRVWVRU
outcomes between the technologies being compared
Costs were considered from an NHS and Personal Social Services perspective
Other considerations If the evidence allows, the following subgroups will be considered: resected vs unresected 
primary tumour; clear cell vs non-clear cell; prognostic risk group; and prior therapy
Guidance will only be issued in accordance with the marketing authorisation
BSC, best supportive care; RCC, renal cell carcinoma; VEGF, vascular endothelial growth factor.
(YHUROLPXVIRUDGYDQFHGDQGRUPHWDVWDWLFUHQDOFHOOFDQFHU
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Results
Summary of submitted 
clinical evidence
The evidence for this submission is based on one 
randomised controlled trial (RCT), the RECORD-1 
(Renal Cell Cancer Treatment with Oral RAD001 
Given Daily-1) study.5 This was a randomised, 
double-blind, placebo-controlled, phase III clinical 
trial of 416 participants. Eligible patients were 
adults aged v 18 years with RCC whose disease 
had progressed on or within 6 months of stopping 
treatment with sunitinib, sorafenib or both drugs, 
a directly relevant population consistent with the 
scope of the appraisal. Of 416 patients, 277 were 
randomised to 10-mg everolimus once daily plus 
best supportive care (BSC), and 139 to an identical 
placebo tablet plus BSC. The blinded phase 
became open-label upon disease progression when 
patients were allowed to cross over from placebo 
to treatment group. Of 139 participants in the 
BSC plus placebo arm, 112 received everolimus 
following disease progression.
The primary outcome was progression-free survival 
(PFS). RECORD-1 (inal analysis) showed an 
improvement in this outcome which was unlikely 
to have occurred by chance alone [hazard ratio 
(HR) 0.33; 95% conidence interval (CI) 0.25 to 
0.43; p < 0.001].5 This equated to a mean PFS of 
4.9 months in the BSC plus everolimus arm and 
1.9 months for BSC plus placebo. No important 
variation in relative PFS estimates by subgroups 
were observed. In addition, a non-statistically 
signiicant treatment-related difference in overall 
survival (OS) was detected (HR 0.82; 95% CI 
0.57 to 1.17; p = 0.137).5 This result was highly 
likely to have been inluenced by the very high 
level of patients in the BSC plus placebo arm 
switching to everolimus treatment. Partial or stable 
tumour response was seen in 69% of patients 
with everolimus against 32% in the placebo arm, 
and stable quality of life (QoL)/patient-reported 
outcomes in the everolimus arm compared with 
placebo.
Summary of submitted cost-
effectiveness evidence
No published economic evaluations of everolimus 
in acute and/or metastatic RCC were identiied and 
so the cost-effectiveness work focused on a new 
model and economic evaluation undertaken by the 
manufacturer.
A Markov state transition cost–utility model 
compared treatment with everolimus plus BSC 
with BSC alone, mirroring the question addressed 
in the RECORD-1 RCT. The four states were: 
stable disease, stable disease with adverse 
events, progressive disease and death. Outputs 
were expressed as cost per quality-adjusted life-
year (QALY). The base-case incremental cost-
effectiveness ratio (ICER) was £61,330; this 
estimate was somewhat reduced when a patient 
access scheme (PAS) was applied. The base-
case ICER when PAS was applied (leading to a 
reduction in the cost of the drug) was £51,613. 
PAS was formally approved by the Department of 
Health during the course of the appraisal, which 
led to cost-effectiveness estimates in the original 
submission no longer being commercially-in-
conidence. The components of the base-case 
ICER (with PAS) were an incremental cost of 
£15,704, mostly attributable to the acquisition 
cost of everolimus, and 0.304 additional QALYs 
(a mean of 0.607 QALYs for BSC plus everolimus, 
compared to 0.302 QALYs for BSC plus placebo).
The Inverse Probability of Censoring Weight 
(IPCW) statistical approach was used to adjust for 
crossover bias in the trial data. This meant that the 
estimate of OS being used in the model was an HR 
of 0.55. In response to a request for clariication, 
the submitting manufacturer indicated that the 
ICER, using the unadjusted OS estimate from 
RECORD-1, was £91,000 (this incorporates the 
reduction in drug price consequent on the PAS).
In a supplementary analysis, the submitting 
manufacturer also used an alternative statistical 
approach, the Rank Preserving Structural 
Favouring Time (RPSFT) method, to adjust 
for crossover. This produced a very similar 
HR estimate to the IPCW of 0.52, and when 
incorporated into the economic model also 
produced an ICER of £53,128. However, on 
examination, the ERG found a signiicant error in 
the supplementary analysis which, when corrected, 
raised this ICER value considerably. This error 
was in addition to those uncovered in the original 
submission (as outlined below).
Commentary on 
the robustness of 
submitted evidence
Clinical effectiveness
The searches were appropriate and included all 
relevant studies. The main RCT, RECORD-1, was 
of high quality. No directly relevant ongoing trials 
were identiied, but there did appear to be studies 
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in progress investigating the role of everolimus 
earlier in the management of advanced RCC.
Cost-effectiveness
The overall approach taken to modelling was 
reasonable and the sources and justiication of 
estimates were also generally reasonable.
Weaknesses
The evidence was based on only one completed 
and published RCT, albeit a well-conducted and 
adequately powered study. The interpretation was 
reasonable, although the ERG would have more 
clearly presented the trial results on the higher 
frequency of adverse events, of a severity likely to 
have an impact on patient QoL, in the everolimus 
arm of the trial relative to the placebo arm. For 
example, 40.1% of participants experienced 
adverse events and serious adverse events in the 
BSC plus everolimus arm, compared to 22.6% 
in BSC plus placebo. Further data illustrating 
the same point were identiied in the Clinical 
Study Report. The trial data available indicated 
that patient health-related QoL was identical in 
the early stage of the trial, despite there being a 
response to treatment in the everolimus arm.
Although the OS results from the RECORD-1 RCT 
are clear and uncontroversial, indicating a survival 
improvement that could have resulted from chance 
alone, the adjustment of the results for switching 
placebo patients to everolimus following disease 
progression is an area of genuine academic debate, 
particularly concerning the most appropriate 
analytical method. The ERG took expert 
statistical advice on this (but could not replicate 
the calculation of OS estimates correcting for 
crossover). There is an alternative, possibly slightly 
preferred, approach to the IPCW method used in 
the original submission, RPSFT. The submitting 
manufacturer provided an additional analysis 
offering an estimate of OS and ICER based on this 
method, which actually led to little change from 
its original submission (see Summary of submitted 
cost-effectiveness evidence, page 44).
More seriously, however, a number of potential 
errors were identiied in the model:
1. Transition probabilities were not converted 
to rates before multiplying by the HRs in the 
model.
2. Introduction of a structural error in 
implementation of the mortality HR, with 
the result that that the observed HR in the 
model in most cycles was substantially less than 
the HR intended, 0.55. This had the effect 
of seriously biasing the result in favour of 
everolimus.
3. Not introducing discounting into the model 
from the irst cycle onwards (as opposed to 
introducing discounting from the irst year 
onwards).
Of these potential errors, the second was the most 
serious. The ERG attempted to recalibrate the 
model to correct for the potential errors, and the 
result was an increase in the base-case model ICER 
to £65,231 (with PAS).
A further concern was that QoL data were not 
based on European Quality of Life-5 Dimensions 
sources. The resulting lack of conidence in the 
utility parameters in models dealing with advanced 
and metastatic RCC has been commented on in 
NICE appraisals before. A speciic concern was that 
the small modelled difference in utility between 
stable disease and progressive disease (0.76 vs 0.68) 
does not seem consistent with the improvement in 
well-being likely to be present in practice.
Conclusions
The ERG was generally in agreement with the 
submitting manufacturer concerning its estimates 
of effectiveness.
There was greater concern about the estimates 
of cost-effectiveness. The ERG judged that if the 
potential errors were corrected, the ICERs offered 
by the submitting manufacturer overstate the cost-
effectiveness of everolimus for the second-line 
treatment of metastatic RCC (this ICER would be 
higher).
Areas of uncertainty
The areas of uncertainty mirrored the areas of 
weakness indicated in the section Weaknesses (page 
45).
Key issues
The key issues were:
t The existence of errors in the model and the 
effects of correcting for them.
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t The validity of adjusting for crossover bias in 
RCTs and the appropriate statistical technique 
required to adjust for it.
t The effect of concerns about utilities (as 
outlined above).
Implications for research
Concerning the estimates of cost-effectiveness in 
RCC, the observations in the ERG report provide 
strong further support for research collecting 
rigorous estimates of utilities associated with 
the main health states likely to be experienced 
by patients with renal cell cancer. This speciic 
appraisal highlights the possibility that the utility 
values associated with stable disease/progressive 
disease may vary depending on the number of 
additional potentially effective lines of further 
treatment available.
Switching in clinical trials for new cancer 
treatments as last line is a common and recurring 
problem in trial analysis. This STA considered a 
number of statistical approaches to adjustment. 
However, the issues highlighted have general 
applicability to other topics where switching 
from placebo to active treatment occurs when the 
primary end point has been reached, and this may 
be further enhanced by methodological research. 
Such research could, for example, focus on the 
appropriateness of alternative approaches in this 
context and towards the development of coherent 
guidelines for both the application of these 
statistical methods in health technology appraisals 
more generally as well as their integration in cost-
effectiveness modelling.
Further investigation of the role of everolimus 
earlier in the management of RCC appears to be 
in progress and would not currently seem to be a 
priority for further research.
Summary of NICE guidance 
issued as a result of the STA
At the time of writing, NICE was yet to issue 
the Appraisal Consultation Document for this 
appraisal.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of bevacizumab 
in combination with luoropyrimidine-based 
chemotherapy for the irst-line treatment 
of metastatic colorectal cancer based on the 
manufacturer’s submission to the National Institute 
for Health and Clinical Excellence (NICE) as part 
of the single technology appraisal (STA) process. 
Evidence was available in the form of one phase 
III, multicentre, multinational, randomised, open-
label study (NO16966 trial). This two-arm study 
was originally designed to demonstrate the non-
inferiority of oral capecitabine plus oxaliplatin 
(XELOX) compared with 5-luorouracil plus folinic 
acid plus oxaliplatin (FOLFOX)-4 in adult patients 
with histologically conirmed metastatic colorectal 
cancer who had not previously been treated. 
Following randomisation of 634 patients, the open-
label study was amended to include a 2 w 2 factorial 
randomised (partially blinded for bevacizumab) 
phase III trial with the coprimary objective of 
demonstrating superiority of bevacizumab in 
combination with chemotherapy  compared with 
chemotherapy alone. Measured outcomes included 
overall survival, progression-free survival, response 
rate, adverse effects of treatment and health-related 
quality of life. The manufacturer’s primary pooled 
analysis of superiority (using the intention-to-treat 
population) showed that after a median follow-
up of 28 months, the addition of bevacizumab to 
chemotherapy signiicantly improved progression-
free survival and overall survival compared 
DOI: 10.3310/hta14suppl2/07
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with chemotherapy alone in adult patients with 
histologically conirmed metastatic colorectal 
cancer who were not previously treated [median 
progression-free survival 9.4 vs 7.7 months 
(absolute difference 1.7 months); hazard ratio (HR) 
0.79, 97.5% conidence interval (CI) 0.72 to 0.87; 
p = 0.0001; median overall survival 21.2 vs 18.9 
months (absolute difference 2.3 months); HR 0.83, 
97.5% CI 0.74 to 0.93; p = 0.0019]. The NO16966 
trial was of reasonable methodological quality and 
demonstrated a signiicant improvement in both 
progression-free survival and overall survival when 
bevacizumab was added to XELOX or FOLFOX. 
However, the size of the actual treatment effect of 
bevacizumab is uncertain. The ERG believed that 
the modelling structure employed was appropriate, 
but highlighted several key issues and areas of 
uncertainty. At the time of writing, NICE was yet to 
issue the guidance for this appraisal.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is speciically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of the Institute. This 
paper presents a summary of the ERG report for 
the STA entitled ‘Bevacizumab in combination with 
fluoropyrimidine-based chemotherapy for the first-line 
treatment of metastatic colorectal cancer’.
Description of the underlying 
health problem
Colorectal cancer is the third most common cancer 
in the UK, with 36,766 new cases diagnosed in 
England and Wales in 2005.2 Metastatic disease is, 
in the majority of cases, incurable and treatment 
is palliative in nature. Although local radiotherapy 
and, less commonly, surgery both have a role, 
metastatic disease is essentially a systemic disease 
requiring systemic treatment. Traditionally this 
has meant cytotoxic chemotherapy although, in 
recent years, passive immunotherapy in the form 
of monoclonal antibody treatment has been added 
to chemotherapy regimens. Commonly used 
regimens include oral capecitabine monotherapy, 
oral capecitabine + intravenous (IV) oxaliplatin 
(XELOX), IV 5-luorouracil + folinic acid + 
oxaliplatin (FOLFOX), IV 5-luorouracil + folinic 
acid + irinotecan (FOLFIRI), IV 5-luorouracil 
± folinic acid, and oral capecitabine + IV 
irinotecan (XELIRI). With current standard irst-
line chemotherapy, median survival is around 
15–20 months.3–5
Scope of the evidence 
review group report
The objective of the appraisal was to evaluate 
the clinical effectiveness and cost-effectiveness 
of bevacizumab, within its licensed indications, 
in combination with oxaliplatin and either 
5-luorouracil or capecitabine for the treatment of 
metastatic colorectal cancer. The comparator was 
oxaliplatin or irinotecan, including chemotherapy 
regimens without bevacizumab. Measured 
outcomes included overall survival, progression-
free survival, response rate, adverse effects of 
treatment and health-related quality of life.
The licensed indication permits the use 
of bevacizumab in combination with 
luoropyrimidine-based chemotherapy for the 
treatment of patients with metastatic colorectal 
cancer but does not specify a line of treatment. The 
NICE scope included the use of bevacizumab in 
combination with oxaliplatin-based chemotherapy 
in individuals with histologically conirmed 
metastatic colorectal cancer as irst-line therapy 
(for patients not previously treated for metastatic 
disease), and as second-line therapy. The 
manufacturer’s submission (MS), however, focuses 
on irst-line use only.
The main evidence presented in support of the 
clinical effectiveness of bevacizumab was based 
on one phase III, multicentre, multinational, 
randomised, open-label study (NO16966 trial).6 
This two-arm study was originally designed 
to demonstrate the non-inferiority of XELOX 
compared with FOLFOX-4 in adult patients with 
histologically conirmed metastatic colorectal 
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cancer who had not previously been treated. 
Following randomisation of 634 patients, the 
open-label study was amended (additional phase II 
and III studies that were published demonstrated 
the beneit of adding bevacizumab to irinotecan, 
5-luorouracil and folinic acid)7,8 to include a 
2 w 2 factorial randomised (partially blinded for 
bevacizumab) phase III trial (n = 1401) with the 
coprimary objective of demonstrating superiority 
of bevacizumab in combination with chemotherapy 
(B-XELOX or B-FOLFOX-4) compared with 
chemotherapy alone (P-XELOX or P-FOLFOX-4). 
The dose of bevacizumab was 5 mg/kg every 
2 weeks (B-FOLFOX-4) or 7.5 mg/kg every 3 weeks 
(B-XELOX).
The scope of the manufacturer’s cost-effectiveness 
submission focused on a comparison with regimens 
containing oxaliplatin which was considered to 
be the most relevant comparator. A comparison 
with irinotecan-based chemotherapy was also 
included for completeness. The manufacturer 
submitted additional analyses in response to the 
ERG clariication questions. Further data and 
analyses were also submitted following the irst 
committee meeting. These included further data 
on the patient access scheme’s (PAS’s) operating 
costs as well as pharmacy and preparation costs for 
bevacizumab.
Methods
The ERG report comprised a critical review of 
the evidence for the clinical evidence and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process.
The manufacturer’s literature searches were 
repeated and a narrative critique of the submitted 
evidence was undertaken. The economic model 
submitted by the manufacturer was considered 
structurally adequate to assess the decision 
problem, but not all of the model inputs were 
considered satisfactory. Additional work carried 
out by the ERG focused on conducting sensitivity 
analyses relating to areas of uncertainty.
Results
Summary of submitted 
clinical evidence
The manufacturer’s main analysis pooled data from 
the initial two arms and the 2 × 2 factorial part of 
the NO16966 trial and compared the addition of 
bevacizumab to chemotherapy with chemotherapy 
alone. The manufacturer’s primary pooled 
analysis of superiority (using the intention-to-treat 
population) showed that after a median follow-
up of 28 months, the addition of bevacizumab to 
chemotherapy (B-XELOX/B-FOLFOX-4 combined) 
signiicantly improved progression-free survival 
and overall survival compared with chemotherapy 
alone (P-XELOX/P-FOLFOX-4/XELOX/FOLFOX-4 
combined) in adult patients with histologically 
conirmed metastatic colorectal cancer who were 
not previously treated [median progression-free 
survival 9.4 vs 7.7 months (absolute difference 
1.7 months); hazard ratio (HR) 0.79, 97.5% 
conidence interval (CI) 0.72 to 0.87; p = 0.0001; 
median overall survival 21.2 vs 18.9 months 
(absolute difference 2.3 months); HR 0.83, 97.5% 
CI 0.74 to 0.93; p = 0.0019].
A secondary pooled analysis of superiority 
(requested by the ERG as it was believed to 
be more appropriate) restricted to patients in 
the second 2 w 2 factorial part of the NO16966 
study as per the original statistical trial plan 
(B-XELOX/B-FOLFOX-4 combined vs P-XELOX/P-
FOLFOX-4 combined) found similar results 
[median progression-free survival 9.4 vs 8.0 months 
(absolute difference 1.4 months); HR 0.83, 97.5% 
CI 0.72 to 0.95; p = 0.0023; median overall survival 
21.3 versus 19.9 months (absolute difference 
1.4 months); HR 0.89, 97.5% CI 0.76 to 1.03; 
p = 0.0769].
The manufacturer’s pooled analysis of non-
inferiority (using the eligible patient population 
and the intention-to-treat population) showed 
that the XELOX (XELOX/P-XELOX/B-
XELOX combined) and FOLFOX-4 (FOLFOX-
4/P-FOLFOX-4/B-FOLFOX-4 combined) based 
regimens were equivalent for both progression-free 
survival and overall survival (p-values were stated as 
not signiicant, but these values were not reported). 
No analysis was undertaken for the factorial design 
(P-XELOX/B-XELOX combined versus P-FOLFOX-
4/B-FOLFOX-4 combined).
A pre-deined subgroup analysis on progression-
free survival found that the statistical superiority 
of bevacizumab plus chemotherapy was evident in 
the XELOX subgroups (B-XELOX vs P-XELOX; 
HR 0.80, 97.5% CI 0.66 to 0.96; p-value not 
reported) but did not reach the signiicance level 
in the FOLFOX-4 subgroups (B-FOLFOX-4 
vs P-FOLFOX-4; HR 0.89, 97.5% CI 0.74 to 
1.06; p-value not reported). Additional post hoc 
%HYDFL]XPDELQFRPELQDWLRQZLWKÁXRURS\ULPLGLQHEDVHGFKHPRWKHUDS\IRUPHWDVWDWLFFRORUHFWDOFDQFHU
50
exploratory analyses, following the results from 
the Adjuvant Colon Cancer End Points (ACCENT) 
study,9 found that there was a signiicant and 
direct correlation between time to recurrence 
after surgery and survival after recurrence in 
patients whose disease recurred after surgery and 
adjuvant treatment. Removing the subgroup of 
patients that may have slower tumour progression 
after adjuvant treatment (an imbalance between 
treatment groups with regard to an important 
prognostic factor that was not recognised at the 
start of the NO16966 trial) signiicantly improved 
(i.e. lowered) the HRs for adding bevacizumab 
to chemotherapy compared with chemotherapy 
alone for both overall survival and progression-free 
survival. Depending on the analyses conducted 
(e.g. exclusion of patients with prior adjuvant 
chemotherapy from all four treatment arms of the 
factorial study, from FOLFOX groups only or from 
P-FOLFOX group only) the HRs for overall survival 
ranged from 0.83 to 0.85 (p < 0.03) and the HRs 
for progression-free survival ranged from 0.74 to 
0.77 (p < 0.0001). Although this may be plausible, 
the ERG notes that caution should be exercised as 
this is a post hoc exploratory analysis.
The majority of adverse events were generally 
associated with cytotoxic chemotherapy. FOLFOX-
4-based regimens were generally associated 
with increased neutropenia/granulocytopenia, 
and XELOX-based regimens were generally 
associated with increased diarrhoea and hand 
and foot syndrome. Adverse events that could 
be potentially related to bevacizumab included 
increased frequencies of high blood pressure, 
proteinuria, bleeding, gastrointestinal perforation, 
thromboembolic events and wound healing 
complications. Serious (grade 3) or life threatening 
(grade 4) adverse events that occurred more 
commonly in patients receiving bevacizumab 
plus chemotherapy (B-XELOX/B-FOLFOX-4 
combined) than those receiving chemotherapy 
alone (P-XELOX/P-FOLFOX-4/XELOX/FOLFOX-4 
combined) were thromboembolic events (7.8% 
vs 5.1%, respectively), hypertension (4.0% vs 
0.8%, respectively), proteinuria (3.5% vs 0.9%, 
respectively) and bleeding problems (1.9% vs 
1.5%, respectively). Grade 3 and 4 gastrointestinal 
perforations and wound healing complications 
were rare (< 1%). Similar results were observed 
when data were restricted to the factorial analyses.
The rates of discontinuation were higher in the 
bevacizumab containing groups (B-XELOX/B-
FOLFOX-4 combined, 30.8%) than in the no 
bevacizumab containing groups (P-XELOX/P-
FOLFOX-4/XELOX/FOLFOX-4 combined, 25.3%), 
Corresponding data, restricted to the 2 w 2 factorial 
analyses, yielded similar results (B-XELOX/B-
FOLFOX-4 combined, 30.8% vs P-XELOX/P-
FOLFOX-4 combined, 20.8%). The statistical 
analysis comparing the rates of discontinuation 
between treatment groups was not reported in 
the MS or in the manufacturer’s supplementary 
evidence.
Summary of submitted cost-
effectiveness evidence
Cost-effectiveness was estimated using a Microsoft 
EXCEL model with four states: pre-progression on 
treatment, pre-progression and post treatment, 
progressive disease and dead. An area under the 
curve approach was used to estimate the disease 
progression of metastatic colorectal cancer patients. 
The distribution of patients between health states 
was used to calculate total direct costs and quality-
adjusted life-years (QALYs) for each intervention. 
Costs were considered from an NHS and Personal 
Social Services perspective. Cost-effectiveness was 
expressed in terms of incremental cost per QALY 
with a time horizon of 8 years, which is equivalent 
to a lifetime horizon in the population of interest. 
The analysis focused on the interventions 
B-XELOX and B-FOLFOX. The model was 
populated with eficacy data from the N016966 
trial but as discussed in the clinical effectiveness 
section these trial data have been analysed in 
several different ways. Data on treatment duration 
and dose intensity were also based on the N016966 
trial. Survival data were modelled using Kaplan–
Meier data up to median survival of 28 months 
and a Weibull distribution after this point. The 
ERG requested several changes to the model inputs 
and modelling assumptions (including additional 
analyses).
A summary of the key incremental cost-
effectiveness ratios (ICERs) included in the 
submission are presented in Table 1. Of the 
several analyses presented by the manufacturer, 
the ERG considered the analysis using the 2 w 2 
part of the N016966 trial, with the XELOX 
and FOLFOX arms pooled, with patients with 
prior adjuvant treatment excluded to be the 
most appropriate. This analysis produced ICERs 
of £36,006 and £31,174 for B-XELOX versus 
XELOX and B-FOLFOX versus FOLFOX, 
respectively. The inclusion of patients with 
prior adjuvant chemotherapy resulted in higher 
ICERs. Unpooling the XELOX and FOLFOX 
arms affected the individual XELOX and 
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TABLE 1 $VXPPDU\RI,&(5VLQFOXGHGLQWKHPDQXIDFWXUHU·VVXEPLVVLRQ06
Scenario
ICERs (£ per QALY saved)
B-XELOX vs 
XELOX
B-FOLFOX vs 
FOLFOX
MS original analysis
Without PAS Analysis using data from all six arms of N016966, XELOX 
and FOLFOX4 arms pooled
£82,098 £94,989
With PAS Analysis using data from all six arms of N016966, XELOX 
and FOLFOX4 arms pooled
£34,170 £41,388
MS supplementary data, requested by ERG
With PAS Analysis using data from all six arms of N016966, XELOX 
and FOLFOX4 arms pooled
£35,912 £36,569
With PAS Analysis using the 2 w 2 part of N016966, XELOX and 
FOLFOX4 arms pooled
£48,111 £39,771
With PAS Analysis using 2 w 2 part of N016966, XELOX and 
FOLFOX4 arms unpooled
£35,662 £62,714
With PAS Analysis using the 2 w 2 part of N016966, XELOX and 
FOLFOX4 arms pooled, without prior adjuvant treatment
£36,006 £31,174
Without PAS Analysis using data from all six arms of N016966, XELOX 
and FOLFOX4 arms pooled, including bevacizumab 
wastage
£90,945 £98,436
Without PAS Analysis using the 2 w 2 part of N016966, XELOX and 
FOLFOX4 arms pooled, without prior adjuvant treatment
£92,698 £96,687
Without PAS Analysis using 2 w 2 part of N016966, XELOX and 
FOLFOX4 arms unpooled
£90,779 £240,324
Without PAS Analysis using the 2 w 2 part of N016966, XELOX and 
FOLFOX4 arms pooled
£129,911 £134,309
06DGGLWLRQDOVXEPLVVLRQSRVWÀUVWFRPPLWWHHPHHWLQJ
With PAS Analysis using the 2 w 2 part of N016966, XELOX and 
FOLFOX4 arms pooled, without prior adjuvant treatment
£36,494 £31,122
ERG, evidence review group; B-FOLFOX4, bevacizumab in combination with FOLFOX4; B-XELOX, bevacizumab in 
FRPELQDWLRQZLWK;(/2;)2/)2;²LQWUDYHQRXVÁXRURXUDFLOSOXVIROLQLFDFLGSOXVR[DOLSODWLQ,&(5VLQFUHPHQWDOFRVW
effectiveness ratios; MS, manufacturers submission; PAS, patient access scheme; QALY, quality-adjusted life-year; XELOX, oral 
capecitabine plus intravenous oxaliplatin.
FOLFOX ICERs in different directions. While no 
systematic review was undertaken with irinotecan 
as a comparator, a cost-effectiveness analysis was 
undertaken (data not presented here).
Commentary on 
the robustness of 
submitted evidence
Strengths
The NO16966 trial was of reasonable 
methodological quality (with some limitations) 
and measured a range of outcomes that were as 
appropriate and clinically relevant as possible. 
The ERG believed that the modelling structure 
employed was appropriate.
Weaknesses
Despite no evidence to suggest that the 
statistical validity of the factorial approach was 
methodologically inappropriate, the validity of 
simply pooling data from essentially two different 
study designs (i.e. a two-arm design and a 2 w 2 
factorial design) without accounting for between-
study variability is inappropriate. Unweighted 
(for uncertainty) pooling of results from different 
studies is not advisable as there are almost certainly 
differences between trials that, if not accounted 
%HYDFL]XPDELQFRPELQDWLRQZLWKÁXRURS\ULPLGLQHEDVHGFKHPRWKHUDS\IRUPHWDVWDWLFFRORUHFWDOFDQFHU
52
for, are likely to lead to biased estimates of effect. 
The appropriateness of combining data from 
the two parts of the study was also questioned by 
the European Medicines Agency.10 The resulting 
pooled data (manufacturer’s primary pooled 
analysis of superiority and non-inferiority) should 
therefore be treated with caution. Additionally it 
is unclear whether patients with prior adjuvant 
chemotherapy should be excluded from the 
analysis.
The restriction to the trial data from the 2 w 2 part 
of the NO16966 study, the pooling of the XELOX 
and FOLFOX arms, and the restriction to the data 
of patients without prior adjuvant chemotherapy 
all had a large impact on the resulting ICERs.
The MS did not make use of the range of utility 
values identiied from the literature review and 
did not explain why these values were not used. 
The sources of the utility values used in the MS 
were poorly referenced, resulting in the ERG being 
unable to verify them. The distributions used for 
the utility values in the probabilistic sensitivity 
analyses (PSA) relected the uncertainty relating 
to the speciic values used but underestimated 
the uncertainty relating to the selection of 
utility values. The ERG noted that using wider 
distributions for utility values would signiicantly 
increase the CIs around the mean ICERs from 
the PSA, and reducing the utility values by 20% 
markedly increased the ICERs.
Chemotherapy can be administered intermittently 
or continuously, but the difference in cost and 
effectiveness between intermittent and continuous 
treatment is unclear. Current care in England is 
often intermittent treatment with chemotherapy, 
but the trial and the model both represent 
continuous treatment chemotherapy. It is unclear 
how this difference may impact the ICERs but, as 
an example, if intermittent treatment was cheaper 
than continuous treatment whilst having a similar 
eficacy, then the ICER for continuous treatment 
with bevacizumab versus intermittent treatment 
would be greater than the ICER for continuous 
treatment with bevacizumab versus continuous 
treatment.
In clinical practice, treatment with non-oxaliplatin 
chemotherapy components may continue beyond 
oxaliplatin cessation although in the N016966 
trial this was rarely seen. Because of the structure 
of the PAS (in which oxaliplatin is received free 
of charge), the incremental cost of continuing 
bevacizumab after oxaliplatin cessation is almost 
three times the incremental cost of adding 
bevacizumab to oxaliplatin. Hence the impact of 
continuing bevacizumab treatment on the ICERs 
could be considerable.
Under the PAS, bevacizumab has a ixed price 
per cycle, but for calculations without the PAS it is 
important that drug wastage should be included 
for both oxaliplatin and bevacizumab. The MS 
‘without PAS’ ICERs did not include drug wastage 
within the base case although bevacizumab wastage 
was included within one analysis as stated in Table 
1. The inclusion of drug wastage resulted in higher 
ICERs.
Conclusions
The NO16966 trial was of reasonable 
methodological quality and demonstrated a 
signiicant improvement in both progression-free 
survival and overall survival when bevacizumab was 
added to XELOX or FOLFOX. However, the size 
of the actual treatment effect of bevacizumab is 
uncertain due to the following:
t trial design limitations (two-part study, open-
label design)
t imbalance of known prognostic factor (time 
between primary treatment and recurrence)
t relatively short duration of chemotherapy 
treatment (approximately 6 months) despite 
the fact that the trial protocol allowed 
continuation of the study therapy until 
progressive disease or unacceptable toxicity
t interpretation of the statistical analyses (pooled 
analysis of all patients versus analysis by 
factorial design).
In addition, there was uncertainty around whether 
bevacizumab treatment should be continued until 
progression of the underlying disease.
The ERG believed that the modelling structure 
employed was appropriate, but highlighted several 
key issues and areas of uncertainty and included 
the following:
t It is unclear which approach to data analysis 
(pooling, excluding adjuvant therapy patients, 
etc.) is most appropriate and the choice of 
approach has a signiicant impact on the 
resulting ICERs.
t Unlike the N016966 trial, in clinical 
practice chemotherapy may be administered 
intermittently rather than continuously. 
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This introduces considerable uncertainty as 
the differences in cost and eficacy between 
intermittent and continuous use are not known.
t At the time of writing the decision on whether 
the proposed PAS scheme would be accepted 
was unknown. The majority of the analysis 
presented by the manufacturer included the 
PAS. Running the model without the PAS 
resulted in much higher ICERs.
t The eficacy associated with the continuation of 
treatment with bevacizumab after cessation of 
oxaliplatin is unknown. However, with the PAS 
the incremental cost of continuing bevacizumab 
after oxaliplatin cessation is almost three times 
the incremental cost of adding bevacizumab to 
oxaliplatin. Hence bevacizumab treatment post 
oxaliplatin cessation has the potential to have a 
signiicant impact on the resulting ICERs.
Research recommendations
The ERG makes three recommendations for areas 
requiring further research:
t research into the likely duration of 
bevacizumab treatment in clinical practice and 
the survival associated with longer treatment 
duration
t research into the cost-effectiveness of 
bevacizumab for patients currently receiving 
intermittent XELOX or FOLFOX
t inding ways to select patients who will beneit 
from bevacizumab.
Summary of NICE guidance 
issued as a result of the STA
At the time of writing, NICE was yet to issue the 
guidance for this appraisal.
Key references
1. National Institute for Health and Clinical 
Excellence. 2006. Guide to the single technology 
appraisal (STA) process. URL: www.nice.org.uk/
nicemedia/pdf/STA_Process_Guide.pdf.
2. Cancer Research UK. Number of new cases of cancer 
diagnosed by site, UK, 2005. URL: http://publications.
cancerresearchuk.org/WebRoot/crukstoredb/CRUK_
PDFs/incidence/cs_inc_t8.3.pdf (accessed 10 July 
2009).
3. Douillard JY, Cunningham D, Roth AD, Navarro 
M, James RD, Karasek P, et al. Irinotecan combined 
with luorouracil compared with luorouracil alone 
as irst-line treatment for metastatic colorectal 
cancer: a multicentre randomised trial. Lancet 
2000;355:1041–7.
4. de Gramont A, Figer A, Seymour MT, Homerin 
M, Hmissi A, Cassidy J, et al. Leucovorin and 
luorouracil with or without oxaliplatin as irst-line 
treatment in advanced colorectal cancer. J Clin Oncol 
2000;18:2938–47.
5. Tournigand C, André T, Achille E, Lledo G, Flesh 
M, Mery-Mignard D, et al. FOLFIRI followed by 
FOLFOX6 or the reverse sequence in advanced 
colorectal cancer: a randomized GERCOR study. 
J Clin Oncol 2004;22:229–37.
6. Saltz LBC. Bevacizumab in combination with 
oxaliplatin-based chemotherapy as irst-line therapy 
in metastatic colorectal cancer: A randomized phase 
III study. J Clin Oncol 2008;26:2013–19 (Erratum 
published in: J Clin Oncol 2008;26:3110; J Clin Oncol 
2009;27:653).
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright 
T, Hainsworth J, Heim W, et al. Bevacizumab 
plus irinotecan, luorouracil, and leucovorin 
for metastatic colorectal cancer. N Engl J Med 
2004;350:2335–42.
8. Kabbinavar FFS. Addition of bevacizumab to bolus 
luorouracil and leucovorin in irst-line metastatic 
colorectal cancer: Results of a randomized phase II 
trial. J Clin Oncol 2005;23:3697–705.
9. O’Connell MJ, Campbell ME, Goldberg RM, 
Grothey A, Seitz JF, Benedetti JK, et al. Survival 
following recurrence in stage II and III colon 
cancer: indings from the ACCENT data set. J Clin 
Oncol 2008;10:2336–41.
10. European Medicines Agency. Assessment Report 
for Avastin. Procedure Number. EMEA/H/C/000582/
II/0014. 2009. URL: www.emea.europa.eu/
humandocs/PDFs/EPAR/avastin/Avastin-H-582-II-
14-AR.pdf (accessed 6 September 2009).
Health Technology Assessment 2010; Vol. 14: Suppl. 2
© 2010 Queens Printer and Controller of HMSO. All rights reserved.
55
Dronedarone for the treatment of atrial 
ÀEULOODWLRQDQGDWULDOÁXWWHU
E Maund,* C McKenna, M Sarowar, D Fox, M Stevenson,  
C Pepper, S Palmer and N Woolacott
Centre for Reviews and Dissemination/Centre for Health Economics, University of York,  
York, UK
*Corresponding author
'HFODUHGFRPSHWLQJLQWHUHVWVRIDXWKRUV none
HTA 08/214/01
'DWHRI(5*VXEPLVVLRQ 
28 October 2009
7$5&HQWUHV 
Centre for Reviews and Dissemination/Centre for Health 
Economics
/LVWRIDXWKRUV 
E Maund, C McKenna, M Sarowar, D Fox, M Stevenson, 
C Pepper, S Palmer and N Woolacott
&RQWDFWGHWDLOV 
Emma Maund, Research Fellow, Centre for Reviews and 
Dissemination, University of York, Heslington, York YO10 
5DD, UK
E-mail: em546@york.ac.uk
The research reported in this article of the journal 
supplement was commissioned and funded by the 
HTA programme on behalf of NICE as project number 
08/214/01. The assessment report began editorial review 
in January 2010 and was accepted for publication in March 
2010. See the HTA programme website for further project 
information (www.hta.ac.uk). This summary of the ERG 
report was compiled after the Appraisal Committees 
review.
The views and opinions expressed therein are those of 
WKHDXWKRUVDQGGRQRWQHFHVVDULO\UHÁHFWWKRVHRIWKH
Department of Health.
Discussion of ERG reports is invited. Visit the HTA website 
correspondence forum (www.hta.ac.uk/correspond).
Abstract
This paper presents a summary of the evidence 
review group (ERG) report on the clinical 
effectiveness and cost-effectiveness of dronedarone 
for the treatment of atrial ibrillation (AF) or atrial 
lutter based upon a review of the manufacturer’s 
submission to the National Institute for Health and 
Clinical Excellence (NICE) as part of the single 
technology appraisal process. The population 
considered in the submission were adult clinically 
stable patients with a recent history of or current 
non-permanent AF. Comparators were the 
current available anti-arrhythmic drugs: class 1c 
agents (lecainide and propafenone), sotalol and 
amiodarone. Outcomes were AF recurrence, all-
cause mortality, stroke, treatment discontinuations 
(due to any cause or due to adverse events) and 
serious adverse events. The main evidence came 
from four phase III randomised controlled trials, 
direct and indirect meta-analyses from a systematic 
review, and a synthesis of the direct and indirect 
evidence using a mixed-treatment comparison. 
Overall, the results from the different synthesis 
approaches showed that the odds of AF recurrence 
appeared statistically signiicantly lower with 
dronedarone and other anti-arrhythmic drugs 
than with non-active control, and that the odds 
of AF recurrence are statistically signiicantly 
higher for dronedarone than for amiodarone. 
However, the results for outcomes of all-cause 
mortality, stroke and treatment discontinuations 
and serious adverse events were all uncertain. 
A discrete event simulation model was used to 
evaluate dronedarone versus antiarrhythmic drugs 
DOI: 10.3310/hta14suppl2/08
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and standard therapy alone. The incremental cost-
effectiveness ratio of dronedarone was relatively 
robust and less than £20,000 per quality-adjusted 
life-year. Exploratory work undertaken by the ERG 
identiied that the main drivers of cost-effectiveness 
were the beneits assigned to dronedarone for 
all-cause mortality and stroke. Dronedarone is 
not cost-effective relative to its comparators when 
the only effect of treatment is a reduction in AF 
recurrences. In conclusion, uncertainties remain 
in the clinical effectiveness and cost-effectiveness 
of dronedarone. In particular, the clinical evidence 
for the major drivers of cost-effectiveness (all-
cause mortality and stroke), and consequently the 
additional beneits attributed in the economic 
model to dronedarone compared to other anti-
arrhythmic drugs are highly uncertain. The inal 
guidance, issued by NICE on 25 August 2010, 
states that: Dronedarone is recommended as an 
option for the treatment of non-permanent atrial 
ibrillation only in people: whose atrial ibrillation 
is not controlled by irst-line therapy (usually 
including beta-blockers), that is, as a second-line 
treatment option, and who have at least one of the 
following cardiovascular risk factors: - hypertension 
requiring drugs of at least two different classes, 
diabetes mellitus, previous transient ischaemic 
attack, stroke or systemic embolism, left atrial 
diameter of 50 mm or greater, left ventricular 
ejection fraction less than 40% (noting that the 
summary of product characteristics [SPC] does 
not recommend dronedarone for people with left 
ventricular ejection fraction less than 35% because 
of limited experience of using it in this group) 
or age 70 years or older, and who do not have 
unstable New York Heart Association (NYHA) class 
III or IV heart failure. Furthermore, ‘People who 
do not meet the criteria above who are currently 
receiving dronedarone should have the option to 
continue treatment until they and their clinicians 
consider it appropriate to stop’.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is speciically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of the Institute. This 
paper presents a summary of the ERG report for 
the STA.2
Description of the underlying 
health problem
Atrial ibrillation (AF) is the most common cardiac 
arrhythmia with a prevalence that increases 
with age. Symptoms of AF include dificulty 
breathing, palpitations, chest pain, dizziness and 
loss of consciousness. AF is also associated with 
an increased risk of thrombus formation and 
consequently a ivefold increased risk of stroke 
compared to people without AF.3 AF and its 
symptoms can be treated using pharmacological or 
electrophysiological/surgical interventions to either 
control ventricular rate, which does not eliminate 
AF but improves AF symptoms, or restore normal 
sinus rhythm. There are three different types of 
AF: paroxysmal, which spontaneously terminates 
within 7 days; persistent, which requires treatment 
(cardioversion) to terminate; and permanent, in 
which normal heart rhythm can not be restored by 
treatment.
Scope of the evidence 
review group report
Dronedarone, Multaq® (Sanoi–Aventis), is an 
antiarrhythmic drug (AAD) that has properties 
belonging to all four Vaughan–Williams’ classes 
of AAD. It is indicated in adult clinically stable 
patients with history of, or current, non-permanent 
AF to prevent recurrence of AF or to lower 
ventricular rate. The recommended dose is 400 mg 
twice daily, with patients expected to remain 
indeinitely on dronedarone unless there is lack of 
eficacy, or intolerability.
The manufacturer (Sanoi Aventis Ltd) presented 
a submission to NICE on the use of dronedarone, 
(within the context of its licensed indication) for 
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the treatment of AF and atrial lutter (AFL), both 
as a irst-line adjunctive treatment to standard 
baseline therapy (with or without beta-blockers 
and anticoagulation therapy) and as a second-line 
treatment compared to other AADs: (i) class 1c 
agents (lecainide and propafenone); (ii) sotalol; 
and (iii) amiodarone.
Evidence for the eficacy and safety of dronedarone 
and other AADs came from randomised controlled 
trials (RCTs), meta-analysis (presenting direct and 
indirect comparisons) and a synthesis of the direct 
and indirect evidence using a mixed-treatment 
comparison (MTC). A total of 39 studies, including 
four studies of dronedarone [EURIDIS (European 
Trial in Atrial Fibrillation or Flutter Patients 
Receiving Dronedarone for the Maintenance of 
Sinus Rhythm) ADONIS (American–Australian–
African Trial with Dronedarone in Atrial 
Fibrillation or Flutter Patients for the Maintenance 
of Sinus Rhythm), ATHENA (A placebo-
controlled, double-blind parallel arm Trial to 
assess the eficacy of dronedarone 400mg bid for 
the prevention of cardiovascular Hospitalisation 
or death from any cause in patiENts with Atrial 
ibrillation/atrial lutter) and DIONYSOS (Eficacy 
and Safety of Dronedarone Versus Amiodarone for 
the Maintenance of Sinus Rhythm in Patients with 
Atrial Fibrillation)] conducted by the manufacturer, 
were considered eligible for inclusion in the direct 
and indirect meta-analyses and the MTC; however, 
the studies included in the direct meta-analysis and 
the MTC were subject to different inclusion criteria. 
Outcomes of interest were: AF recurrence, all-cause 
mortality, stroke, treatment discontinuation (due 
to any cause or adverse events) and serious adverse 
events of treatment (SAEs).
The manufacturer’s submission included a 
discrete event simulation model which was used 
to estimate the cost-effectiveness of dronedarone 
with other licensed AADs and standard therapy 
alone for AF. The comparison with standard 
therapy alone was restricted to high-risk elderly 
AF patients with a CHADS
2
 score v 4 (CHADS
2
 is 
a stroke risk stratiication scheme which is based 
on speciic risk factors including congestive heart 
failure, hypertension, age > 75 years, diabetes 
mellitus, and prior stroke or transient ischaemic 
attack). This model was used to evaluate the cost-
effectiveness of ive main patient groups according 
to their clinical AF type and baseline risk factors 
in line with UK guidelines: (i) paroxysmal AF with 
no structural heart disease (SHD); (ii) paroxysmal 
AF with coronary heart disease; (iii) paroxysmal AF 
with left ventricular dysfunction; (iv) persistent AF 
with no SHD; and (v) persistent AF with SHD.
Methods
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process.
The ERG critiqued the search strategy, 
study selection, validity assessment, outcome 
selection and the statistical methods used in the 
manufacturer’s submission of clinical effectiveness. 
It also explored the inconsistency of inclusion 
and exclusion of studies and use of continuity 
corrected data both within and between different 
types of statistical analyses. In addition, the ERG 
also checked the validity of the MTC analysis 
by running it using WINBUGS software. The ERG 
critiqued the methods used in the manufacturer’s 
economic evaluation. It corrected the cost-
effectiveness results presented by the manufacturer, 
undertook additional exploratory work to identify 
the main drivers of cost-effectiveness and key 
assumptions for the different comparisons, and 
explored the robustness of the cost-effectiveness to 
speciic assumptions and additional uncertainties 
identiied by itself.
Results
Summary of submitted 
clinical evidence
The EURIDIS/ADONIS trials (see Table 1 for 
study details) demonstrated that dronedarone 
was statistically signiicantly more effective than 
placebo for maintenance of sinus rhythm [hazard 
ratio (HR) 0.75; 95% conidence interval (CI) 0.65 
to 0.87, p < 0.001] and in reducing the ventricular 
rate during recurrence of AF/AFL [103.4 ± 25.9 
beats per minute (b.p.m) vs 117.1 ± 30.4 b.p.m, 
p < 0.001].4
The ATHENA study (see Table 1), which recruited 
only moderate- to high-risk elderly AF patients, 
75% of whom were in sinus rhythm, showed that 
dronedarone resulted in a signiicant reduction in 
the primary composite end point of time to irst 
cardiovascular hospitalisation or death from any 
cause (HR 0.76; 95% CI 0.69 to 0.84, p < 0.001). 
The primary end point appeared to be mainly 
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TABLE 1 6XPPDU\RIGURQHGDURQHWULDOVLQFOXGHGLQWKHPDQXIDFWXUHU·VVXEPLVVLRQ
ADONIS/EURIDISa ATHENA DIONYSOS
Population characteristics
n 1237 4628 504
Dose 400 mg BD 400 mg BD 400 mg BD
Age range Dronedarone: mean 63.5 
(10.7) years
Placebo: mean 62.2 (11.1) 
years
Mean: 71.6 (SD 9.0) years
< 65 years: 18.9%
65 to < 75 years: 39.5%
v 75 years: 41.6%
Mean 64 years
Range 2890 years
< 65 years: 52%
> 75 years: 19%
Type of AF Paroxysmal and persistent 
AF
Paroxysmal and persistent 
AF
At least one risk factor 
for cardiovascular 
hospitalisation
Persistent (cardioversion 
indicated); (although 
excluded, some were 
classed as having paroxysmal 
or permanent AF) 
Anticoagulation used? Majority of patients were 
receiving anticoagulants
44% receiving aspirin Yes
Hypertension Dronedarone: 60%
Placebo: 50.1%
86.3% 67%
SHD Dronedarone: 42.4%
Placebo: 39.7%
59.6% 28%
CHF Dronedarone: 17.3%
Placebo: 17.87%
21.2% 22% (not III or IV at time of 
randomisation)
Treatment duration 12 months Minimum 12 months > 6 months
Outcome measure
Primary outcome measure Recurrence of 
AF (measured by 
transtelephonic ECG when 
symptomatic)
First hospitalisation due to 
CV events or death 
AF recurrence or 
premature discontinuation 
due to intolerance or lack 
RIHIÀFDF\$)UHFXUUHQFH
measured by unscheduled 
ECG)
Secondary outcomes Symptoms related to AF
Mean ventricular rate during 
ÀUVWUHFXUUHQFHRI$)
Death from any cause
Death from CV causes
First hospitalisation due to 
CV event
Occurrence of major safety 
end point
2FFXUUHQFHRIGUXJVSHFLÀF
AEs
Post hoc analyses AF recurrence (measured 
by scheduled ECGs, 
hospitalisation for AF/AFL, 
electrical cardioversion)
Stroke
$(VDGYHUVHHYHQWV$)DWULDOÀEULOODWLRQ$)/DWULDOÁXWWHU%'WZLFHDGD\&+)FRQJHVWLYHKHDUWIDLOXUH&9FDUGLRYDVFXODU
ECGs, electrocardiograms; SHD, structural heart disease; SD, standard deviation.
a These two trials have identical protocols and are often considered as a single trial.
driven by a reduction in time to irst cardiovascular 
hospitalisation due to a signiicant reduction in 
hospitalisation for AF (HR 0.63; 95% CI 0.55 
to 0.72, p < 0.001). There was no statistically 
signiicant difference in all-cause mortality 
between patients receiving dronedarone and those 
receiving placebo (HR 0.84; 95% CI 0.66 to 1.08, 
p = 0.18). A post hoc analysis showed that there 
was a statistically signiicant reduction in the risk of 
stroke in patients receiving dronedarone compared 
to those receiving placebo (HR 0.66; 95% CI 0.46 
to 0.96, p = 0.027).5
The DIONYSOS trial (see Table 1), which directly 
compared dronedarone with amiodarone, 
showed that the incidence of recurrence of AF 
or premature study drug discontinuation was 
statistically signiicantly greater for dronedarone 
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TABLE 2 ,QFUHPHQWDOFRVWSHU4$/<UHVXOWVIRUWKHEDVHFDVHDQDO\VLVDVHQVLWLYLW\DQDO\VLVH[SORULQJWKHDVVXPSWLRQWKDWVRWDORODQG
DPLRGDURQHKDYHWKHVDPHHIIHFWRQPRUWDOLW\DVGURQHGDURQHDQGDVHQVLWLYLW\DQDO\VLVH[SORULQJWKHDVVXPSWLRQRIDWUHDWPHQWHIIHFWRQ
$)UHFXUUHQFHDORQH
Summary of incremental cost per QALY results for each of the base case populations
Paroxysmal AF Persistent AF
No SHD CAD LVD No SHD SHD
Dronedarone vs standard therapy £3620 £4014 £3577 £3358 £3520
Dronedarone vs sotalol £1692 £1,988 NA £1848 NA
Dronedarone vs class 1c £18,206 NA NA £18,955 NA
Dronedarone vs amiodarone NA NA £1895 NA £2349
Incremental cost per QALY results for each base case population when amiodarone and sotalol are assumed to have 
the same effect on mortality as dronedarone
Paroxysmal AF Persistent AF
No SHD CAD LVD No SHD SHD
Dronedarone vs sotalol £119,704 £102,668 NA £92,009 NA
Dronedarone vs amiodarone NA NA £55,063 NA £71,306
ERGs incremental cost per QALY results for each of the base case populations when the model assumes a treatment 
effect on AF recurrences alone
Paroxysmal AF Persistent AF
No SHD CAD LVD No SHD SHD
Dronedarone vs standard therapy £7,486,908 £70,323,846 £1,355,984 £1,630,715 £2,254,522
Dronedarone vs sotalol £5,232,678 D NA D NA
Dronedarone vs class 1c D NA NA D NA
Dronedarone vs amiodarone NA NA £5,694,862 NA D
$)DWULDOÀEULOODWLRQ&$'FRURQDU\DUWHU\GLVHDVH'GRPLQDWHG/9'OHIWYHQWULFXODUG\VIXQFWLRQ1$QRWDSSOLFDEOH
SHD, structural heart disease.
than for amiodarone (73.9% vs 55.3%, p-
value < 0.0001).
Overall, the results from the direct and indirect 
meta-analyses and the MTC showed that the odds 
of AF recurrence appeared statistically signiicantly 
lower with all AADs than with non-active control, 
but that the odds of AF recurrence are statistically 
signiicantly higher for dronedarone than for other 
AADs.
There were no statistically signiicant differences 
between AADs for all-cause mortality based on 
the head-to-head RCT (DIONYSOS) or the 
results from the indirect comparison. However, 
in the MTC, dronedarone was reported to have 
a statistically signiicant reduction in the odds of 
all-cause mortality compared to both sotalol and 
amiodarone.
For stroke, results from the MTC analysis only 
were reported in the manufacturer’s submission. 
Dronedarone was associated with a statistically 
signiicant reduction in stroke compared to control. 
No signiicant difference was reported between 
dronedarone and either amiodarone or sotalol 
based on the results from the MTC.
With regard to treatment discontinuations, the 
results reported from the direct and indirect 
meta-analyses were inconsistent with the MTC, 
suggesting considerable uncertainty. Results from 
the different synthesis approaches showed that 
compared with other AADs, dronedarone had the 
lowest odds of SAEs. However, the omission of data 
from the EURIDIS/ADONIS trial for this outcome 
means that the results are unreliable.
Summary of submitted cost-
effectiveness evidence
No previous published cost-effectiveness studies 
of dronedarone in patients with AF/AFL were 
identiied by the manufacturer. The results from 
the manufacturer’s submission demonstrated that 
dronedarone appeared highly cost-effective in each 
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of the populations compared to using standard 
baseline therapy alone as irst-line treatment, 
or compared to sotalol or amiodarone as a irst-
line antiarrhythmic (Table 2). The results for 
dronedarone, relative to class 1c agents, showed 
that dronedarone was borderline in terms of cost-
effectiveness, with an incremental cost-effectiveness 
ratio (ICER) just above £20,000 per quality-
adjusted life-year (QALY) and a 50% probability of 
being cost-effective at this threshold. The indings 
were reported to be robust across a wide range of 
alternative assumptions. The results appeared most 
sensitive to assumptions regarding the beneits 
from AADs on mortality.
The main driver of cost-effectiveness for the 
comparisons of dronedarone versus standard 
therapy as irst-line treatment, and sotalol or 
amiodarone as irst line antiarrhythmics, is 
the additional mortality beneit attributed to 
dronedarone. If sotalol and amiodarone are 
assumed to have the same effect on mortality as 
dronedarone, dronedarone is no longer considered 
to be cost-effective (see Table 2). Stroke beneits 
and differences in treatment-related adverse 
events have only a very limited impact on cost-
effectiveness for these comparisons. In contrast, 
the main drivers of cost-effectiveness for the 
comparison of dronedarone versus class 1c agents 
are a combination of the beneits assumed from 
stroke and a reduction in adverse events. The 
ERG noted that if only the potential beneits of 
AF recurrence are included in the model then 
dronedarone does not appear cost-effective for any 
of the populations considered (see Table 2).
Commentary on the robustness 
of submitted evidence
Strengths
The manufacturer conducted a comprehensive 
systematic review that identiied not only all 
relevant trials of dronedarone but also additional 
RCTs for other relevant comparator AADs, 
including class 1c agents, sotalol and amiodarone. 
A range of alternative synthesis approaches was 
employed by the manufacturer in order to assess 
the relative effectiveness of dronedarone compared 
to other AADs that are currently used in the NHS. 
The results of these separate comparisons were 
reported for each of the main clinical outcomes.
In general, the ERG considered the economic 
submission to be of high quality, meeting the 
requirements of the NICE reference case. The 
economic model structure was considered 
appropriate for the decision problem, and the 
detailed sensitivity analyses were thorough and 
informative in exploring the robustness of the 
results.
Weaknesses
Potential weaknesses that the ERG identiied in 
relation to the clinical effectiveness evidence were:
1. The inclusion/exclusion criteria applied to 
studies to be included in the direct and indirect 
analyses were not explicitly stated.
2. Different inclusion/exclusion criteria were 
applied to studies for the direct meta-analysis 
and the MTC, with a substantial reduction 
in the number of studies entering the MTC 
compared to the direct meta-analysis.
3. Issues of clinical and statistical heterogeneity 
between the different studies were insuficiently 
reported or were not explored.
4. Neither the exchangeability of the ATHENA 
study with lower risk and younger AF 
populations nor the generalisability of 
the ATHENA population to the overall 
AF population managed in the NHS were 
considered.
The ERG identiied a number of potential 
weaknesses related to the economic submission and 
electronic model which were considered to impact 
on the validity of the cost-effectiveness results. 
These included:
1. The treatment pathways evaluated by the 
manufacturer may not represent the full range 
of relevant strategies or sequences.
2. The use of baseline data from the ATHENA 
trial may not be generalisable to the UK AF 
population.
3. The use of a restricted set of studies to inform 
the relative effectiveness estimates applied in 
the model.
4. The assumptions used for class 1c agents, that 
for all-cause mortality there is no difference 
between dronedarone and class 1c agents, 
whilst for stroke, class 1c agents have no effect 
compared to standard care alone.
5. The estimates of the mortality effects of 
amiodarone and dronedarone.
6. Uncertainty surrounding the health-related 
quality of life (HRQoL) data used in the model.
7. Uncertainty in relation to the acquisition 
costs, initiation and monitoring costs of 
dronedarone.
Health Technology Assessment 2010; Vol. 14: Suppl. 2
© 2010 Queens Printer and Controller of HMSO. All rights reserved.
61
The ERG explored the robustness to a number 
of these uncertainties. The ICER of dronedarone 
remained relatively robust throughout (< £20,000 
per QALY) except for the following assumptions: 
(i) amiodarone and sotalol have the same effect on 
all-cause mortality as dronedarone; and (ii) class 1c 
has the same effect on stroke as dronedarone. In 
these situations, the ICER of dronedarone was well 
above £30,000 per QALY (see Table 2).
Finally, the submission does not explicitly consider 
the potential clinical effectiveness or cost-
effectiveness of dronedarone for patients with AFL.
Areas of uncertainty
The relative effectiveness and cost-effectiveness 
of dronedarone versus other AADs remains 
subject to a number of areas of uncertainty in 
terms of informing current NHS practice. These 
uncertainties include: (i) the generalisability of 
evidence from the ATHENA study to inform 
the management of a lower risk and younger 
AF population; (ii) the relative eficacy of 
dronedarone compared to other AADs; (iii) 
the validity of pooling the individual studies 
in the different synthesis approaches given the 
lack of consideration of clinical and statistical 
heterogeneity across the different studies; (iv) the 
clinical evidence for the major drivers of cost-
effectiveness (e.g. all-cause mortality and stroke) 
and consequently, the additional beneits attributed 
in the economic model to dronedarone compared 
to other AADs; (v) the clinical evidence for the 
eficacy of dronedarone and other AADs to lower 
ventricular rate as rate control was not included 
as an outcome measure in the submission; and 
(vi) the presence and potential magnitude of any 
quality of life beneits attributed to dronedarone as 
HRQoL have not been directly assessed in any of 
the existing dronedarone RCTs.
There remains a number of additional sources 
of uncertainty related to the cost-effectiveness of 
dronedarone that the ERG has been unable to 
adequately address. This includes establishing 
the most appropriate source of data to inform 
the baseline event rates applied in the model; 
the position for dronedarone in the pathway 
of treatment sequences; HRQoL beneits of 
dronedarone; and the maintenance of beneits over 
the longer term.
Conclusions
The effectiveness of dronedarone as an adjunctive 
treatment to standard care is highly uncertain, the 
key issue being the generalisability of the ATHENA 
study which relects a moderate- to high-risk 
elderly AF population relative to the general AF 
population.
In terms of the broader comparison of 
dronedarone with AADs, the ERG considers that 
the clinical evidence is highly uncertain for the key 
drivers of the cost-effectiveness of dronedarone: 
all-cause mortality and stroke. The uncertainty 
arises because the potential clinical and statistical 
heterogeneity of the included RCTs has not been 
adequately considered, and the exchangeability 
of the ATHENA study with the other studies is 
questionable. Also, the additional restrictions 
imposed on the inclusion of RCTs in the MTC are 
likely to increase the overall decision uncertainty 
compared to a fuller use of this evidence. 
Furthermore, the question of how the reduction in 
all-cause mortality or stroke is mediated, given that 
dronedarone is the least effective AAD in terms of 
AF recurrence, remains to be elucidated.
Key issues speciically relevant to the economic 
evaluation include: establishing the most 
appropriate source of data to inform the baseline 
event rates applied in the model; the potential 
cost-effectiveness of dronedarone in a range of 
alternative and feasible treatment sequences; the 
potential HRQoL beneits of dronedarone and the 
maintenance of beneits over the longer term; and 
the absence of a inal conirmed acquisition price 
at the time of the submission of the ERG report. 
Finally, the lower initiation and monitoring costs 
assumed for dronedarone are uncertain, although 
these do not appear to have a signiicant impact on 
the inal ICER results.
Implications for research
Further and longer term trials or the 
implementation of registries would be helpful 
to further establish the eficacy and safety of 
dronedarone relative to other AAD treatments that 
are regularly used in this indication within UK 
clinical practice. This is of particular importance 
in regard to outcomes of all-cause mortality and 
stroke, as these appear to be the key drivers of the 
cost-effectiveness results. Given the lack of existing 
HRQoL data, future RCTs of dronedarone and 
other AADs should also consider using a relevant 
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HRQoL measure. Additional evidence related to 
the effectiveness of AADs for patients with AFL 
would also be valuable.
Summary of NICE guidance 
issued as a result of the STA
The inal guidance, issued by NICE on 25 August 
2010, states that: 
Dronedarone is recommended as an option for 
the treatment of non-permanent atrial ibrillation 
only in people: whose atrial ibrillation is not 
controlled by irst-line therapy (usually including 
beta-blockers), that is, as a second-line treatment 
option, and  who have at least one of the following 
cardiovascular risk factors: - hypertension requiring 
drugs of at least two different classes, diabetes 
mellitus, previous transient ischaemic attack, 
stroke or systemic embolism, left atrial diameter 
of 50 mm or greater, left ventricular ejection 
fraction less than 40% (noting that the summary of 
product characteristics [SPC] does not recommend 
dronedarone for people with left ventricular 
ejection fraction less than 35% because of limited 
experience of using it in this group) or age 70 years 
or older, and who do not have unstable New York 
Heart Association (NYHA) class III or IV heart 
failure. 
Furthermore, ‘People who do not meet the criteria 
above who are currently receiving dronedarone 
should have the option to continue treatment until 
they and their clinicians consider it appropriate to 
stop’.
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Abstract
This is a summary of the evidence review group 
(ERG) report on the clinical effectiveness and cost-
effectiveness of adjuvant imatinib post resection 
of KIT-positive gastrointestinal stromal tumours 
(GISTs) compared with resection only in patients at 
signiicant risk of relapse. The ERG report is based 
on the manufacturer’s submission to the National 
Institute for Health and Clinical Excellence (NICE) 
as part of the single technology appraisal (STA) 
process. The bulk of the clinical evidence submitted 
was in the form of one randomised controlled 
trial (RCT), the Z9001 trial, funded by the 
manufacturer, which compared resection + adjuvant 
imatinib for 1 year to resection only. Results were 
immature, with median recurrence-free survival 
(RFS) not yet having been reached at the time of 
analysis. The trial did provide evidence of a delay 
in disease recurrence [1-year RFS rate of 98% 
in the imatinib arm vs 83% in the placebo arm 
[hazard ratio (HR) 0.35, 95% conidence interval 
(CI) 0.22 to 0.53, p < 0.0001)] but no evidence of 
an overall survival beneit. There was no long-term 
evidence around the rate of imatinib resistance 
over time with different treatment strategies 
(t adjuvant treatment). The relevant patient 
group for this appraisal is those at signiicant risk 
of relapse. These form a subgroup of the Z9001 
trial, and all information regarding this group was 
designated ‘Commercial-in-Conidence’ (CIC). 
DOI: 10.3310/hta14suppl2/09
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Median observation time for RFS was also CIC. 
The manufacturer constructed a Markov model 
comprising 10 health states designed to estimate 
costs and effects of treatment over a lifetime time 
horizon. The manufacturer’s estimate of the base-
case incremental cost-effectiveness ratio (ICER) was 
£22,937/quality-adjusted life-year (subsequently 
amended by the manufacturer to £23,601). While 
the structure of the model reasonably relected 
the natural history of the disease, the ERG had 
numerous concerns regarding the selection of, and 
assumptions around, input parameters (utilities, 
monthly probabilities of recurrence and death). 
Furthermore, the model was set up in such a way 
that any delay in recurrence translated directly 
into a survival beneit, an assumption that has no 
evidence base. A further assumption not supported 
by evidence was that any treatment beneit gained 
in the irst year is carried on for a further 2 
years at the same rate. Appropriate probabilistic 
sensitivity analysis was undertaken on the base 
case only, but not on scenario analyses, or choice 
of model used to estimate long-term survival data. 
The model was not amenable to changes in input 
values, thus limiting any additional analyses by 
the ERG to test assumptions. Due to the large 
number of uncertainties and assumptions, the 
estimated ICERs should be regarded as highly 
uncertain. The guidance issued by NICE in June 
2010 as a result of the STA does not recommend 
imatinib as adjuvant treatment after resection 
of gastrointestinal stromal tumours, although 
individuals currently receiving adjuvant imatinib 
should have the option to continue treatment until 
they and their clinician consider it appropriate to 
stop.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the UK NHS that is responsible for 
providing national guidance on the treatment and 
care of people using the NHS in England and 
Wales. One of the responsibilities of NICE is to 
provide guidance to the NHS on the use of selected 
new and established health technologies, based on 
an appraisal of those technologies.
NICE’s single technology appraisal (STA) process1 
is speciically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence lies 
with one manufacturer or sponsor (here, Novartis 
Pharmaceuticals UK Ltd). Typically, it is used 
for new pharmaceutical products that are close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition,  a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of the Institute. This 
paper presents a summary of the ERG report for 
the STA entitled ‘Imatinib as adjuvant treatment 
following resection of KIT-positive gastrointestinal 
stromal tumours (GISTs)’.2
Description of the underlying 
health problem
Patients eligible for adjuvant imatinib according 
to the UK licence are those who have had a 
resection of KIT (CD117)-positive GIST and 
are deemed to be at signiicant risk of relapse. 
‘Signiicant’ risk is not deined in the licence. In 
the industry submission it includes those patients 
in the moderate- and high-risk groups as deined 
by the Miettinen and Lasota criteria,3 which take 
into account tumour size, location and mitotic 
count. Risk of relapse and choice of treatment 
also depend on the speciic type of KIT exon gene 
mutations.
Based on the indings of studies in different 
countries, GIST has an annual incidence of 
between 6.8 and 14.5 per million; around two-
thirds of patients with GIST are thought to be 
resectable. Of the resected patients, around one-
half may have a signiicant risk of relapse.4
Survival after resection ranged from 48% to 80% at 
5 years for low-risk GIST before the introduction 
of imatinib; the 5-year survival rate (approximately 
95%) is similar to that of the general population, 
while for high-risk GISTs the 5-year survival rate 
ranged from 0% to 30% before the introduction 
of imatinib.5 As imatinib is a relatively recent 
treatment for GIST, there are fewer long-term 
survival estimates. In a trial of imatinib for 
advanced GIST, with a reported follow-up of up to 
71 months, median overall survival increased from 
18 months to 60 months.6
Most patients eventually show resistance to imatinib 
due to secondary mutations in the KIT and/or 
PDGFRA (alpha-type platelet-derived growth factor 
receptor) kinase domains. One study found that 
secondary or acquired resistance develops after a 
median of about 2 years of treatment.7
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Current guidelines state that imatinib increases 
recurrence-free survival (RFS) and suggest that it 
may be an effective treatment to prevent recurrence 
following primary surgery in those patients with 
a high risk of recurrence; these patients should 
be considered for inclusion in clinical trials of 
neoadjuvant and adjuvant therapy with imatinib.8 
Optimal treatment duration with adjuvant imatinib 
is not yet established, nor whether adjuvant 
treatment was a clinically effective or cost-effective 
option.
Scope of the ERG report
The research question was the clinical effectiveness 
and cost-effectiveness of adjuvant imatinib 
following resection compared with resection only 
in patients with KIT-positive GISTs who are at 
signiicant risk of relapse. This is consistent with 
the licence indication.
The clinical effectiveness data was primarily based 
on one ongoing randomised controlled trial 
(RCT), the Z9001 trial4 (n = 713), which compared 
resection + adjuvant imatinib for 1 year with 
resection alone.
Data on those patients who were at signiicant 
risk of relapse and who formed a subgroup of the 
trial (n = 302) were supplied as ‘Commercial in 
Conidence’ (CIC) data. Classiication of patients 
according to risk was retrospective and was 
performed for only 78% of patients, making the 
results susceptible to bias. It is likely that patients 
in this trial are similar to patients in the UK who 
would be eligible for treatment with adjuvant 
imatinib, although there is a possibility of differing 
thresholds for what constitutes ‘signiicant’ risk.
Outcome measures in the Z9001 trial were RFS, 
overall survival (OS) and adverse events. Quality-
of-life outcomes were not collected. Median follow-
up time for OS was 19.7 months (data is CIC for 
RFS and for both RFS and OS in the signiicant-
risk subgroup). It should be noted that on disease 
progression, all patients received treatment with 
imatinib or other treatment options (e.g. sunitinib) 
as appropriate, regardless of the treatment arm to 
which they were allocated; it is, in effect, different 
treatment strategies (one commencing with 
adjuvant imatinib) that are being compared long 
term.
The manufacturer submitted an economic model 
to assess the cost per quality-adjusted life-year 
(QALY) of resection with 3 years’ adjuvant imatinib 
(note: this differs from the trial where imatinib is 
given for 1 year) compared with resection only. 
Recurrence results were taken from the trial and 
extrapolated for longer time periods. Mortality 
results for patients in various health states were 
obtained from a variety of literature sources. Utility 
estimates were not available from the trial and were 
therefore taken from other literature sources or 
estimated by the manufacturer.
Methods
The ERG report comprised a critical review of 
the evidence for the clinical evidence and cost-
effectiveness of the technology based on the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process.
Additional searches to conirm the completeness 
of published data on effectiveness and cost-
effectiveness were undertaken. The ERG 
independently assessed the validity of the Z9001 
trial and analysed CIC results for the signiicant-
risk subgroup, which were provided separately by 
the manufacturer.
The model provided by the manufacturer 
was complex and not amenable to changes in 
parameter values, particularly with regard to 
running alternative probabilistic sensitivity analyses 
(PSAs). This limited the scope for the ERG to fully 
validate the model, and thus reduced the ERG’s 
conidence in the results of the model. There was 
also a lack of information around uncertainty 
estimates for certain parameters, particularly utility 
values, again restricting any additional sensitivity 
analyses.
Results
Summary of submitted 
clinical evidence
All information relating to the relevant subgroup 
of patients (those at signiicant risk of relapse) was 
CIC and therefore cannot be reported here. The 
total trial population included patients at low risk 
of relapse, who would not be eligible for adjuvant 
treatment in the UK. For this total population, the 
estimated 1-year RFS rate was 98% in the imatinib 
arm and 83% in the placebo arm (HR 0.35, 95% 
CI 0.22 to 0.53, p < 0.0001), therefore a delay in 
recurrence was evident (Figure 1). Median RFS had 
not yet been reached at the time of analysis and 
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few patients were evaluable at later time points. 
The OS rates for the total population were similar 
and most patients were still alive at the time of 
data analysis (Figure 2). Results from the Z9001 
trial on subsequent use of imatinib in patients who 
have previously had adjuvant imatinib were also 
CIC. The ERG identiied no additional results on 
imatinib resistance rates with subsequent use in the 
long term.
Summary of submitted cost-
effectiveness evidence
The manufacturer’s estimate of the base-case 
incremental cost-effectiveness ratio (ICER) was 
£22,937/QALY (subsequently amended by the 
manufacturer to £23,601). This estimate relies on 
patients receiving adjuvant imatinib for 3 years, 
for which there is no evidence from the Z9001 
trial, which used 1 year of adjuvant treatment. 
The manufacturer’s base-case analysis suggested 
that there was an approximately 60% chance that 
imatinib was cost-effective at willingness-to-pay 
thresholds of between £20,000 and £30,000 per 
QALY. Four additional analyses were submitted: 
(1) signiicant-risk patients, receiving imatinib 
for 1 year; (2) the overall at-risk population (no 
treatment time speciied); (3) the high-risk only 
population, receiving 1 year of imatinib; and (4) 
the high-risk only population, receiving 3 years of 
imatinib. ICERs were £13,550, £32,981, £6109 and 
£19,813, respectively.
Commentary on the robustness 
of submitted evidence
Clinical effectiveness
The population relevant to this appraisal was 
a subgroup of patients with signiicant risk 
of recurrence. Assignment of risk level was 
retrospective, and only 78% of patients were 
categorised according to risk. There is therefore 
a possibility of imbalances at baseline and risk of 
bias. Baseline characteristics of the signiicant risk 
population in the two trial arms are CIC.
There was some uncertainty around the handling 
of missing data and which deinition of ‘recurrence’ 
was used for the analyses in the submission; the 
ERG was unable to gauge the potential impact on 
results. The results from the trial were immature, as 
follow-up times were short, and results at later time 
points were based on few patients at risk. There is 
no evidence to show that adjuvant imatinib given 
for 1 year prolongs overall survival. Median overall 
survival estimates were not reached in either 
treatment arm (total trial population). There is 
no good long-term evidence on recurrence rates 
(resistance) when imatinib is given repeatedly. 
Quality of life was not measured as part of the 
Z9001 trial.
Cost-effectiveness
The model provided by the manufacturer 
contained no programming errors and the 
structure of the model reasonably relected the 
natural history of the disease. However, the ERG 
was unable to conduct more than a limited range 
of alternative analyses to test assumptions made by 
the manufacturers, as the model was not amenable 
to changes in input values. Furthermore, the ERG 
had a number of concerns relating to the monthly 
probabilities of death in various health states and 
their application in the model. The manufacturer 
assumed that all monthly probabilities post health 
states A, B and D (Figure 3) were the same in both 
treatment arms, i.e. the probability of recurrence 
or death did not depend on whether a patient 
received adjuvant treatment or resection only. This 
seems implausible to the ERG. The result of this 
is that any differences in a delay in progression 
translate directly into a survival gain of the same 
length.
The manufacturer also provided no justiication 
for the selection of studies from which the input 
parameters were derived, no details on how 
the death and recurrence rates were calculated, 
and there appeared to be some errors and 
inconsistencies. The impact on the ICER is unlikely 
to be large – because of the model structure, 
patients in both treatment arms received the same 
inputs post health states A, B and D – but this does 
not impart conidence in the modelling process.
The assumption of sustained beneit from 
treatment for 2 years beyond the evidence base is a 
generous one and systematically favours imatinib, 
resulting in a reduced ICER. Because of this way of 
extrapolating the treatment beneit, and because of 
the model structure, the logic of the model is that 
it is not sensible to stop adjuvant imatinib at any 
time point but to continue indeinitely. The ERG 
suggests that there is no proven beneit for this 
treatment strategy.
A further concern is that appropriate PSA was 
undertaken on the base case only, and not on the 
other scenario analyses. In particular, PSA was not 
undertaken on the subgroup analyses. One-way 
sensitivity analyses were conducted as part of the 
clariication process, but no scenario analyses were 
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undertaken on choice of model used to estimate 
long-term survival data. The absence of PSA for the 
subgroup analyses provided further exacerbates the 
paucity of the evidence on the uncertainty around 
the cost-effectiveness estimates provided in the 
submission.
The utility values used relied heavily on one study 
(Chabot et al.9) based on treatment with sunitinib 
(after imatinib failure). The authors of this study 
advised caution in the interpretation of their results 
due to large uncertainty. The ERG also identiied 
laws in how health-state utilities were modelled, 
for example relating to age adjustment, and the use 
of a mean utility value only (rather than a range).
Table 1 shows ERG estimates of the likely impact on 
the ICER of a number of parameter assumptions/
changes.
Conclusions
A survival beneit with adjuvant imatinib has to 
date not been shown. There is a lack of good 
long-term evidence around the rate of imatinib 
resistance over time with different treatment 
strategies (t adjuvant imatinib, for 1 year or 3 
years), and the effect on overall survival. There 
are serious concerns around the validity and 
application in the manufacturer’s model of a 
number of input parameters, such as utilities and 
monthly probabilities of death. The model also 
makes a basic assumption that any beneit in delay 
of recurrence translates directly into an increase in 
survival over the long term; this assumption is not 
supported by any evidence and does not take into 
account the possibility of differing rates of imatinib 
resistance between the two treatment arms. Due to 
the large number of uncertainties and assumptions, 
Health Technology Assessment 2010; Vol. 14: Suppl. 2
© 2010 Queens Printer and Controller of HMSO. All rights reserved.
69
TABLE 1 (IIHFWRISDUDPHWHUFKDQJHVRQ,&(5(5*HVWLPDWHV
Parameter
Effect on ICER  
(p = increase, r = decrease)
Decrease in utility value for RFS to 0.95 and 0.9 (manufacturer assumed a utility value of 1) p (small)
1RHVWLPDWHRIXQFHUWDLQW\DVVRFLDWHGZLWKUHFXUUHQFHIUHHKHDOWKVWDWHLQPRGHOEHQHÀW
for patients likely to have been overestimated)
p
No utilities < 0 included (should have been included as within range of possible utilities) p
No disutility associated with adverse events of adjuvant treatment p
Gradual increase in recurrence rates after year 1 with adjuvant treatment (rather than 
VXVWDLQHGEHQHÀWRYHU\HDUVZKLFKVHHPVLPSODXVLEOH
p
Correction of potential double-counting of utility loss (for health state and age) p
(UURULGHQWLÀHGE\PDQXIDFWXUHUUHODWLQJWRUHFXUUHQFHUDWHV p (also wider 95% CI)
Increased resistance to imatinib over time (manufacturers sensitivity analysis found a 
reduced ICER  this seems implausible to the ERG and no adequate explanation was given)
p
5HGXFWLRQLQVXUYLYDOEHQHÀWZLWKDGMXYDQWWUHDWPHQWPDQXIDFWXUHU·VVHQVLWLYLW\DQDO\VLV
IRXQGDUHGXFHG,&(5²WKLVVHHPVLPSODXVLEOHDVWKLVPHDQVDQHWEHQHÀWIURPSDWLHQWV
dying earlier)
p
Reduction in length of time of imatinib use (1 year only) r
Use of adjuvant imatinib in high-risk population only r
&,FRQÀGHQFHLQWHUYDO(5*HYLGHQFHUHYLHZJURXS,&(5LQFUHPHQWDOFRVWHIIHFWLYHQHVVUDWLR5)6UHFXUUHQFHIUHHVXUYLYDO
the estimated ICERs should be regarded as highly 
uncertain. It is possible that results from ongoing 
trials will inform this issue. The EORTEC 62024 
trial10 in particular has as an end point time to 
imatinib resistance, which may be a more useful 
proxy for overall survival. Should adjuvant imatinib 
treatment be shown to be beneicial in the future, 
further research would also be required into the 
type of patient most likely to beneit from adjuvant 
treatment based on mutational analysis.
Summary of NICE guidance 
issued as a result of the STA
NICE guidance issued in June 2010 does not 
recommend imatinib as adjuvant treatment after 
resection of gastrointestinal stromal tumours, 
although individuals currently receiving adjuvant 
imatinib should have the option to continue 
treatment until they and their clinician consider it 
appropriate to stop.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of geitinib 
for the irst-line treatment of locally advanced or 
metastatic non-small cell lung cancer, in accordance 
with the licensed indication, based upon the 
manufacturer’s submission to the National Institute 
for Health and Clinical Excellence (NICE) as 
part of the single technology appraisal process. 
The submitted clinical evidence consisted of the 
IRESSA Pan-ASian Study (IPASS); a phase III 
open-label randomised controlled trial conducted 
in 87 centres in East Asia which compared the 
use of geitinib with paclitaxel/carboplatin in 
1217 chemotherapy (CTX)-naive patients with 
stage IIIB/IV pulmonary adenocarcinoma. The 
manufacturer’s submission focused on a subgroup 
of patients in IPASS who were epidermal growth 
factor receptor (EGFR) gene mutation-positive 
(M+) (n = 261; 21% of the total IPASS population). 
The primary clinical outcome was progression-
free survival (PFS). Secondary outcomes included 
overall survival, clinically relevant improvement 
in quality of life and adverse events (AEs). Cost-
effectiveness was measured in terms of incremental 
cost per quality-adjusted life-year (QALY). In the 
overall population, PFS was signiicantly longer in 
patients treated with geitinib than in those treated 
with paclitaxel/carboplatin (hazard ratio 0.74, 
95% conidence interval 0.65 to 0.85; p < 0.0001). 
The manufacturer reported an incremental cost-
effectiveness ratio (ICER) of £20,744 per QALY 
gained for the target population. The probabilistic 
sensitivity analysis illustrated that for patients 
who are EGFR M+, geitinib compared with 
DOI: 10.3310/hta14suppl2/10
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doublet CTX was not likely to be cost-effective 
at what would usually be considered standard 
levels of willingness to pay for an additional 
QALY; the mean ICER for geitinib EGFR M+ 
versus doublet CTX EGFR M+ was reported as 
£35,700 per QALY. Additional analysis by the ERG 
included amendments to the base-case analysis, 
including an alternative approach to projecting 
survival, inclusion of two important additional 
comparators, sensitivity to EGFR M+ prevalence, 
and AE costs and disutilities. The manufacturer’s 
submission provides clinical evidence to support 
the use of geitinib in EGFR M+ patients with 
adenocarcinoma histology only. Before patients can 
be offered irst-line treatment with geitinib they 
must undergo EGFR mutation status testing which 
is currently not routinely available in the NHS. At 
the time of writing, the guidance document issued 
by NICE on 28 July 2010 states that ‘Geitinib 
is recommended as an option for the irst-line 
treatment of people with locally advanced or 
metastatic non-small-cell lung cancer (NSCLC) if 
they test positive for the epidermal growth factor 
receptor tyrosine kinase (EGFR-TK) mutation and 
the manufacturer provides geitinib at the ixed 
price agreed under the patient access scheme’.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is speciically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of the Institute. This 
paper presents a summary of the ERG report for 
the STA entitled ‘Gefitinib for the first-line treatment of 
locally advanced or metastatic non-small cell lung cancer 
(NSCLC)’.
Description of the underlying 
health problem
Lung cancer is the leading cause of cancer death 
worldwide and is responsible for over 33,000 
deaths a year in England and Wales.2 NSCLC is 
the most common subtype, accounting for 80% 
of all lung cancer cases. Despite advances in early 
detection, most patients still present with late-stage 
disease.
Survival rates for lung cancer are very poor. In 
England, for patients diagnosed between 1993 
and 1995 and followed up to 2000, 21.4% of men 
and 21.8% of women with lung cancer were alive 
1 year after diagnosis and less than 1% of advanced 
NSCLC lung cancer patients were alive after 
5 years.3,4
The majority of patients with lung cancer are 
diagnosed, or relapse, with incurable disease and 
receive palliative treatment only. For otherwise 
it patients with stage III/IV NSCLC, irst-line 
treatment consists of platinum-based combination 
chemotherapy (CTX) followed by docetaxel CTX 
or erlotinib, as currently recommended in NICE 
clinical guidelines.3
Scope of the evidence 
review group report
Geitinib is an orally active, selective epidermal 
growth factor receptor (EGFR) gene tyrosine 
kinase inhibitor which helps to slow the growth and 
spread of the cancer.
Geitinib is indicated for the treatment of adult 
patients with locally advanced or metastatic NSCLC 
with activating mutations of EGFR;5 the scope 
issued by NICE is for irst-line treatment only.
Before patients can be offered irst-line treatment 
with geitinib they must undergo EGFR mutation 
status testing which is currently not routinely 
available in the NHS.
The ERG report includes an assessment of both the 
clinical effectiveness and cost-effectiveness evidence 
submitted by the manufacturer (AstraZeneca) for 
the use of geitinib compared with doublet CTX 
for the treatment of CTX-naive patients with 
stage IIIB/IV pulmonary adenocarcinoma who 
tested positive (M+) for the EGFR mutation. Data 
were presented for all patients and a subgroup of 
patients who were EGFR M+.
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The primary clinical outcome was progression-
free survival (PFS). Secondary outcomes 
included overall survival (OS), clinically relevant 
improvement in quality of life (QoL) and adverse 
events (AEs). Cost-effectiveness was measured in 
terms of incremental cost per quality-adjusted life-
year (QALY).
Methods
The ERG report comprised a critical review of 
the evidence for the clinical evidence and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process.
The ERG evaluated the quality of the 
manufacturer’s clinical effectiveness review which 
comprised of a systematic review, meta-analysis 
and mixed-treatment comparison (MTC). Searches 
conducted by the manufacturer were assessed for 
completeness and the single trial put forward as 
evidence of effectiveness was critically appraised 
using the manufacturer’s responses to speciic 
questions in the submission template.
Cost-effectiveness evidence submitted by the 
manufacturer consisted of a systematic review and 
a de novo economic evaluation. The ERG assessed 
the manufacturer’s searches for completeness, 
critically appraised the submitted economic model 
using the NICE reference case checklist6 and the 
Drummond 10-point checklist,7 and conducted a 
detailed evaluation of the model and the validity of 
the MTC results for economic analysis of non-trial 
comparators.
Additional analysis by the ERG included 
amendments to the base-case analysis, including 
an alternative approach to projecting survival, 
inclusion of two important additional comparators, 
sensitivity to EGFR M+ prevalence, and AE costs 
and disutilities.
Results
Summary of submitted 
clinical evidence
Only one relevant randomised controlled trial 
(RCT) was identiied by the manufacturer; the 
IRESSA Pan-ASian Study (IPASS).8 IPASS8 is 
a phase III open-label RCT conducted in 87 
centres in East Asia which compared the use 
of geitinib with paclitaxel/carboplatin in 1217 
CTX-naive patients with stage IIIB/IV pulmonary 
adenocarcinoma.8 The manufacturer’s submission 
focused on a subgroup of patients in IPASS8 who 
were EGFR M+ (n = 261; 21% of the total IPASS 
population).
In the overall population, PFS was signiicantly 
longer in patients treated with geitinib than in 
those treated with paclitaxel/carboplatin [hazard 
ratio (HR) 0.74, 95% conidence interval (CI) 0.65 
to 0.85; p < 0.0001]. In a subgroup analysis of 261 
patients who were EGFR M+, PFS was signiicantly 
longer among those who received geitinib than 
among those who received paclitaxel/carboplatin 
(HR 0.48, 95% CI 0.36 to 0.64; p < 0.0001). In the 
subgroup of patients who were EGFR mutation-
negative (M–) (n = 176), PFS was signiicantly 
longer among those who received paclitaxel/
carboplatin (HR with geitinib 2.85, 95% CI 2.05 to 
3.98; p < 0.001).
Overall survival estimates were based on an 
interim analysis (37% maturity) and were similar 
for geitinib and paclitaxel/carboplatin patients 
in the overall trial population [18.6 months for 
geitinib vs 17.3 months for paclitaxel/carboplatin 
(HR 0.91, 95% CI 0.76 to 1.10)]. There was no 
signiicant difference in OS between geitinib and 
paclitaxel/carboplatin in EGFR M+ patients groups 
(HR 0.78, 95% CI 0.50 to 1.20). Median OS was 
12.1 months in the geitinib EGFR M– subgroup 
and was 12.6 months in the paclitaxel/carboplatin 
EGFR M– subgroup.
Signiicantly more patients in the geitinib group 
than in the paclitaxel/carboplatin group had a 
clinically relevant improvement in QoL, as assessed 
by scores on the Functional Assessment of Cancer 
Therapy – Lung questionnaire,9 [odds ratio (OR) 
1.34, 95% CI 1.06 to 1.69; p = 0.01] and by scores 
on the Trial Outcome Index (OR 1.78, 95% CI 1.40 
to 2.26; p < 0.001). Geitinib was associated with 
fewer grade 3 or 4 AEs.
After late identiication of interim analysis 
data from an ongoing RCT, the manufacturer 
performed a meta-analysis using data from 
IPASS8 and the North East Japan Geitinib Study 
Group (NEJGSG).10 Meta-analysis demonstrated 
signiicant improvement in PFS for EGFR M+ 
patients in the geitinib arm compared with EGFR 
M+ patients in the paclitaxel/carboplatin arm (HR 
0.43, 95% CI 0.34 to 0.53; p < 0.00001).
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The manufacturer conducted an MTC comparing 
doublet CTX in CTX-naive patients with NSCLC, 
using paclitaxel/carboplatin evidence from IPASS8 
as a baseline and including 29 RCTS. The MTC 
did not identify any individual doublet CTX 
as offering both signiicant clinical beneit and 
signiicantly improved tolerability over the other 
doublet CTX regimens.
Summary of submitted cost-
effectiveness evidence
The manufacturer conducted a de novo economic 
evaluation. A Markov model was developed 
to evaluate the cost-effectiveness of geitinib 
compared to four different doublet CTX regimens. 
The clinical data used in the economic evaluation 
were generated from a variety of sources. The 
HR for PFS for geitinib EGFR M+ patients was 
derived from a meta-analysis conducted by the 
manufacturer and the HR for OS for geitinib 
EGFR M+ patients was extrapolated from IPASS.8 
Estimates of the HRs for PFS and OS for the 
doublet CTX regimens were sourced indirectly 
from the MTC. Although the economic evaluation 
is primarily trial-based, there is a modelling 
component with regard to the extrapolation of 
health effects because IPASS8 is ongoing. The 
economic evaluation adopts a lifetime horizon 
for consideration of costs and beneits and the 
perspective is that of the UK NHS and Personal 
Social Services.
The manufacturer reported an incremental cost-
effectiveness ratio (ICER) of £20,744 per QALY 
gained for the target population. In addition to the 
main cost-effectiveness results, ICERs for selected 
subgroups were presented. Univariate sensitivity 
analysis, scenario analyses and probabilistic 
sensitivity analysis (PSA) were undertaken by the 
manufacturer.
The PSA illustrated that for patients who are EGFR 
M+, geitinib compared with doublet CTX was not 
likely to be cost-effective at what would usually be 
considered standard levels of willingness to pay for 
an additional QALY; the mean ICER for geitinib 
EGFR M+ versus doublet CTX EGFR M+ was 
reported as £35,700 per QALY.
Commentary on the robustness 
of submitted evidence
Clinical evidence
Before patients can be offered irst-line treatment 
with geitinib they must undergo EGFR mutation 
status testing. Currently, EGFR mutation testing is 
not routinely available in the NHS. It is uncertain 
how future testing of newly diagnosed patients 
with NSCLC will be orchestrated within the NHS 
in England and Wales. In addition, patients with 
adenocarcinoma histology would need to be 
identiied prior to EGFR mutation testing. This 
diagnostic service is not routinely available to 
patients in the NHS.
The ERG highlighted that the clinical validity 
characteristics of EGFR tests could impact on 
treatment outcomes with geitinib. In particular, 
a positive result for EGFR mutation status does 
not guarantee a good outcome, as a proportion 
(clinical false-positives) of such patients receiving 
geitinib will not experience any beneit (shorter 
PFS) compared with current treatment with doublet 
CTX and may in fact be worse off by not receiving 
doublet CTX (Figure 1). The implications of using 
EGFR mutation tests must be carefully considered 
for both EGFR M+ and EGFR M– patients.
The number of patients requiring irst-line 
treatment for NSCLC who are EGFR M+ in 
England and Wales is currently uncertain. A recent 
publication has estimated this igure to be between 
5% and 10% in the Western population.11
The clinical evidence was derived from a high 
quality trial in patients with NSCLC; convincing 
eficacy and QoL evidence were presented by the 
manufacturer for a speciic group of patients.
The main evidence cited by the manufacturer 
was derived from the IPASS8 trial; this study has 
reached only 37% maturity for the determination 
of OS. The inal OS estimates for patients in 
IPASS8 will be available in 2010. However, it may 
be dificult for the investigators to interpret the 
inal OS data from IPASS8 owing to the substantial 
number of patients in both groups who went on to 
receive a variety of second-line CTX regimens.
Clinical data from two other smaller trials [the 
NEJGSG10 trial and the First-SIGNAL (First-
line Single agent Iressa versus Gemcitabine 
and cisplatin trial in Never-smokers with 
Adenocarcinoma of the Lung)12 trial] comparing 
geitinib with doublet CTX are also available.
The main focus of the manufacturer’s submission 
was on patients who were EGFR M+; this subgroup 
of patients cannot be considered to have been 
truly randomised in the trial as the randomisation 
process did not include stratiication by biomarker 
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type. In addition, the trial was not powered to 
perform this subgroup analysis.
The generalisability of the IPASS8 study to patients 
in England and Wales is limited. None of the 
IPASS8 centres were based in the UK; all of the 
patients were from East Asia. All of the IPASS8 
patients had adenocarcinoma histology; in the 
UK patients with adenocarcinoma are estimated 
to make up approximately 25% of the population 
with NSCLC.13 IPASS8 includes patients with 
performance status (PS) 2; in England and Wales, 
CTX is not recommended by NICE for patients 
with metastatic disease with PS 2 unless as part of 
a clinical trial.3 The demographic characteristics 
of patients in IPASS8 do not match those of the 
relevant population in England and Wales; IPASS8 
patients are predominantly female and never 
smokers.
In the UK, the most common irst-line CTX 
regimen for patients with NSCLC is gemcitabine 
with either carboplatin or cisplatin. In IPASS,8 
geitinib is compared with paclitaxel/carboplatin; 
it has been estimated by the manufacturer 
that approximately only 5% of patients receive 
paclitaxel/carboplatin as a irst-line treatment for 
NSCLC in England and Wales.
The MTC methods used by the manufacturer to 
compare paclitaxel/carboplatin with a range of 
doublet CTX regimens in unselected populations 
are appropriate. However, the ERG considered 
that the MTC was weak as it was reliant on the 
assumption that EGFR mutation status does not 
affect treatment outcomes if patients are receiving 
doublet CTX. The ERG believes this assumption 
is too strong as it is wholly reliant on the results of 
a subgroup analysis from a single RCT of patients 
with adenocarcinoma histology. The evidence base 
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for the studies used in the comparison of geitinib 
with doublet CTX may not be generalisable to the 
EGFR M+ population.
Economic evidence
The manufacturer’s economic evaluation did not 
compare geitinib with docetaxel or pemetrexed; 
both of these CTX regimens are listed as relevant 
comparators in the inal NICE scope. In response 
to the ERG’s clariication letter, the manufacturer 
provided an updated version of the MTC and 
included pemetrexed. The ERG considered 
that not including pemetrexed or docetaxel as 
comparators in the economic evaluation was a 
major weakness of the manufacturer’s submission.
The ERG identiied key areas where corrections 
and/or adjustments to the economic model are 
required: CTX costs, cycles, and exposure; OS 
and PFS modelling; and use of discounting and 
continuity correction methods. Taken together, 
the ERG’s corrections and/or adjustments to the 
submitted model increased the size of the ICER 
for the base-case population from £20,010 to over 
£70,000 per QALY (Tables 1 and 2). This suggests 
that the cost-effectiveness of geitinib compared to 
doublet CTX for CTX-naive EGFR M+ patients 
may be less favourable than presented by the 
manufacturer in the manufacturer’s submission.
The ERG highlighted that the results of the 
manufacturer’s economic evaluation were 
predicated on the use of the EGFR mutation test 
(or similar) described in IPASS.8 This means that 
if a different EGFR mutation test is used and/
or does not demonstrate similar analytic validity, 
the manufacturer’s cost-effectiveness results may 
no longer be valid. This assessment does not 
relate solely to use of geitinib, but to the speciic 
combination of mutation testing and geitinib 
treatment studied in IPASS.8
Finally, during the clariication process the 
manufacturer was asked to provide individual 
patient data (IPD) from IPASS8 that would allow the 
ERG to explore a number of weaknesses identiied 
in the economic model. The manufacturer replied 
that it could not share IPD, but would be willing to 
conduct speciic analyses on behalf of the ERG. A 
request was made to the manufacturer to conduct 
these analyses. The manufacturer responded that 
it would not able to provide the results of the 
requested analyses within the timeframe of the STA 
process.
Conclusions
The manufacturer’s submission provides clinical 
evidence to support the use of geitinib in EGFR 
M+ patients with adenocarcinoma histology only. 
Before patients can be offered irst-line treatment 
with geitinib they must undergo EGFR mutation 
status testing which is currently not routinely 
available in the NHS.
Major weaknesses in the clinical section of the 
manufacturer’s submission identiied by the ERG 
include: (i) the clinical results of IPASS8 are not 
generalisable to the majority of patients with 
NSCLC in clinical practice in England and Wales; 
and (ii) to date, there are no direct clinical trial 
data to demonstrate that use of geitinib as a irst-
line treatment by EGFR M+ patients leads to 
improved OS compared with the use of paclitaxel/
carboplatin.
The ERG’s corrections and/or adjustments to the 
submitted economic model have increased the 
size of the ICER for the base-case population; the 
cost-effectiveness of geitinib compared to doublet 
CTX for CTX-naive EGFR M+ patients may be less 
favourable than presented by the manufacturer in 
the manufacturer’s submission.
Summary of NICE guidance 
issued as a result of the STA
The guidance document issued by NICE on 28 July 
2010 states that:
Geitinib is recommended as an option for the irst-
line treatment of people with locally advanced or 
metastatic non-small-cell lung cancer (NSCLC) if:
they test positive for the epidermal growth factor 
receptor tyrosine kinase (EGFR-TK) mutation and
the manufacturer provides geitinib at the ixed 
price agreed under the patient access scheme. 
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TABLE 1 (IIHFWRIFRUUHFWLRQVDQGDPHQGPHQWVPDGHE\(5*WRWKHPDQXIDFWXUHU·VPRGHOIRUWKHEDVHFDVHDQDO\VLVRWKHUPRGHOOHGFRPSDUDWRUVRYHU\HDUV
Model amendment
Gemcitabine/carboplatin Vinorelbine/cisplatin Gemcitabine/cisplatin
Inc. Costs Inc. QALYs
ICER  
(£/QALY) Inc. Costs Inc. QALYs
ICER  
(£/QALY) Inc. Costs Inc. QALYs
ICER  
(£/QALY)
Submitted model £3666 0.1767 £20,744 £8024 0.2229 £35,992 £4138 0.1445 £28,633
Base case with 6-year horizon £3761 0.1767 £21,284 £8151 0.2229 £36,562 £4222 0.1445 £29,217
Revised MTC £3858 0.1824 £21,151 £8149 0.2229 £36,557 £4218 0.1445 £29,181
$PHQGÀUVWOLQH&7;FRVWV £4057 0.1767 £22,956 £8447 0.2229 £37,890 £4077 0.1445 £28,215
Reduced cycles of CTX £5599 0.1735 £32,278 £9547 0.2194 £43,512 £6244 0.1409 £44,308
Revise OS models £1985 0.1174 £16,907 £7175 0.1893 £37,905 £2245 0.0788 £28,509
Revise PFS models £5019 0.1630 £30,788 £9299 0.2097 £44,356 £5409 0.1313 £41,209
IPASS PFS HR (not MA) £4450 0.1678 £26,520 £8840 0.2140 £41,304 £4911 0.1356 £36,219
Revise discounting method £3674 0.1796 £20,453 £8123 0.2266 £35,839 £4146 0.1469 £28,229
Omit GCSF prophylaxis £4039 0.1767 £22,855 £8429 0.2229 £37,809 £4500 0.1445 £31,141
Continuity correction £3362 0.1767 £19,024 £7891 0.2229 £35,398 £3895 0.1445 £26,956
Correct misaligned cycles £3762 0.1767 £21,290 £8152 0.2229 £36,567 £4223 0.1445 £29,223
Correct second-line CTX costs £4380 0.1767 £24,785 £8085 0.2229 £36,264 £4657 0.1445 £32,228
Common CTX outcomes £5114 0.1892 £27,028 £7043 0.1896 £37,148 £5149 0.1880 £27,394
CTX treatment exposure £4543 0.1767 £25,706 £8737 0.2229 £39,189 £5067 0.1445 £35,062
Combined effect of all changes £7554 0.1253 £60,273 £8842 0.1256 £70,390 £7322 0.1241 £59,016
CTX, chemotherapy; GCSF, granulocyte colony stimulating factor; HR, hazard ratio; ICER, incremental cost-effectiveness ratio; Inc., incremental; IPASS, IRESSA Pan-ASian Study; MA, 
meta-analysis; MTC, mixed-treatment comparison; OS, overall survival; PFS, progression-free survival; QALY, quality-adjusted life-year.
*HÀWLQLEIRUORFDOO\DGYDQFHGRUPHWDVWDWLFQRQVPDOOFHOOOXQJFDQFHU
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TABLE 2 (IIHFWRIFRUUHFWLRQVDQGDPHQGPHQWVPDGHE\(5*WRWKHPDQXIDFWXUHU·VPRGHOIRUWKHEDVHFDVHDQDO\VLVRWKHUPRGHOOHG
FRPSDUDWRUVRYHU\HDUVFRQWLQXDWLRQRI7DEOH
Docetaxel/cisplatin Pemetrexed/cisplatin
Model amendment Inc. costs Inc. QALYs
ICER  
(£/QALY) Inc. costs Inc. QALYs
ICER  
(£/QALY)
Submitted modela -     
With revised MTC £4434 0.1627 £27,252 £134 0.0601 £2223
Reduced cycles of CTXb £6254 0.1593 £39,263 £2484 0.0565 £43,984
Revise OS models £2591 0.1013 £25,590 £3115 0.0379 £82,125
Revise PFS models £5636 0.1494 £37,735 £1091 0.0469 £23,271
IPASS PFS HR (not MA) £5123 0.1538 £33,311 £555 0.0512 £10,838
Revise discounting method £4356 0.1654 £26,340 £264 0.0610 £4323
Omit GCSF prophylaxis £4712 0.1627 £28,961 £144 0.0601 £2402
Continuity correction £4024 0.1627 £24,728 £600 0.0601 £9984
Correct misaligned cycles £4435 0.1627 £27,257 £134 0.0601 £2223
Correct second-line CTX 
costs
£4944 0.1627 £30,385 £842 0.0601 £14,004
CTX treatment exposure £5200 0.1627 £31,961 £958 0.0601 £15,931
Combined effect of all changes £6285 0.0862 £72,908 £1574 0.0560 £28,080 
JHÀWLQLE
dominated)
CTX, chemotherapy; GCSF, granulocyte colony stimulating factor; HR, hazard ratio; ICER, incremental cost-effectiveness 
ratio; Inc., incremental; IPASS, IRESSA Pan-ASian Study; MA, meta-analysis; MTC, mixed-treatment comparison; OS, overall 
survival; PFS, progression-free survival; QALY, quality-adjusted life-year.
a Submitted model did not include these comparators.
b Submitted model did not include costs for these comparators.
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